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    In cancer plasmonic photothermal therapy (PPTT), gold nanoparticles (AuNPs) are used 
to convert light energy into localized heat leading to cancer cell death. Among plasmonic 
nanoparticles, gold nanorods (AuNRs) have been widely used as they absorb near-infrared 
(NIR) laser light (safe to biological system). Detailed background information was 
introduced in Chapter 1. Herein, 1) we developed new AuNRs formulations techniques, 
yielding better generation of AuNRs, for enhancing PPTT (Chapter 2). 2) We studied 
PPTT in vitro (Chapter 3).  We developed novel surface conjugations, greatly enhance the 
endocytosis of gold nanoparticles and the PPTT efficacy in cells. We explored its 
molecular mechanism. We also studied the AuNPs’ effect on inhibiting cancer cells 
migration. 3) Moving from cells to animals (Chapter 4). We studied the efficacy, 
molecular mechanism and long-term toxicity of AuNRs in mice. Furthermore, the 
feasibility of PPTT has been verified on natural tumors in dogs and cats without any relapse 
or toxicity effects even after 1 year of treatment. In conclusion, together these data on cells, 
mice, cats and dogs demonstrated that our AuNR-PPTT inducing apoptosis is effective and 







CHAPTER 1. INTRODUCTION 
    Cancer remains to be one of the leading causes of death worldwide. In the United States 
cancer is the second cause of death surpassed by heart disease. 1,658,370 new cancer cases 
and 589,430 cancer deaths are projected to occur in the United States in 2015 [1,2]. Current 
mainstream treatments include surgery, radiotherapy, chemotherapy, etc. Surgery is highly 
effective to access tumors but it is not successful in many cases. On the other hand, 
radiotherapy and chemotherapy can also cause damage to healthy tissues close to the cancer 
cells. Thus, the development of plasmonic photothermal therapy (PPTT) as an effective 
and safe approach has recently gained increasing attention. PPTT [1] offers a relatively 
noninvasive and gentle alternative for cancer treatment using targeted gold nanoparticles 
of specific shapes, that absorb NIR light and produces localized heat for tumor ablation. 
This photo-absorbers (gold nanoparticles) are then injected locally into the tumor to 
selectively increase the temperature under laser irradiation. Tumor destruction is thus 
achieved as sufficient temperature rise over desired period is carried out in the tumor 
region.  
 
1.1 Plasmonic Photothermal Therapy of Cancer 
    Photothermal therapy is a minimally-invasive therapeutic strategy in which photon 
energy is converted into heat sufficient to destroy cancer cells, and  has been used to treat 
cancer to some degree in the past few decades 4.2. It does not have the severe infection 
problems commonly encountered after surgery [3]. It also overcomes the side effects of 
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chemotherapy by circumventing the use of toxic drugs. Heating sources including NIR or 
visible light5, radiofrequency waves [4],  microwaves [5],  and ultrasound waves [6] are 
used to induce moderate temperature rise, which is clinically termed as hyperthermia, in a 
specific target region to destroy the cancer cells. Due to the low absorption efficiency of 
the natural tissue absorbents, synthetic organic dye molecules (photo sensitizers) such as 
indocyanine green and porphyrins coordinated with transition metals [7-8] are externally 
injected into the tumor sites to enhance the photothermal effects when NIR light is used. 
However, the dye molecules photobleach quickly, rendering insufficient therapeutic 
outcomes.  
    Nanotechnology is expected to bring about breakthroughs in medicine by generating 
new diagnostic and therapeutic technologies. By their reduced size, nanoscale materials 
(generally 1-100 nm) exhibit new properties that make them very useful in cellular 
imaging, molecular diagnosis and targeted therapy depending on their structure, 
composition and shape9. Plasmonic gold nanoparticles (Au NPs) are very useful in 
biomedical applications because of their strongly enhanced radiative (scattering) and 
nonradiative (absorption) and photothermal properties due to the surface plasmon 
resonance (SPR) properties. SPR is the coherent collective oscillation of the free electrons 
in the plasmonic metals upon their excitation with resonant incident light [9-17]. While the 
radiative properties can be utilized for cancer imaging [1, 10-11] and molecular diagnosis 
[12-13], the non-radiative properties have shown to have great potential in photothermal 
cancer therapy [14-17]. The rationale is that nanoparticles absorb light 105-106 times 
stronger than most strongly light-absorbing dye molecules [25]. The absorbed light by 
certain size and shape nanoparticles is converted into heat rapidly (on the picosecond time 
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scale) and highly efficiently converted (nearly 100%) into non-radiative processes 
including electron-electron and electron-photon interactions [17-18]. Thus, if Au NPs are 
bound to cancer cells, and exposed to resonant electromagnetic radiation of an optical laser, 
intense heat capable of destroying cells are produced. Compared to conventional strategies 
of using dye molecules, Au NPs enabled PPTT is envisaged to be much more effective. In 
addition, Au NPs overcomes the photobleaching problems of dye molecules and thus make 
the photo-thermal method using gold nanorods is more robust in photo-thermal clinical 
applications.   
    For in vivo applications, Au NPs have to be active in the NIR region, where optical 
penetration of electromagnetic radiation through tissue is optimal, and thus cylinder-
shaped gold nanorods (Au NRs) [1, 19], silica/gold nanoshells [14] and nanocages [20] are 
generally preferred because of their tunable NIR absorption properties. Au NRs exhibit 
two absorption bands a strong band in the NIR region corresponding to electron oscillations 
along the long axis of the rod, referred to as the longitudinal band, and a weak band in the 
visible region corresponding to electron oscillations along the short axis of the nanorod, 
referred to as the transverse band (see  Figure 1.1C and 1.1D below).[14] The longitudinal 
absorption band wavelength can be precisely tuned to any desired wavelength in the NIR 




Figure 1-1: Characterization of Gold nanorods: 
(A) TEM images with dimensions of 50×12 nm. (B)  are UV-Vis spectrum for AuNRs 
[21] 
 
1.2 The Previous Work of Gold Nanorods (AuNRs)-Assisted Plasmonic 
Photothermal Therapy (PPTT) 
    In 2006, our group (El-Sayed’s group) demonstrated for the first time highly effective 
and selective photothermal cancer therapy using Au NRs through in vitro studies [3]. 
Results showed that Au NRs functionalized with the epidermal growth factor receptor 
(EGFR) antibodies specifically target EGFR-positive human oral cancer cells, as detected 
by dark field light scattering imaging (Fig. 2A and B). After exposure to a beam of focused 
NIR light (Ti: Sapphire laser, 800 nm, 10 W/cm2, 4 mins), the two types of cancer cells 
were destroyed (dead cells are shown in blue color) without affecting the normal cells 
(Figure 1-2C). Cells displayed no loss of viability in the absence of Au NRs at laser 
intensities as high as 100 W/cm2. The success of Au NR-assisted PPTT has later been 
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reported on other cell lines. Compared to gold nanoshells [14], the energy threshold for 
effective treatments using Au NRs is lowered by three times.  
It has been shown that the tumor uptake of EGFR-targeted Au NPs is 10-fold greater than 
that of non-targeted particles after systemic delivery [20]. In addition, the targeted particles 
are internalized into the EGFR-positive tumor cells while the non-targeted particles remain 
in the tumor interstice. These facts strongly suggest that targeted AuNR would offer greater 
success in PPTT of cancer compared to non-targeted ones. 
 
Figure 1-2: Gold nanoparticles differentiate between the cancer and healthy cells 
(A) Dark field light scattering images of anti EGFR/Au nanospheres after incubation 
with normal and two types of head and neck cancer cells for 30 min at room 
temperature. (B) Light scattering images of anti-EGFR/Au nanorods after incubation 
with cells for 30 min at room temperature. (C) Selective photothermal therapy of 
cancer cells with anti-EGFR/Au nanorods incubated. The circles show the laser spots 
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on the samples. At 10 W/cm2, the HSC and HOC malignant cells are obviously 
injured while the HaCat normal cells are not affected [3].  
    In 2008, our group showed the feasibility of the treatment of cancer tumor in mice using 
a cancer xenograft mouse model [51]. Therapeutic efficiencies were examined for both 
intratumoral and intravenous (i.v.) injections. Following i.v. injection, Au NRs accumulate 
in tumors from the bloodstream by the enhanced permeability and retention (EPR) effect, 
which results from the leaky, defective architecture and impaired lymphatic drainage of the 
tumor tissue. The existence of the nanorods in the tumor was confirmed by NIR imaging. 
Tumor growth was significantly inhibited ( 
Figure 1-3) after exposure to low dose of NIR light (diode laser, 808 nm, 1-2 W/cm2, 10-
15 mins), with higher efficiency by direct injection because of the higher concentration of 
Au NRs that can be deposited in the tumor volume. Thermal transient measurements 
showed that the temperature increased by over 20 oC, and was thereby capable of inducing 
efficient tumor destruction. Recently, Bhatia and co-workers conducted similar studies on 
a melanoma cancer (MDA-MB-435) xenograft [51]. The results show that single i.v. 
injection of PEGylated AuNRs enables complete eradication of all irradiated tumors in 







Figure 1-3: Efficacy of PPTT on mice 
(A) NIR transmission images of mice prior to PPTT treatments. Inset shows intensity 
line-scans of NIR extinction at tumor sites for control, intravenous, and direct 
administration of pegylated gold nanorods. Control mice were interstitially injected 
with 15 lL 10 mM PBS alone, while directly administered mice received interstitial 
injections of 15 lL pegy- lated gold nanorods (ODk=800 = 40, 2 min accumulation), 
and intravenously administered mice received 100 lL pegylated gold nanorod 
(ODk=800 = 120, 24 h accumulation) injections.22 (B) Average change in tumor 
volume for HSC-3 xenografts following near-infrared PPTT treatment by control, 











1.3 Motivation for The Thesis/Challenges of Current PPTT 
     Since the PPTT could be a good alternative for treating cancer, it is very promising to 
improve the PPTT, to recognize the challenges and overcome them. 
 
1.3.1 Designing new AuNRs synthesis methods for producing a new AuNRs size 
with homogenous yield, then optimize the best dimensions of the AuNRs that 
can increase the PPTT efficacy 
    Of all the plasmonic AuNPs developed, gold AuNRs exhibit the most ideal NIR 
absorption cross section [23] the need demonstrates extremely efficient AuNRs to be the 
best for NIR photothermal heat conversion [19]. The size and shape are the primary factors 
that determine their catalytic, optical and surface activity, and photo-thermal properties of 
the gold nanoparticles [14]. This is especially important when the nanoparticles are rod 
shaped with different aspect ratios (length/width) [24]. When comparing the different 
AuNRs structures in terms of their application in PPTT, the most important plasmonic 
properties to consider are the absorption cross section, absorption efficiency, and thermal 
transduction per particle.  
     The most common size of AuNR utilized for use in successful PPTT now is over 40 nm 
in length and 10 nm in diameter, with a longitudinal plasmon resonance around 800 nm, 
synthesized by seed-mediated method. Since the accumulation and toxicity of smaller 
AuNRs （diameter lower than 10nm ） in the tumor interstitial and the organs of the 
reticuloendothelial system (RES) could be more ideal than that of the larger AuNRs. Also, 
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as previously shown theoretically by Jain et.al., plasmonic absorption becomes dominant 
as the nanoparticle size is decreased [25]. In the in-vivo studies in animal models, complete 
clearance of these nanoparticles was not accomplished and was retained especially in the 
liver and spleen [26]. That gives more evidence that the smaller AuNRs might enhance 
nanoparticle clearance. Therefore, the smaller size AuNRs could be more favorable to use 
in PPTT. 
    More specifically, the extinction of the AuNRs increases with the size of the AuNRs, 
while the contribution of scattering also increases, essentially decreasing the absorbance: 
scattering ratio as the AuNR size increases. This ultimately suggests that as the particle 
size decreases, the absorbance: scattering ratio increases, allowing for greater photothermal 
heat conversion and therefore potentially enhancing PPTT efficacy with decreased particle 
size. Another plasmonic property associated with photothermal heat conversion is the 
electric field around the AuNRs. It has previously been shown that excitation at the 
plasmon wavelength creates very strong electromagnetic fields, [27] and the field strength 
trends with absorbance, not scattering or extinction [28]. Since the field strength is derived 
from absorbance, not scattering, greater absorbance with smaller AuNRs would indicate a 
stronger field, which in turn would result in greater photothermal heat conversion and, 
again, enhanced PPTT efficacy. 
     In the synthesis of AuNRs, control over these properties has been one of the most 
important and challenging tasks. Different methods are utilized to synthesize different 
shapes of gold nanoparticles. In general, for the synthesis of gold nanorods using 
surfactants, three approaches are used: electrochemical, ultraviolet irradiation 
photoreduction,[29] and the seed mediated growth methods [30]. In the latter method, 
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cetyltrimethylammonium bromide (CTAB) has proven to be an effective surfactant in gold 
nanoparticle preparation [43]. Gold nanorods have been produced with a width greater than 
10 nm, and lengths of about 50 nm depending on the silver ion content [41]. A seedless 
growth technique was previously published which described the purpose in using their 
synthetic scheme to produce gold nanorods in a gram scale.  Jana’s method produced gold 
nanorods that ranged in size from 4-50 nm [31]. The limitation of Jana’s method was the 
low monodispersity of gold nanorods and formation of a large concentration of spherical 
nanoparticles. This makes the use of the resulting small gold nanorods useless for 
biological work.  
     Ali et al [21] have developed a new a synthetic seedless technique, previous limitations 
have been overcome by adjusting the pH of the growth solution while utilizing NaBH4 as 
the reducing agent to produce small monodisperse widths lower than 10 nm [21]. 
     The need to study a theoretical, and experimental comparison between different sizes 
of AuNRs to find which size could be the most effective size to be used for the PPTT 
applications. In Chapter 3.1 we studied deeply which is the most effective size the AuNRs 
that could effectively increase the heat generation, which is more favorable in PPTT [32]. 
Furthermore, in chapter 3.2, 3.3 we synthesized a new dimension of the AuNRs also a new 
shape we called gold nanobones (AuNBs), which have edges by the end, showed a novel 
plasmonic properties for PPTT or surface enhanced raman spectroscopy (SERS) 
applications.   
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1.3.2 Improving the PPTT mainly depends on enhancing the AuNRs selectivity to 
the cancer cells compared to the healthy ones. Thus, increasing the efficacy 
of PPTT by increase cellular uptake of AuNRs 
    Effective internalization of AuNRs in tumor tissue is another significant challenge [33-
36]. In PPTT, two selective targeting methods can be applied: 1) active targeting and 2) 
passive targeting. In active targeting, specific surface modifications (ligands) of NPs can 
recognize and bind to the receptors on the surface of cancer cells. On the other hand, in 
passive targeting, NPs are usually injected directly to solid tumor and accumulate inside 
the tumor mainly via the enhanced permeability and retention effect. The enhanced 
permeability and retention effect has been regarded as a primary rationale for the delivery 
of NPs due to the leaky tumor blood vasculature. To increase the uptake of AuNRs, surface 
modification with ligands that assist endocytosis or block exocytosis has been used. 
Chapter 4, we aim at new surface modifications on AuNRs for greater nanoparticle 
retention inside cancer cells .  
 
1.3.3 To optimize the PPTT conditions, all the drawbacks of the PPTT need to be 
understood, moleculare mechanisms of the PPTT are needed 
     Despite the operational success of PPTT, the molecular mechanisms associated with 
PPTT-induced apoptosis remain largely unknown or under dispute. We observed PPTT 
induce apoptosis initiate through heat shock proteins while several reports indicate it is 
mediated by the mitochondrial apoptotic pathway via Bid activation and caspase 3 activity. 
[18-19]. Although the surface enhanced Raman spectroscopy (SERS) reports on the real-
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time, biomolecular dynamics in the microenvironment associated with the PPTT process, 
SERS spectra from cells are incredibly complex, reflecting overlapping signals from a 
variety of proteins and metabolites that are difficult to assign to individual species. It has 
been reported, for example, that the 1000 and 1580 cm-1 peaks showed significant increase 
during cell apoptosis [8, 20] with great debate in their assignment [21]. Per published 
literature, the 1000 cm-1 signal has been assigned to phenylalanine,22 while a different 
report assigned it to tryptophan [21]. Furthermore, it has been argued8 that these SERS 
signals reflect changes in protein structure, a topic still being intensively debated. One 
hypothesis states that the 1000 cm-1 signal is indicative of the exposure of protein 
hydrophobic rings following conformational changes, [8] while others report that the 
protein conformation change induced by adding methanol or SDS [23] or increasing 
temperature [9] does not alter the intensity of the 1000 cm-1 peak, therefore contradicting 
the hypothesis that this signal is associated with alterations in protein conformation.  
    Herein, we monitored the SERS spectral signature in vitro during apoptosis as a function 
of PPTT exposure time. We also performed metabolomics and proteomic studies on cell 
lysates under the same exact PPTT conditions. Integrative multi-omics network analysis 
revealed specific alterations that explain the underlying changes in SERS spectral data, 
demonstrating the power of combining SERS with MS for studying cellular processes 
following PPTT.  
    To better understand the cellular responses to PPTT, more systematic studies in vivo are 
required. Most previous reports concerning the mechanism of PPTT were only conducted 
in vitro [60] and focus on a single protein or pathway. Several mechanisms have been 
proposed in vitro. Pérez-Hernández et al reported that apoptosis during PTT using gold 
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nanoprisms is mediated by proteins Bak and Bax, through the activation of protein Bid 
[60]. To better understand the mechanisms involved, in Chapter 4.3 systematic analysis 
such as mass spectrometry (MS)-based proteomics is necessary SERS has explored the 
dynamic events that report in the cells [61]. 
1.3.4 The nano-bio interaction is still not clearly addressed. As an example, how 
the AuNPs could impact the mechanical properties of the cancer cell, can the 
AuNPs inhibit cancer cell migration?  
     Metastasis, a process in which cancer cells migrate to other locations of the human body, 
is responsible for most cancer-related mortality. It usually begins with local invasion to the 
surrounding tissues, followed by intravasation into the lymph and blood microvasculature 
before the cancer cells finally colonize within the microenvironment of other locations in 
the patient’s body [39, 62]. Many treatments for inhibiting metastasis are based on drugs 
that target specific proteins that promote the cell migration process; however, past attempts 
to develop anti-metastasis drugs have not been efficacious in clinical trials [63]. Moreover, 
in many cases, the anti-cancer drugs that target specific proteins might lose their efficacy 
after several months of treatment due to protein mutations, thus conferring drug resistance 
to cancer cells,[64] and could also cause side effects on healthy tissues [65]. 
    Recent advances in nanomedicine provide us with a great opportunity to avoid the 
drawbacks of current drugs [14, 64, 66, 67, 42, 68]. Nanoparticles have been widely used 
in cancer diagnosis and cancer therapy thanks to their intrinsic chemical, physical and 
optical properties [42, 69-71]. Nanoparticles with proper surface modifications can target 
tumors selectively, [14, 72-75].  and their effects on cancer cell migration or metastasis 
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have drawn attention from many researchers [76, 77-78, 79]. In 2013, Murphy et al. 
reported that gold nanoparticles (AuNPs) with different surface charges and sizes can affect 
cancer cell migration [76]. In 2014, Chor Yong Tay et al [78]. found that after incubation 
with nano-ceramics, such as titania, silica and hydroxyapatite, cells showed significantly 
impaired wound healing capability by disruption of the intracellular microtubule assembly. 
In the same year, Zhou et al [79]. showed that gold nanorods (AuNRs) coated with bovine 
serum albumin (BSA) exhibited reduced cell migration and invasion by impairing ATP 
synthesis, which subsequently inhibits the F-actin cytoskeletal assembly and decreases 
cancer cell migration [79]. Arvizo et al. used non-specific targeted gold nanospheres 
(AuNSs) to inhibit cancer cell migration by abrogating MAPK signaling and reversing the 
epithelial-mesenchymal transition [16] For most of the related works, non-specific targeted 
nanoparticles have been used, for instance, Zhou et al [79] used BSA coated AuNRs that 
showed inhibitory effects on cancer cell migration, but the high concentration of AuNRs 
(50-200 µM) that they used might be an obstacle for clinical usage.  To maintain the 
nanoparticle effect on slowing the cancer cell migration with a minimized amount of 
nanoparticles, the intracellular locations of nanoparticles could be an important factor to 
consider. It is thus promising to design nanoparticles that can target specific intracellular 
regions to enhance the inhibition of cancer cell migration.  
 
    Mechanical stiffness of cancer cells has been shown to grade metastatic potential in 
patient tumor cells,[80] as well as in cultured cancer cell lines [81-82] Lower stiffness is 
related to more invasive cells [83] In eukaryotic cells, the nucleus contains most of the 
cell's genetic material and controls cell activities by transcriptional regulation. It is the 
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largest and stiffest organelle in most cells and largely determines the cell migration ability 
[84-86] Lamin A/C (LMNA) proteins are an important factor in nuclear stiffness. They 
form a dense protein network that connects the nuclear membrane and chromatin structures 
on the interior of the nuclear membrane. Recent studies have shown that nuclear lamin A 
protein scales with tissue stiffness [87] and generate a barrier to cells migrate through three-
dimensional (3D) environments.88 It is shown that lamin A/C deficiency hampers cell 
mechanics, polarization, and migration [89-90]. 
In chapter 4.4 and 4.5, targeted AuNPs were used to locate the AuNPs to the cells, because 
of their specific physical and chemical properties and better biocompatibility than other 
nanomaterials such as nano-ceramics or silver nanoparticles. By targeting and locating the 
AuNPs to the cell in a manner to modulate the stiffness of its nucleus, we could improve 
the inhibition effect on cell migration. In our experiment, we used three ligands, methoxy-
polyethylene glycol thiol (PEG) for 
 
1.3.5 Toxicity of gold nanoparticles to the biosystem is a major concern, there is 
still a lack of systematic long term studies. This will decide whether the AuNRs 
can go for clinical trials or not 
    The safety profile of AuNRs remains largely undefined [91]. Gold is a chemically 
inert material. Therefore, it is generally considered biocompatible and has been used in 
some routine clinical practices for many years, e.g. in treating rheumatoid arthritis. Several 
studies have reported no significant short term toxicity of AuNPs (1 day to 3 months) [92-
94] . You et al [95] have reported a lack of both acute and chronic toxicity over 3 months 
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following multiple injections of PEGylated hollow gold nanospheres in mice. However, 
other studies have contradictorily reported that the presence of nanoparticles causes 
cytotoxicity such as actin stress [96], induces apoptosis, or causes inflammation in mouse 
livers [97]. Some studies have explored how gold nanoparticle exposure (aside from any 
heat-induced effects) impacts cells at the molecular level, affects pathways such as 
mitochondrial oxidative phosphorylation, and causes oxidative stress [98]. The dose-
dependent effects of gold nanoparticles on biological systems have been widely 
recognized99. A high dose of NPs or the desorbed surfactants from their surface could 
result in “toxic” behavior [100] Of concern for AuNRs is the incomplete purification of 
surfactant CTAB, which may cause cytotoxicity [101]. Therefore, the optimal dose and 
purification of AuNRs is of great importance in minimizing toxic effects. The preservation 
of spherical AuNPs without complete clearance over six months has been reported [102]. 
You et al. [95] also reported slow clearance of gold nanoparticles from the body during the 
3-month period. Such body deposition of metallic NPs over a long-time period raises 
significant concerns regarding their long-term safety. Therefore, a comprehensive 
investigation of the organ uptake, biodistribution, longer-term fate and toxicity of AuNRs 
is essential to fundamentally understand their in vivo biological interactions and to use this 
knowledge to minimize their toxicity [93].  In chapter 5.1 we reported a long term for (15 
months) toxicity on xenograft mice. Our data shown that the AuNRs remains in the liver 




1.3.6 Most of PPTT studies have been performed in vitro or in induced tumors, 
which do not exactly represent their human equivalents. There is a need to 
apply PPTT in natural tumors in animals, this might give us better application 
of PPTT to humans: 
    One of the novelty points of this study was the extension of AuNRs-assisted PPTT to 
natural tumors in animals larger than ones used in any previous study. Mammary gland 
tumors of epithelial origin are very common neoplasms of canines and felines. The 
similarity of molecular and biological machinery of canines/felines and that of humans 
suggests the suitability of using mammary tumors of these animals as a model for the study 
of human mammary tumors. (23-25) In chapter 5.3 We tested PPTT on canine and feline 
natural mammary gland tumors. To minimize side effects, we optimized PPTT dosages to 
enable a slow cancer cell apoptosis. Using our optimized protocol, adjusting the 
photothermic temperature to 44°C, we were able to ablate 100% of tumors in seven animals 
without any relapse or toxicity effect after 1 year from the tumor treatment.(103) 
 
1.3.1 Furthermore, modulating PPTT conditions to generate cancer cell apoptosis 
(a favorable death pathway)  
    PPTT can induce cell death mainly via two pathways: necrosis and apoptosis [37]. 
During necrosis, the heat induced by PPTT (if above 50 oC) could disrupt the plasma 
membrane, causing the cellular components to leak out and cause inflammation, metastasis 
[38], and harm to surrounding normal tissues. Apoptosis is a programmed cell death 
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pathway that triggers cancer cell death [39-40], attenuates inflammatory activities, and is 
regarded as a “cleaner” process of cell elimination.  
    Skewing the response toward apoptotic cell death rather than necrotic death will 
minimize inflammatory responses that may promote the damage or destruction of healthy 
tissues. Therefore, modulating PPTT to trigger apoptosis would be more favorable in 
clinical settings [41-42]. 
     It has been reported that different intracellular locations of AuNRs or laser strength 
regulate the switch between necrosis and apoptosis in PPTT [43-44]. However, lower 
heating would decrease the efficacy of PPTT, and might not be very effective for cells that 
exhibit thermo-resistance. Therefore, it is important to know the major players that 
contribute to thermo-resistance. Based on this, we can develop new PPTT strategies that 
prevent the thermo-resistance and enhance apoptosis. Heat induced apoptosis can also be 
resisted by a class of proteins called Heat Shock Proteins (HSPs) [45-48]. When binding 
to denatured proteins or partially unfolded intermediates, HSPs prevent their aggregation 
and initiate protein refolding [49-50]. Interestingly, PPTT induces the expression of most 
HSPs [51-53], and multiple studies have shown the importance of the HSP in enabling 
cancer cells to resist heat-induced apoptosis [54-59]. In chapter 4.2 We fabricated novel 
HSP70 inhibitor (Quercetin) conjugated AuNRs and compared to non-conjugated AuNRs, 
the new conjugate displayed a superior ability to combat thermo-resistance, causing a 
higher percentage of cells to undergo apoptosis. Therefore, AuNRs act as integrally in 
delivering of Quercetin to cancer cells as well as acting as an inducer of apoptosis-
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CHAPTER 2. IMPROVING AND UNDERSTANDING THE 
PLASMONIC PHOTOTHERMAL THERAPY IN VITRO 
2.1 Fabrication and Optical Properties of Different Sizes of Gold nanorods [1-3] 
    Anisotropic nanoparticles, such as rods, are an evolution of the nanocrystal system as 
new properties may emerge due to unexpected thermodynamic geometries.  The unique 
catalytic performance of anisotropic nanoparticles. Great studies in the field of 
nanotechnology have made the synthesizing of gold nanorods with a desired aspect ratio 
possible. Controlling the precision of gold nanorods’ (AuNRs) size and shape remains 
challenging as it adds more optical, catalytic and mechanical character to the AuNRs. The 
synthesis of variant sizes or shapes of AuNRs has shown more interesting results, which 
was often not easy to achieve. Herein, we developed a new synthesitic technique, named 
seedless growth technique.  In this method, the pH was found to play a crucial role in the 
monodispersity of the nanorods. Instead of seeds, the concentration of NaBH4 in the growth 
solution was adjusted to control the reduction rate of the gold ions, smaller gold nanorods 
were produced. In addition, we used anionic surfactant, 5-bromosalicylic acid as a unique 
co-surface capping competitor with cetyltrimethylammonium bromide (CTAB) to guide 
the particle geometry evolution during nanorod overgrowth. The 5-bromosalicylic acid 
plays a role as a co-surfactant in a highly controllable and selective manner. The 
concentration of the 5-bromosalicylic acid played a key role in the development of the bone 
shape. In conclusion, the preparation of gold nanorods with different sizes and shapes using 
the the optimizied seedless method was found to be dependent on the NaBH4 concentration 
used in the growth solution. Based on the results, the size and shape of the formed AuNPs 
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are dependent on the reduction rate of the gold ions in the solution. By using the seedless 
growth method, we have succeeded in the preparation of monodisperse AuNRs and AuNBs 
with low dimensions and aspect ratios, which enables the AuNRs and AuNBs to absorb in 
the nearinfrared radiation for we found to be useful for many catalytic activities: such as 
surface-enhanced Raman spectroscopy as an ultrasensitive spectroscopic tool with unique 
time-resolving and molecular finger-printing capabilities, for studying the cellular changes. 
In addition, potential use in in vivo photothermal therapeutic applications. 
 
 
2.1.1 Introduction:  
    In recent years, gold nanoparticles (AuNPs) have been utilized in various fields. The 
interaction of light with the conduction band electrons gives rise to their collective 
oscillation which is known as localized surface plasmon resonance (LSPR) [3-4].  Within 
the realm of AuNPs, gold nanorods (AuNRs) show distinct physicochemical properties. 
AuNRs have two peaks, the transverse and longitudinal peaks. The latter could absorb near 
infrared light and convert it into heat rapidly and efficiently by non-radioactive processes 
such as electron-electron interactions and electron-photon interactions [3, 5-10]. The seed 
mediated method of synthesis is preferred to optimize the aspect ratios of AuNRs. In the 
seed mediated method, gold ions (Au+) are guided by silver ions (Ag+) in the presence of 
cetyltrimethylammonium bromide (CTAB), a surfactant template used to produce 
longitudinal and transverse dimensions of cylindrical AuNRs. Constricted control over the 
AuNRs’ aspect ratios allows one to fine-tune the plasmon resonances over a broad spectral 
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range that spans the entire visible and near-infrared regions through either the first (650-
900 nm) or (900-1200 nm) second window [5]. The AuNRs’ tunability and their 
interactions with light yield unique absorption and scattering properties, which combined 
with the surface modification, endows AuNRs with significant potential for broad 
applications. In the synthesis of AuNPs, controling over these properties has been one of 
the most interesting and challenging tasks. The ability to control the surface structure of 
the AuNR with atomic precision while specifying the AuNR aspect ratio is crucial. The 
crystal facets exposed on the AuNRs determine the dynamic interaction between AuNRs 
as well as the interaction between the AuNR and the surface ligands. Furthermore, precise 
facet control allows for the opportunity to functionalize the nanorod surfaces with a desired 
geometry in a site-selective manner, enabling the molecularly guided assembly of AuNRs 
for spectroscopic applications [11]. This is especially important when the nanoparticles are 
rod shaped with overgrowth at their edges, which creates a hot spot for electrons. A 
nanoparticle with this feature is beneficial for generating a strong surface-enhanced raman 
spectroscopy (SERS) signal, which is sensitive to the shape (edges), size of the particles, 
and the nanoparticle assembly. A recent synthesis method that obtained AuNRs with 
variant atomic distribution at the edges was shown to be helpful for enhancing the SERS 
peaks [12]. However, this method involved cupper in the synthesized particles, which could 
be toxic for the bio-system. In addition, fabrication of small AuNRs that lower than 8 nm 
is not easy to achieve. Herein, we show our new seedless growth technique and include 5-
bromosalicylic acid as an anionic surfactant can obtain different sizes, shapes of AuNRs 
with narrow distribution.  
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2.1.2 Experimental methods  
2.1.2.1 Materials and equipments 
     HAuCl4, NaBH4, AgNO3, ascorbic acid, CTAB, 5-bromosalicylic acid, were purchased 
from Sigma-Aldrich. Hydrochloric acid was purchased from the VWR Company. 
Characterization was carried out using a Cary 500 UV-Vis spectrometer and a JEOL 100 
CX transmission electron microscope. An axial inductively coupled plasma (ICP) atomic 
emission spectrometer machine was used to determine the concentration of AuNPs in the 
solutions. A minimum of three ICP measurements were made for each sample. 
 
 
2.1.2.2 Synthesis of Gold Nanorods using seed-mediated growth [1] 
    The seed solution was created with HAuCl4 (0.025 mL, 0.1 M) in an aqueous solution 
of CTAB (10 mL, 0.1 M). A freshly prepared, ice-cold NaBH4 solution (0.6 mL, 0.01 M) 
was then added into the mixture under vigorous stirring conditions for 2 minutes. The 
solution was left to age for 2 hours. The growth solution was prepared using the seed 
mediated method.  Briefly, HAuCl4 (100 μL, 0.1 M) was added to CTAB (20 mL, 0.1 M) 
and 80 μL of 5-bromosalicylic acid (0, 0.001 μL, 0.01 M). Then, 550 μL ascorbic acid 
(0.1M) was added, followed by gentle mixing to form the growth solution. Varied volume 
of seed solution (8-80 μL) was then added to the growth solution and allowed to react for 
6 h. 
2.1.2.3 Synthesis of gold nanobones by seed-mediated growth [1] 
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    Gold nanobones with variant lengths and widths were synthesized by following the seed-
mediated protocol.  In the first step, the seed nanoparticles were synthesized by adding 5.0 
mL of HAuCl4 (1.0 mM) to 5.0 mL of CTAB (0.2 M) followed by the addition of ice-cold 
NaBH4 (0.6 mL, 10.0 mM). The solution was then stirred for 2 min.  In the second step, 
(80-240 µL) of seed solution was added to the growth solution containing 1 mL of 5-
Bromosalysilice acid (4.6 mM), 100 mL of HAuCl4 (1.0 mM), 100 mL of CTAB (0.2 M), 
5 mL of AgNO3 (4.0 mM), HCl (160 μL, 37%) and 1.4 mL of ascorbic acid (78.8 mM). 
After the injection of seed solution, the growth solution kept undisturbed for 6 h. The 
resultant CTAB stabilized AuNRs were purified by centrifugation and redispersion in 
deionized (DI) water. 
2.1.2.4 Synthesis of gold nanorods/ nanbones by seedless mediated growth [1-3] 
    We followed our early reported procedure [1-3]. Briefly1 mL of 5-Bromosalysilice acid 
(4.6 mM) and 50 mL of HAuCl4 (1.0 mM) were added to 100 mL of CTAB (0.2 M), 5 mL 
of AgNO3 (4.0 mM) and HCl (160 μL, 37%). Then, 700 µL of ascorbic acid (78.8 mM) 
was added, followed by immediate injection of ice-cold NaBH4 (15-150 µL, 10.0 mM), the 
higher concentration is the lower sizes were obtained. The solution left undisturbed for 6 
h. 
2.1.2.5 Using centrifugation to concentrate and prepare monodisperse nanoparticles. 
    The solution was centrifuged for 15 min at 14,500 rpm. The supernatant was removed, 
and the solution was then spun down again. The precipitate was dispersed in deionized 




2.1.3 Results and discussion  
The seed solution is usually prepared under chemical supersaturation, as required for the 
rapid nucleation of particles in the growth solution. The growth solution is used in a two-
step reduction process. The first reduction occurs by the reaction with ascorbic acid (Au3+ 
→Au+). The second reduction (Au+→Au0) requires a seed to act as a catalyst. This results 
in gold nanorods in the presence of the Ag+ ions. To achieve gold nanobones (AuNBs), the 
5-bromosalicylic acid is required to facilitate particle overgrowth while NaBH4 is used as 
a reducing agent in the growth solution to enhance the reduction of Au+ Au0. The 
resulting gold nanorods have an average width of 25 to 2.5 nm in another setting. 
2.1.3.1 The influence of 5-bromosalicylic acid concentration on the bone shape 
distribution: 
Different molar ratios of 5-bromosalicylic acid to HAuCl4 were used in the growth 
solution. After the first reduction where ascorbic acid was utilized in the seed mediated 
method, 5-bromosalicylic acid was added, which plays an essential role in growth. The 
nucleation of the nuclei and the growth of these nuclei happen under high chemical 
supersaturation. These conditions ensure the generation and immediate growth of the gold 
nuclei and rapid overgrowth at the edges. A UV-Vis spectrometer and a transmission 
electron microscope were used to track the rod to bone evolution in shape and size. Separate 
growth solutions with different molar ratios of 5-bromosalicylic acid to HAuCl4, as shown 
in (Figure 2-1A &Figure A2), has two plasmon bands. The transverse plasmon band has 
an absorption peak of around 525 nm and is nearly identical for each solution. However, 
the longitudinal plasmon band, which is attributed to the rod or bone shape of the particle, 
appears at a longer wavelength in each solution. Increasing the concentration of 5-
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bromosalicylic acid in the separate growth solutions prompted the longitudinal peaks to 
red shift.  
 
2.1.3.2 The influence sodium borohydride and seed concentrations on producing 
different rods with the same length but different widths:  
 The synthesis of three different sizes of AuNRs with the same length but variant widths 
comparing the absorbance spectra in sample (Figure 1-2) revealed that they have the 
different absorption. It has been observed that by increasing the concentration of 5-
bromosalicylic acid in the growth solution, the length of the rod increased, which is evident 
from the increasing longitudinal surface plasmon (LSP) intensity in comparison to the 
transverse surface plasmon (TSP) intensity. (Figure 2-2B & Figure A.1)  
2.1.3.3 The influence of 5-bromosalicylic acid, sodium borohydride and seed 
concentrations on producing different rods with the same length but different 
widths:  
 
By repeating the above experiment in the presenece 5-bromosalicylic acid with 
increasing seed solution concentrations, the effect of seed size on the growth solution was 
studied. Three separate growth solutions with different molar ratios of 5-bromosalicylic 
acid (HAuCl4) were used in the growth solution, as described above.  Figure 2-3A shows 
the UV-Vis-NIR absorption spectra with different molar ratios. We determined the FWHM 
for the longitudinal band of the samples prepared at the variant addition of the 5-
bromosalicylic acid, all the samples showed very small FWHM (Figure 2-3) was found 
for the sample prepared by adding 0.001 M of 5-Bromosalicylic acid.  The 5-
 56 
bromosalicylic acid in the solution plays a crucial role in both the reduction of Au3+  Au+ 
as well as Au+  Au0. The homogeneity of the bones increased also increased alongside 
the increasing concentration of 5-bromosalicylic acid. The resulting AuNBs were small 
and the sample was monodisperse as shown in the TEM (Figure 2-3B-D). The 
homogeneity for the produced nanorods increased.  
2.1.3.4  Assembling Pattern Comparing the AuNBs with the AuNRs:   
Recently, electrostatic-force-based assembly of nanoparticles has been proposed as a 
general, precise, and reliable methodology.  In the most direct type of electrostatic-force-
based assembly, charge patterns are created by scanning-probe or micro contact charging 
techniques onto electret materials via electron- or hole-tunneling processes. As the electret 
materials, can retain electric charge or polarization for a long time, these charge patterns 
can be used as templates for assembling charged or polarizable nanoparticles. As shown in 
figure 2-4, the AuNBs shows great assembling from edges when diluted in water. We have 
observed the from the UV-vis in figure 2-4, that a new longitudinal plasmon peak appears 
in the second window near IR after an hour of assembling in water. This introduce new 
catalytic properties of the AuNBs.  
 
2.1.3.5  Comparison between Gold Nanorods of the Same Aspect Ratio Prepared by 
Seedless and Seeded Methods: 
 Different parameters can influence small gold nanorods growth such as silver ions content 
on the growth solution. By adding 270 μL of 4.0 mM AgNO3 to the seeded and seedless 
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growth solutions nanorods with the same aspect ratios, but with different sizes, were 
obtained. The longitudinal surface plasmon absorbance of the nanorods that was prepared 
from the two methods is nearly 800 nm (Figure 2-5). As shown in the TEM images, the 
gold nanorods obtained using the seeded method showed average particle dimensions of 
54.0 × 11.2 nm. The gold nanorods prepared by seedless method have average particle 
dimensions of 25.0 × 5.2 nm (Figure 2-5). The aspect ratio for both sets of nanorods is 4.8 
± 0.6. Table 2 shows a comparison between the extinction coefficients for the two gold 
nanorods. The extinction coefficient is smaller for the gold nanorods prepared using the 
seedless method than those prepared using the seeded technique. The ratio of the extinction 
coefficients (seeded/seedless) having the same aspect ratio (4.8) is ∼26 and a volume ratio 
of ∼10. Obviously, the two ratios are not the same. It is possible that as the nanoparticle 
gets smaller, its surface is more defective giving rise to surface scattering of the coherent 
motion of the conduction band electrons. This leads to weaker plasmonic fields and thus 







Figure 2-1: The UV-Vis-NIR absorption spectra with different additions of 5-bromo 
salicylic acid.  
The synthesis media was maintained at a constant of 8 µL of seed solution D) Rod 
shaped E) Bone shaped, F) Semi-bone shape. Samples from (G-I) synthesis media was 
maintained at 12 µL of seed G) Rod shaped, H) Semi-bone shape, I) Bone shape. 
Samples (J-K) maintained at 80 µL of seed., J) Rod shaped, K) Rod shaped, L) Rod 
shaped. The three additions of 80 µL of 5 bromosalicylic acids at different 
concentrations   0 (A), 0.0001 µL (B), and 0.001 µL (C). Gold nanoparticles TEM 
images showing the effect 5 bromosalicylic acid on the AuNRs/AuNBs distributions. 
The three sample (D-F) are prepared at the molar ratios of the effect 5 bromosalicylic 
acid: Au. While the synthesis media was maintained at a constant of 8 µL of seed 
solution D) Rod shaped with dimensions of 64 x 24 nm, E) Bone shaped with 
dimensions of 65 x 31 nm, F) Semibone shape with dimensions of 60 x 24 nm. Samples 
from (G-I) synthesis media was maintained at 12 µL of seed G) Rod shaped with 
dimensions of 59 x 18 nm, H) Semi-bone shape with dimensions of 57 x 16 nm, I) Bone 
shaped with dimensions of 58 x 21 nm. Samples (J-K) maintained at 80 µL of seed., 
J) Rod shaped with dimensions of 36 x 6 nm, K) Rod shaped with dimensions of 36 x 




Figure 2-2 AuNRs with the same length but variant widths: 
  A) UV-Vis absorbance spectra of three different sizes of AuNBs. B) TEM of small 
bones (Length 60±2 x Width 15±0.5 nm)., black). C (Length 62±4 x Width 24±2 nm., 
red). and D) (Length 60±6 x Width 6±1 nm).  CTAB- stabilized AuNBs, The SPR 




Figure 2-3 AuNBs with the same aspect ratio: 
 A) UV-Vis absorbance spectra of three different sizes of AuNBs. B) TEM of small 
bones (Length 15±2 x Width 4±0.5 nm)., black). C (Length 60±4 x Width 16±2 nm., 
red). and D) (Length 20±2.5 x Width 5±1 nm).  CTAB- and 5-bromosalusilic acid 





Figure 2-4. Comparison between Au nanorods and Au nanobones grown: 
A) UV-Vis-NIR absorption spectra of AuNBs showing self-assembling in water with 
time. The spectra clearly show that the transverses peak at 760nm decreases and a 
new peak at 950 nm develops with time. B) top, TEM images shown above are fromor 
the AuNBs after they were left in deionized water with respect to time: 2,10,20, and 
60 minutes. B) bottom TEM of AuNRs showing different assemebly in water. C) High-
resolution STEM projections model of the facet transition from rods to bones shape, 
oriented along the [220] direction    
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Figure 2-5: Two different sizes of AuNRs with the same aspect ratio: 
 A) UV-Vis absorbance spectra of the large (Length 72 nm, black) small (Length 25 
nm, black) CTAB-stabilized AuNRs, (B) TEM of large rods (Length 72±7 x Width 
19±4 nm) small rods Length 25±2 x Width 5±1 nm). The SPR peaks of the large and 




2.1.4 Conclusion and Future Outlook   
Relatively small gold nanorods or nanobones with widths lower than 10 nm:  ranging 
from 2.5 in one setting and 5.5 nm in another setting with different aspect ratios were 
synthesized using a one-step seedless growth procedure. Seeds are necessary for large gold 
nanorods, but NaBH4 was used as a substitute in the seedless growth process.  The pH of 
the solution also plays an important role in the synthesis of nanorods. Decreasing the pH 
results to the decreases the rate of the reduction, which increases the growth time (if the 
concentration of NaBH4 has been optimized in the growth solution) and gives a more 
monodisperse solution. CTAB is an important contributor in controlling the gold nanorods 
dimension in seedless growth technique. Increasing the CTAB concentration produces rods 
with smaller size. The growth kinetics of the length and the width of gold nanorods can be 
controlled by changing the CTAB as well as the silver ion concentrations in the reaction 
mixture.  By increasing the amount of NaBH4 added to the solution in the absence of silver 
ions, smaller gold nanospheres were synthesized.  While the extinction coefficient is found 
to depend linearly on either the aspect ratio or the wavelength of the longitudinal plasmonic 
band for the large nanorods, it is found to be independent for the small nanorods. This was 
explained by the fact that the extinction band of the plasmonic nanoparticle is dominated 
by scattering processes, while for small nanoparticles they are determined by absorption 
processes. Each of these properties has different dependences on the size of the 
nanoparticle.  From conclusion and the fact that the extinction coefficient of the large rods 
are more sensitive to size than the small rods, that the scattering processes are more 
sensitive to size changes than absorption, as one expects. We have optimized a new gold 
 64 
nanoparticles synthesis technique, obtained variant sizes and shapes of AuNRs, and 
showed variend plasmonic properties for several potential applications.  
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2.2 Enhancing the Efficiency of Gold Nanoparticles Treatment of Cancer by 
Increasing Their Rate of Endocytosis and Cell Accumulation by Using 
Rifampicin [1] 
To minimize the toxicity of gold nanoparticles (AuNPs) in cancer treatment, we have 
developed a technique, which uses less amount gold NPs but increases the treatment 
efficiency. Rifampicin (RF) is known to enhance the multidrug resistance (MDR) by 
imprisoning higher concentrations of the drug inside the cancer cell. In this work, we have 
shown that RF-conjugated Au NPs can greatly enhances the rate as well as efficiency of 
endocytosis of nanoparticle hence their concentration inside the cancer cell. This is 
expected to decrease the demand on the overall amount of Au NPs needed for treating 
cancer and thus decreasing its toxicity. 
 
2.2.1  Introduction  
Cancer, often described as one of the most dreadful disease, remains as an important 
challenge across the world. Enhancing the efficiency of delivering anticancer drugs 
precisely to the cancer sites is critical for its successful treatment. [2, 3] Hence, ongoing 
cancer researchers are keenly focused on identifying innovative ways to enhance the 
targeting efficiency of targeting nanoparticles to elevate the rate of endocytosis hence to 
decrease the toxicity. Though nanotechnology-based methods have showed promising 
results in view of screening cancer cells [4-6] and targeted drug delivery, [7-9] it is still 
challenging to bypass the efflux of drug carrying nanoparticles through multidrug 
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resistance (MDR) mechanism [10-12] in cancer cells. In view of minimizing the toxicity 
during the gold NPs-based plasmonic chemotherapy, it is highly desirable to develop novel 
functionalized nanomaterials, which could effectively deliver the drug carrying 
nanoparticles into the cancer cells, without being accumulated outside the cells. 
Among the nanoparticles, gold nanorods (AuNRs) have been considered as an efficient 
drug delivery platform owing to their unique optical and photothermal properties. [7, 13] 
Though many molecules such as PEG PNIPAM, SiO2, etc. are well-known [2, 7, 14, 15] 
for passivation of AuNRs against its toxic effect and carrying the drug to the target cells, 
proteins are more convenient and efficient carrier system as they can accommodate more 
drug molecules per molecules and their biocompatible nature. [16, 17] The concept of 
plasmonic chemotherapy [18-21] using near-infrared (NIR) absorbing AuNRs carrying 
anticancer drug molecules as an efficient drug delivery vehicle has greater relevance in this 
regards as it can reduce the side effects of chemotherapy. Here, we introduce a novel 
multifunctional AuNR-based plasmonic chemotherapy platform, carrying rifampicin (RF) 
(an antibiotic used to treat infections, including tuberculosis), for efficient delivery of 
paclitaxel (Ptxl) carrying bovine serum albumin (BSA)-conjugated AuNRs into the cancer 
cells. Our study confirms that RF can act as a chemosensitizer to bypass the multidrug 
resistance [22, 23] in cancer cells and enhancing the efficiency of endocytosis of drug 
carrying nanoparticles into the cancer cells. Moreover, the fast endocytosis of the 
nanoparticels could be an attractive treatment modality, which could decrease the 
possibility of targeted nanoparticles being excreted through extracellular fluids during their 
intravenous administration.  
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As a drug carrier system, BSA has been used to conjugate AuNRs due to their excellent 
biocompatibility, low cost and presence of two primary drug-binding sites. [17, 24, 25] The 
conjugation of BSA with the AuNRs has been confirmed using various spectroscopic 
techniques (experimental details are given in the supporting information (SI) 1). For this 
study, we used three different nanoparticle systems such as spherical Au@Citrate 
nanoparticles (AuNSs) (~20 nm), small Au nanorods (sAuNRs) [26] (17 nm length, and 
3.5 nm diameter), and bigger Au nanorods (bAuNRs) (47 nm length and 10 nm diameter). 
Conjugations of BSA with these nanoparticles were obvious from their extinction spectra, 
as all the nanoparticles showed a distinct red shift in their absorption maxima after binding 
with BSA (Figure 2-6A-C). TEM images of each nanoparticle used in this study are also 
given in Figure 1 D-F. 
 
2.2.2  Methods and Experimental Methods  
 
2.2.2.1 Synthesis of Gold Nanorods (47 Nm Length and 10 Nm Width) by Seed-
Mediated Growth 
Gold nanorods (AuNRs) were synthesized by following the modified seed-mediated 
protocol of Nikoobakhat et al [27]. and Ali et al [26].  In the first step, the seed 
nanoparticles were synthesized by adding 5.0 mL of HAuCl4 (1.0 mM) to 5.0mL of CTAB 
(0.2 M) followed by the addition of ice-cold NaBH4 (0.6 mL, 10.0 mM). The solution was 
then stirred for 2 min.  In the second step, 240 µL of seed solution was added to the growth 
solution containing 100 mL of HAuCl4 (1.0 mM), 100 mL of CTAB (0.2 M), 5 mL of 
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AgNO3 (4.0 mM), HCl (160 μL, 37%) and 1.4 mL of ascorbic acid (78.8 mM). After the 
injection of seed solution, the growth solution kept undisturbed for 12 h. The resultant 
CTAB stabilized AuNRs were purified by centrifugation and redispersion in deionized (DI) 
water. 
 
2.2.2.2 Synthesis of Gold Nanorods (17 Nm Length and 3.5 Nm Width) by Seedless 
Growth Technique 
For making smaller AuNRs we followed our early reported procedure in Ali et al. [26] 
Briefly, 50 mL of HAuCl4 (1.0 mM) was added to 100 mL of CTAB (0.2 M), 5 mL of 
AgNO3 (4.0 mM) and HCl (160 μL, 37%). Then, 700 µL of ascorbic acid (78.8 mM) was 
added, followed by immediate injection of ice-cold NaBH4 (150 µL, 10.0 mM). The 
solution left undisturbed for 12 h, which was then centrifuged at 16000 rpm for 20 min and 
redispersed in DI water.  
 
2.2.2.3 Synthesis of Au@Citrate Nanoparticles  
Citrate-capped gold nanospheres (AuNSs) with an average diameter of 15–20 nm was 
synthesized by the reduction of HAuCl4.3H2O (Sigma Aldrich) with trisodium citrate 
(Sigma Aldrich). [28] In this method, 5 mL of 5 mM HAuCl4.3H2O was diluted with 90 
mL of deionized (DI) water and heated until it begins to boil. An amount measuring 5 mL 
of 0.5% trisodium citrate solution was added and continued heating until the solution 
turned wine red. It was cooled under ambient conditions and used for further studies. 
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2.2.2.4 Preparation of Drug-Loaded, BSA-Conjugated Nanorods (Aunrs@BSA-
Drug@RGD) 
Conjugation of BSA with various gold nanoparticles were carried out by adding 50 ml of 
0.5 mM bovine serum albumin (BSA) (Sigma-Aldrich, USA) into the nanoparticles 
solution (AuNRs or spheres) (1 nM), which was then incubated for 10 h at room 
temperature. The excess BSA was removed from the nanoparticle solution by 
centrifugation. For making multifunctional drug (RF or Ptxl)-loaded AuNRs@BSA, 5 mL 
of 5 mM drug solution was added to the 50 mL of Au@BSA nanoparticles (1 nM). The 
solution was gently shaken and kept for 5 h. To this solution, 1 mL of 5 mM RGD 
(CGPDGRDGRDGRDGR) solution was added. The resultant AuNRs@BSA-drug-RGD 
nanoparticles were centrifuged to remove unbound drug molecule as well as RGD 
molecules. Similar procedure was used to make AuNSs@BSA-drug-RGD. 
The number of RF molecules per AuNR has been calculated from the absorption spectra 
of RF solution before and after treating them with AuNRs@BSA. The value was obtained 
by subtracting the concentration of RF in the supernatant solution from their original 
concentration. The extinction coefficient of RF at 334 nm was 28000 M−1cm−1. [29] 
 
2.2.2.5 Photothermal Studies 
For the photothermal studies, RF-functionalized nanoparticles (1 mL, 1 OD) were exposed 
for to CW laser of 808 nm (5.8 W/cm2) for various time intervals. Afterwards, each sample 
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were centrifuged and the UV-vis absorption spectra of the supernatant solutions were 
measured. 
 
2.2.2.6 Cell Culture 
Human oral squamous cell carcinoma (HSC) cells were cultured in Dulbecco’s modified 
Eagles’ medium (DMEM, Mediatech), without phenol red, supplemented with 10% v/v 
fetal bovine serum (FBS, Mediatech) and 1% antimycotic solution (Mediatech) in a 37 ºC, 
5% CO2 humidified incubator. 
 
2.2.2.7 Cell Viability Assay 
HSC cells were plated in a 96-well tissue culture plate and incubated for 24 h. The culture 
medium was then removed and replaced with culture medium containing the various 
nanoparticles (details about the nanoparticles are given in the manuscript). Cells were 
incubated for 24 h. Afterwards the cells were washed with PBS and the XTT solution and 
incubated for 6 h. A Biotek Synergabsoy H4 multi-mode plate reader was used for reading 
the cell viability results. The error bar is expressed as +/- the percent relative standard 
deviation (% rsd). 
Experiments were also conducted by exposing the similar set of cell samples by exposing 
them to the laser (808 nm) for 2 min. The cell viability was measured after 6 h by following 
the method described earlier. 
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For the cell uptake studies, the cells were grown on sterilized round coverslips that were 
placed in 12-well dish and treated with different conjugated nanoparticles (details of 
nanoparticles are given in the manuscript) for 0.5, 2, and 24 h. Then the rounded cover 
slips incubated with 1 mL of 4% paraformaldehyde for 30 minutes, which were washed 
with DI water and analyzed under dark field microscope. 
Statistical analysis: Statistical significance (p-value), which is indicated by *, was 
calculated by a t-test calculator (GraphPad Software, Inc.). Data is considered statistically 
significant when p < 0.05. 
 
2.2.3  Results and Discussion  
 Loading of drug molecules (RF and Ptxl) with BSA has been performed in aqueous 
solution under physiological conditions and their binding with BSA was confirmed 
fluorometrically, which showed a distinct reduction in the fluorescence emission (~350 
nm) intensity of BSA (excitation at 294 nm) as well as slight shift in their emission after 
the addition of 5 mM of drug into 1 mM BSA solution. 
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Figure 2-6 Conjugated of gold nanoparticles with BSA 
(A, D), (B, E), and (C, F) are UV-vis absorption spectra and respective TEM image of 
AuNSs, bAuNRs, and sAuNRs, respectively 
Similar result was also found when BSA-conjugated AuNRs were treated with 5 mM RF 
(see SI 3). The observed red shift in fluorescence emission of BSA after drug binding can 
be attributed to an increased polarity of the region surrounding the tryptophan site. [30] 
Whereas, quenching of fluorescence is mainly due to the process of energy transfer by the 
intermolecular interaction of drug molecules with tryptophan moiety present in the 
proximity of drug binding site in BSA. [31, 32] Interestingly, we also found that the 
solubility of Ptxl considerably increased when it is conjugated with BSA the amount of RF 
bound to BSA-conjugated nanoparticles was calculated from their absorption spectra, 
before and after addition to the nanoparticles. RF shows characteristic absorption bands at 
256 and 334 nm corresponds to the π-π* transitions of the chromophore. The band at 474 
nm is assigned to a π-π* CT (electron charge transfer) transition between the electron 
donating group (CO) and the substituent (OH) of the naphthohydroquinone chromophore 
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in RF. (33) Further, the conjugation of RF and Ptxl was confirmed by surface enhanced 
Raman spectroscopic (SERS) studies (SI 5 and SI 6). All the SERS spectra were measured 
in the solution state. The RF-loaded BSA-conjugated AuNRs (AuNRs@BSA-RF) showed 
clear Raman features 0f RF, which was in concordance with the Raman features of pure 
RF [33] (see SI 5). Absence of any prominent Raman features of CTAB or BSA can be 
due to their low Raman cross-section compared to the RF.  
To study the efficiency of drug release for each nanorods (sAuNRs and bAuNRs), we 
used their RF-loaded analogue as they showed distinct features of RF in the absorption 
spectra (Figure 2-7A). The charge transfer band of RF found at 474 nm slightly red shifted 
to 482 nm after addition into BSA-conjugated AuNRs, which clearly suggests the binding 
of RF with BSA. The triggering of drug release was achieved by irradiating the AuNRs 
solution with a CW laser source with excitation wavelength of 808 nm, which overlaps 
with the longitudinal surface plasmon resonance (LSPR) band of AuNRs. Exact 
concentrations of liberated RF after laser irradiation was calculated using the extinction 
coefficient of RF and the absorption at 334 nm (Figure 2-7B). Photothermal studies 
suggest an enhancement in the drug release for sAuNRs compared to bAuNRs, when RF-
loaded nanorod solutions of same optical density were used. Due to the higher absorption 
and lower scattering properties, sAuNRs are a good candidate in plasmonic chemotherapy. 
Enhanced drug release capability of sAuNRs is attributed to their higher efficiency in 
generating heat upon laser irradiation compared to the bAuNRs of same optical density. 
We found that laser irradiation of sAuNRs (OD=1) for 2 min can increase the solution 
temperature from 27 0C to 82±0.5 0C. Whereas, laser irradiation of bAuNRs (OD=1) for 2 
min resulted in the enhancement of the temperature from 27 0C to 65±0.5 0C, suggests the 
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higher photothermal ability of sAuNRs. A plot of laser irradiation time versus amount of 
RF released at different irradiation time is depicted in Figure 2-2B. There was no 
significant enhancement in the temperature observed in the case of AuNSs, owing to their 
mismatch between the laser excitation source (808 nm) and surface plasmon resonance 
band (525 nm).  
 
Figure 2-7 Conjugation gold nanoparticles with RF 
(A) Absorption spectra of BSA-conjugated bAuNR after binding with RF (red trace). 
Spectra correspond to bare bAuNR (black trace) and RF (blue trace) is also given. 
(B) Plots showing the release of RF (function of laser exposure time) from 
bAuNRs@BSA-RF (red trace) and sAuNRs@BSA-RF (black trace). 
    Cellular uptake of bAuNRs was monitored using dark field microscopy as function of 
time.  Interestingly, we found that the amount as well as the rate of endocytosis of 
nanoparticles was substantially high, when it was introduced along with the RF-loaded 
nanoparticles. The schematic showing the enhanced uptake of nanorods in presence of RF-
loaded nanorods is shown in Figure 2-8A. Here, the human squamous carcinoma (HSC) 
cells were incubated with a 19:1 solution of 0.1 nM of bAuNRs@BSA@RGD solution and 
0.1 nM of RF-loaded Au nanorods (bAuNRs@BSA-RF@RGD). Figure 3B-D shows the 
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dark-field images of the HSC cells, treated with only 0.1 nM bAuNRs@BSA@RGD, 
collected at 0.5, 2, and 24 h, respectively. Similarly, the dark-field images of the HSC cells, 
treated with 19:1 solution of 0.1 nM bAuNRs@BSA@RGD and bAuNRs@BSA-
RF@RGD (0.1 nM) collected at 0.5, 2, and 24 h is shown in Fig. 3E-G, respectively. The 
experiment was conducted by keeping the amount of AuNRs constant in each experiment. 
We did not use sAuNRs for this study as the scattering due to the sAuNRs were very 
negligible, hence we could not image under the dark field microscope, effectively. Even 
after 30 min of cell uptake study, the cells exposed with bAuNRs in presence of 5% of RF-
loaded bAuNRs showed remarkably high uptake compared to the experiment conducted in 
the absence of RF-loaded bAuNRs. This was very clear from the dark field images (Figure 
2-8). The enhancement in the efficiency of plasmonic chemotherapy by using RF-loaded 
AuNRs was further confirmed by conducting various cell viability experiments (see later). 
The capability of RF in enhancing the endocytosis of nanoparticles can be attributed to the 
chemo-sensitizing activity [23, 34, 35] of RF by down regulating the activity of multi-drug 
resistant plasma membrane protein (P-glycoprotein). 
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Figure 2-8: Endocytosis of AuNRs  
(A) Schematic showing higher uptake of conjugated AuNRs in presence of RF 
conjugated nanorods (B-D) Dark field images of HSC cells collected at 0.5, 2, and 24 
h, respectively during the uptake of AuNRs@BSA@RGD. (E-G) Dark field images of 
HSC cells collected at 0.5, 2, and 24 h, respectively during uptake of 
AuNRs@BSA@RGD (0.1 nM) along with 5% of AuNRs@BSA-RF@RGD (0.1 nM). 
    The cell viability studies clearly showed a distinct decrease in the percentage of viability 
(~30%) for the HSC cells exposed to laser (808 nm) for 2 min in presence of 19:1 solution 
of bAuNRs@BSA@RGD (0.1 nM) and bAuNRs@BSA-RF@RGD (0.1 nM). At the same 
time, the viability was around 80% during the laser exposure in the absence of RF-loaded 
bAuNRs (Figure 2-9A). The higher killing efficiency in the former case is attributed to the 
higher internalization of AuNRs to the cancer cells by the influence of RF-loaded nanorods 
and subsequent enhancement in the resultant heat generated inside the medium during the 
laser exposure. Among the nanorods, sAuNRs exhibited higher efficiency in killing the 
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cancer cells (viability~20%), when exposed to laser in presence of RF-loaded nanorods 
(Figure 2-4B). 
 
Figure 2-9 Cell viability results for exposure of HSC cells to 0.1 nM of AuNRs 
solutions of different sizes and functionalities 
(A) For bAuNRs and (B) for sAuNRs. The amount of AuNRs in each case was made 
constant. Different AuNRs solutions used for the experiments are also given in panel 
B. 
In absence of RF-loaded nanorods, the viability was nearly 70%. In AuNRs, due to the 
higher absorbance, the generation of net heat was very high (from 27 0C to 82±0.5 0C) 
compared to bAuNRs (from 27 0C to 65±0.5 0C). Similarly, the viability was very low 
(28%) when the Ptxl-loaded nanorods (AuNRs@BSA-Ptxl@RGD) were used. This 
reduction in the viability has been attributed to the photothermal effect as well as the 
chemotherapeutic nature of Ptxl-loaded nanorods. The viability was very low in sAuNRs 
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(18%) compared to bAuNRs (30%) (Figure 2-9B), which further confirms the higher 
photothermal efficiency of sAuNRs. 
 
2.2.4 Conclusion and Future Outlook   
    We developed a novel multifunctional gold nanoparticle-based drug delivery platform 
capable of enhancing the internalization of drug-loaded nanoparticles more effectively into 
the cancer cells. This was achieved by introducing trace amount of rifampicin-loaded Au 
nanoparticles into the cancer cells along with the drug-loaded nanoparticles. Fast and 
enhanced internalization of nanoparticles inside the cells during this approach was probed 
by using darkfield microscopy. A range of cell viability studies has demonstrated the 
advantages of this approach over conventional plasmonic chemotherapy. The current 
method has greater impact in prospect of conquering new avenues in bypassing multidrug 
resistance in various cancer cells thereby to decrease the demand on the overall 
concentration gold NPs needed for plasmonic chemotherapy.  
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2.3 Targeting Heat Shock Protein 70 using Gold Nanorods Enhances Cancer Cell 
Apoptosis in Low Dose Plasmonic Photothermal Therapy [1] 
    Plasmonic photothermal therapy (PPTT) is a promising cancer treatment where 
plasmonic nanoparticles are used to convert near infrared light to localized heat to cause 
cell death, mainly via apoptosis and necrosis. Modulating PPTT to induce cell apoptosis is 
more favorable than necrosis. Herein, we used a mild treatment condition using gold 
nanorods (AuNRs) to trigger apoptosis and tested how different cell lines responded to it. 
Three different cancer cell lines of epithelial origin: HSC (oral), MCF-7 (breast) and 
Huh7.5 (liver) had comparable AuNRs uptake and were heated to same environmental 
temperature (under 50oC). However, Huh7.5 cells displayed a significant increase in cell 
apoptosis after PPTT as compared to the other two cell lines. As HSP70 is known to 
increase cellular resistance to heat, we determined relative HSP70 levels in these cells and 
results indicated that Huh7.5 cells had ten-fold decreased levels of HSP70 as compared 
with HSC and MCF-7 cells. We then down-regulated HSP70 with a siRNA and observed 
that all three cell lines displayed significant reduction in viability and an increase in 
apoptosis after PPTT. As an enhancement to PPTT, we conjugated AuNRs with Quercetin, 
an inhibitor of HSP70 which displayed anti-cancer effects via apoptosis. 
 
2.3.1 Introduction  
    In the last decade, many publications associated with the use of gold nanorods (AuNRs) 
in plasmonic photothermal therapy (PPTT) have shown great promise for combating cancer 
[2-4]. PPTT relies on the principle that AuNRs show distinct physicochemical properties 
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compared to other gold nanoparticles [5-7]. AuNRs absorb near infrared light and convert 
it into heat rapidly and efficiently by non-radioactive processes, including electron-electron 
and electron-photon interactions [8-11]. Thus, when AuNRs are targeted to cancer cells, 
electromagnetic irradiation with an optical laser induces enough heat to selectively destroy 
cancerous cells [12-16]. 
     PPTT causes cancer cell death mainly via necrosis and apoptosis [17, 18]. One of the 
main challenges in PPTT is the overheating caused by large dose of nanoparticles or laser 
exposure, which can easily cause necrosis. During necrosis the plasma membrane is broken 
causing cytoplasmic components to leak out and inflammation which is known to induce 
metastasis and cancer growth [19-21]. Additionally, the overheating could hurt the 
neighboring healthy cells. On the other hand, PPTT induced apoptosis occurs through a 
programming cell death, which does not cause inflammation [22]. Therefore, developing a 
new strategy targeting cancer cell apoptosis and avoiding necrosis would be of great 
importance for the next generation of PPTT.  
     It has been reported that different intracellular locations of AuNRs or laser strength 
regulate the switch between necrosis and apoptosis in PPTT [13, 23]. However, lower 
heating would decrease the efficacy of PPTT, and might not be very effective for cells that 
exhibit thermo-resistance. Therefore, it is important to know the major players that 
contribute to thermo-resistance. Based on this, we can develop new PPTT strategies that 
prevent the thermo-resistance and enhance apoptosis. Many factors could contribute to 
thermo-resistance such as: the inhibition of cell death signals, inhibition of endocytosis or 
increased exocytosis of nanoparticles [17, 18]. Heat induced apoptosis can also be resisted 
by a class of proteins called Heat Shock Proteins (HSPs) [24-27]. When binding to 
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denatured proteins or partially unfolded intermediates, HSPs prevent their aggregation and 
initiate protein refolding [28, 29]. Interestingly, PPTT induces the expression of most HSPs 
[30-32], and multiple studies have shown the importance of the HSP in enabling cancer 
cells to resist heat-induced apoptosis [33-38]. However, the specificity of these inhibitors 
to individual heat shock proteins has not been tested [36].  
    As HSP70 inhibits cell apoptosis directly by preventing the cytochrome c/dATP-
mediated caspase activation [39] and binds with multiple other HSPs to mediate protein 
refolding [30], we conducted PPTT on multiple cell lines and positively correlated HSP70 
levels with PPTT response. We then used siRNA to remove HSP70 and observed an 
enhancement in PPTT. These results led us to fabricate novel HSP70 inhibitor (Quercetin) 
conjugated AuNRs and compared to non-conjugated AuNRs, the new conjugate displayed 
a superior ability to combat thermo-resistance, causing a higher percentage of cells to 
undergo apoptosis. Therefore, AuNRs act as integrally in delivering of Quercetin to cancer 
cells as well as acting as an inducer of apoptosis-associated PPTT.  
 
2.3.2 Experimental Methods 
 
2.3.2.1 Cell Culture and Transfections 
    HSC (human squamous carcinoma), MCF-7 (human breast cancer) and Huh7.5 (human 
hepatocellular carcinoma) cells were cultured in Dulbecco’s modified Eagles’ medium 
(Mediatech) supplemented with 10% fetal bovine serum (Mediatech) and 1% antibiotic 
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antimycotic solution (Mediatech). Lipofectamine 2000 (Invitrogen) was used for siRNA 
transfections per the manufacturer’s protocol. The following siRNAs (Sigma-Aldrich) 
were used: control (SASI_HS SIC001) and HSP70 (GCCUUUCCAAGAUUGCUGU). 
The siRNA control was a sequence that had no homology to any human gene. Cells were 
incubated with the siRNA for two days before incubating cells with AuNRs. 
 
2.3.2.2  Preparation of AuNRs and Conjugation with different surface modifications 
    AuNRs were prepared similarly as previously described. [7, 37] Specifically, AuNRs 
were synthesized by a seedless growth technique where the growth solution was prepared 
at 25-30°C. Briefly, 5 mL of 1.0 mM HAuCl4 was added to 5 mL 0.20M 
cetyltrimethylammonium bromide.  Then 250 μL of 4.0 mM AgNO3 250 μL was added 
and the solution was gently shaken. 8 μL of 37% HCl was then added to obtain a pH of 1-
1.15. Next, 70 μL of 78.8 mM ascorbic acid was added to the solution with gentle shaking 
until the solution was clear. 15 μL of 0.01M ice-cold NaBH4 was injected immediately to 
the unstirred growth solution and allowed to react for six hours. The resulting gold AuNRs 
had dimensions of 25 × 5.5 nm, aspect ratio of approximately 4.5, and longitudinal plasmon 
absorption ~ 800 nm [7]. The solution was centrifuged for 15 min at 14 500 RPM and the 
supernatant was removed. The resulting precipitate was suspended in water and centrifuged 
at the same speed and time. To conjugate the AuNRs with BSA, 50 mL of 0.5 mM bovine 
serum albumin (Sigma-Aldrich, USA) into a 1 nM nanoparticles solution and then 
incubated for 10 hours at room temperature. The excess BSA was removed from the 
nanoparticle solution by centrifugation.  To this solution, 1 mL of 5 mM RGD 
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(CGPDGRDGRDGRDGR) (Genscript) solution was added. To conjugate rifampicin (RF) 
to AuNRs, 5 mL of 5 mM RF (Sigma-Aldrich) was added to the solution containing 50 mL 
of 1 nM AuNRs. The resulting solution was gently shaken and incubated for 5 hours. The 
resultant BSA+RF-RGD conjugated nanoparticles (AuNRs) were centrifuged to remove 
unbound RF molecule. [37] To conjugate Quercetin (QE) to AuNRs, 5 mL of 5 mM QE 
(Sigma-Aldrich) was added to the solution containing 50 mL of 1 nM AuNRs. The 
resulting solution was gently shaken and incubated for 5 hours. The resultant BSA-QE-
RGD conjugated AuNRs were centrifuged to remove unbound QE molecule. To determine 
if the QE release from the surface of the AuNRs after laser irradiation or not; 1 nM of the 
AuNRs@ QE in solution has been irradiates exposed to a near Infra-red (NIR) CW laser 
(808 nm, M2W dragon laser) at 5.8 W / cm2 for 2 minutes with a spot size of approximately 
5.6 mm.   Then we separated the AuNRs from the supernatant using centrifugation (15 min 
at 14 500 RPM). Both the supernatant and the pellet were examined using UV-Vis 
spectrometer. 
 
2.3.2.3 TEM, Fluorimetry and UV-vis and zeta potential Measurements 
    UV-vis absorption measurements were carried out using a Cary 500 UV−vis 
spectrometer, while the transmission electron microscopic (TEM) images were taken on a 
JEOL 100CX-2 microscope and the average diameter was determined using Image J 
software. Excitation and emission measurements were carried out using a Quanta Master™ 
300 — Phosphorescence/Fluorescence Spectrofluorometer. For quenching experiments 
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BSA was used at the concentration of 10-4 M). Zeta potentials were measured by a 
ZetaSizer 3000 (Malvern Instruments). 
 
2.3.2.4 Measurement of AuNRs Endocytosis 
    Cell lines were grown until 60-70% confluence in 12-well dishes and then treated with 
AuNRs for 24 hours. The supernatant was then removed and the intensity of the AuNRs 
for the three cell lines was measured using Cary 500 UV−vis spectrometer, the calculations 
established by subtracting the intensity of the supernatant from the AuNRs before 
endocytosis.  
 
2.3.2.5 Plasmonic Photothermal Therapy (PPTT) 
    Cells were plated on either 96 or 12 well tissue culture plates and incubated for 24 hours 
[48]. The culture medium was then removed and replaced with culture medium containing 
the conjugated nanoparticles and the left in DMEM containing 2.5 nM AuNRs. Afterwards, 
each sample was exposed to a near Infra-red (NIR) cw laser (808 nm, M2W dragon laser) 
at 5.8 W / cm2, for 2 minutes with a spot size of approximately 5.6 mm.   
 
2.3.2.6 Apoptosis/Necrosis Assay 
    Cells were washed with PBS and then trypsinized (Clonetech). [39] After trypsinization 
cells were subsequently centrifuged and washed with PBS. Cells were then resuspended in 
 92 
493 µL 1x Annexin binding buffer (Invitrogen) with 2 µL working Propidium Iodine PI 
(BioLegend) and 5 µL Annexin-V-FITC (BioLegend) before being incubated at room 
temperature for 15 minutes. Cells were then filtered and subjected to flow cytometry using 
a BSR LSR II flow cytometer (BD Biosciences). Samples were excited with a 488-nm 
laser, and FITC was detected in FL-1 by a 525/30 BP filter while PI was detected in FL-2 
by a 575/30 BP filter. FlowJo software (Tree Star Inc.) was used to count Annexin V+ cells 
from at least 10000 events. 
 
2.3.2.7 Cell Viability Assay: 
    Cells were washed with PBS and then an XTT assay was performed per the 
manufacturer's protocol (Biotium). A Biotek Synergabsoy H4 multi-mode plate reader 
measured the intensity of orange formazan that viable cells produce. 
 
2.3.2.8 Immunoblots: 
     Cells were lysed in RIPA (20 mM Tris pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM 
EGTA, 0.1% Sodium Deoxycholate, 1% Triton X-100, 0.1% SDS) supplemented with 
protease inhibitors (Sigma-Aldrich). [51] Post-nuclear supernates were subjected to a BCA 
assay (Pierce) and equal amounts of protein were loaded on a SDS-PAGE gel. After SDS-
PAGE, resulting gels were transferred to PVDF membranes (Millipore) overnight and then 
blocked with 5% milk in TBS (20 mM Tris 150 mM NaCl). A rat monoclonal (6B3) 
antibody to HSP70 was used as the primary antibody (Cell Signaling). A goat anti rat HRP 
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labeled antibody was used as the secondary antibody (Jackson Immuno Research 
Laboratories). Blots were washed 3 times in TBS after primary and secondary antibodies. 
Hyglo enhanced chemiluminescence (Denville) and a Konica Minolta developer were used 
to develop the immunoblots. 
 
2.3.2.9 Immunofluorescence Labeling and Confocal Microscopy: 
    Cells were plated on 8 well chamber slides (Fisher). After siRNA and PPTT treatment 
cells were fixed in 4% Paraformaldehyde for 20 mins at room temperature. Cells were then 
permeabilized with 0.1% Triton X-100 for 5 minutes at room temperature. Cells were then 
blocked with 5% BSA and incubated with the same primary antibody as stated in the 
immunoblot method. Cells were then incubated for 1 hour with an Alexa Fluor donkey anti 
rat 488 secondary antibody (Invitrogen) for 1 hour before mounting with Prolong Gold 
(Invitrogen). Lastly images were taken with a Zeiss LSM 700-405 confocal microscope 
and the fluorescence intensity was quantified in Image J. 
 
2.3.2.10 Statistics: 
    The statistical significance was determined by a t-test calculator (Graph Pad Software, 




2.3.3  Results and Discussion 
    To better define which cancers might be best treated with PPTT and to determine if and 
how PPTT displays effectiveness against different cancer types, we created nanorods 
(AuNRs) using a novel technique [8, 40]. We performed transmission electron microscopy 
(TEM) to determine the quality and homogeneity. These AuNRs were uniformly shaped 
(Figure 2-10a) with an approximate length and width of 25 ± 3 nm × 5.5 ± 0.8 nm (Figure 
A.9. a, b). Additionally, these AuNRs displayed an excitation at 800 nm (Figure 2-10b). 
AuNRs were then conjugated with bovine serum albumin (BSA), to block nonspecific 
interactions, arginylglycylaspartic acid (RGD) to enable integrin-mediated endocytosis, 
and Rifampicin (RF), an inhibitor of drug exocytosis [40]. To confirm conjugation with 
RF we measured the absorption spectra of AuNRs before and after conjugation with RF. 
AuNRs conjugated only with BSA absorb at 530 nm and 800 nm (Figure 2-10b). RF alone 
has two absorption wavelengths:  330 nm and 470 nm (Figure 2-10b). When the AuNRs 
were conjugated with RF two new peaks appeared at the same absorption wavelength as 
RF, suggesting a successful conjugation with RF [40]. The effectiveness of these AuNRs 
was then tested on three different cancer cell lines: HSC (human squamous carcinoma), 
MCF-7 (human breast cancer) and Huh7.5 (human hepatocellular carcinoma) cells. To 
ensure each cell line endocytosed similar amounts of AuNRs the absorbance of the AuNRs 
in the media before and after PPTT was measured by ultraviolet-visual spectroscopy (UV-
vis). We observed a similar loss in AuNR absorbance from the media in all three cell lines 
before laser treatment, suggesting that all three cell lines endocytosed similar amounts of 
AuNRs (Figure 2-10c). When performing PPTT we chose an 808 nm laser with a power 
of 5.8 W / cm2 for duration of 2 minutes. The duration and strength of these laser settings 
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have been shown not to harm cells in culture [10, 11, 39-43]. Under these laser settings we 
observed that the media from all three cell lines consistently reached approximately 50oC 
after PPTT treatment as measured by a hypodermic thermocouple. 
 
Figure 2-10 . Characterization of conjugated AuNRs and measurement AuNRs of 
endocytosis 
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 (A) Transmission Electron Microscopic (TEM) image of conjugated nanorods 
(AuNRs). Scale bar = 100 nm. (B) UV-vis absorption spectra of the unconjugated 
AuNRs or the nanorods conjugated with Rifampicin (AuNRs+RF-RGD). (C) The UV-
vis spectra for the AuNRs in cell culture media before and after incubation with HSC 
(human squamous carcinoma), MCF-7 (human breast cancer) and Huh7.5 (human 
hepatocellular carcinoma) cells for 24 hours. 
    Noticing no differences in the amount of AuNRs uptake or temperature of the media we 
used two different methods to measure the effectiveness of PPTT. To measure apoptosis 
and necrosis we labeled cells with Annexin V and propidium iodide and then performed 
flow cytometry. Similar percentages of apoptotic cells (AnnexinV+) were observed 
between AuNR treated without laser and AuNR with laser treated HSC and MCF-7 cells 
(Figure 2-11a). However, PPTT treated Huh7.5 cells displayed a significant increase in 
apoptosis after PPTT as compared to HSC and MCF-7 cells. We did not observe 
propdidium iodide staining under any conditions suggesting necrosis was not occurring 
(Figure A. 10. a), as has been previously observed for other cell lines [44]. To measure the 
effectiveness of PPTT by another method we performed an XTT assay. All three cell lines 
displayed similar levels of cell viability without laser treatment after AuNRs treatment, 
indicating the AuNRs alone were not toxic to the cells. Consistent with the flow cytometry 
data Huh7.5 cells were significantly less viable than HSC or MCF-7 cells after PPTT 
(Figure 2-11b). 
    Next we wanted to determine if the differences in cell viability and apoptosis after PPTT 
observed between cancer cell lines could be explained by differences in protein 
composition. As Heat Shock Proteins (HSPs) are known to enable cells to resist 
temperature-induced apoptosis [25, 45, 46], and PPTT can induce apoptosis, we 
hypothesized that the increased efficacy of PPTT against Huh7.5 cells could be explained 
 97 
by differences in HSP levels. We first tested and chose to focus on HSP70 as HSP70 is the 
major heat shock protein in mammalian cells as it complexes with both HSP40 and HSP90 
to refold denatured proteins [47-49]. Immunoblots of HSP70 from cells treated with 
AuNRs with or without laser treatment demonstrate that MCF-7 and HSC cells have similar 
amounts of HSP70 in relation to a loading control, actin (Figure 2-11c). However, with 
and without laser treatment Huh7.5 cells have greater than 10-fold less HSP70 than MCF-
7 and HSC cells. We also observed a 2-fold decrease in HSP70 protein levels in MCF-7 
cells after PPTT treatment and a modest 10 percent decrease in HSP70 protein levels in 
HSC cells after PPTT. These results suggest that the level of HSP70 impacts the 




Figure 2-11. Huh7.5 cells have less HSP70 and are more susceptible to cell death 
following PPTT than MCF-7 or HSC cells 
(A) Histograms were generated from flow cytometry data of Annexin V+ Huh7.5 
(human hepatocellular carcinoma), MCF-7 (human breast cancer) or HSC (human 
squamous carcinoma) cells with (PPTT) and without (Ctrl) laser treatment. 
Mean±SEM. * p<0.05 (B) Cell viability results from an XTT assay data performed on 
cells treated with laser but no AuNRs (Ctrl), with AuNRs but no laser (AuNR) or with 
AuNRs and laser treatment (PPTT). Mean±SEM. * p<0.05 (C) The relative amounts 
of HSP70 in all three cell lines with and without laser treatment was determined by 
immunoblotting. Error bars are presented as the Mean±SEM. * p<0.05. 
 99 
    There are many methods to determine if HSP70 levels play a role in the efficacy of PPTT 
including: down-regulation, overexpression or small molecule inhibitors. Since transient 
overexpression experiments can lead to non-specific effects such as decreased cell viability 
due to sequestering of translational machinery and protein overcrowding [50], we first 
chose to down-regulate HSP70 with an siRNA, confirm protein loss by 
immunofluorescence microscopy and then determine cell viability. After siRNA treatment, 
HSP70 was immunolabeled and then confocal microscopy was performed. All control 
siRNA treated cell lines displayed a cytoplasmic distribution of HSP70 and a 89% and 93% 
loss of signal was seen in HSC and MCF-7 cells after siRNA treatment, respectively 
(Figure 2-12a). Confirming immunoblot results, the relative amount of HSP70 between 
control siRNA treated Huh7.5 cells was decreased as compared to control siRNA treated 
MCF-7 and HSC cells. Again, we used flow cytometry to measure the percentage of cells 
undergoing apoptosis (Annexin V+). The percentage of MCF-7 cells treated with the 
HSP70 siRNA undergoing apoptosis increased 1.8-fold compared to the siRNA control 
(Figure 2-12b). Huh7.5 cells treated with the HSP70 siRNA exhibited slight but significant 
increases in apoptosis as compared to control siRNA treated cells, however 80% of Huh7.5 
control siRNA treated cells were already undergoing apoptosis after PPTT. We did not 
observe any differences in apoptosis between control siRNA treated cells after laser 
treatment and HSP70 siRNA without laser treatment. Additionally, we did not observe any 
increases in the percentage of cells undergoing necrosis in siRNA treated cells (Figure 
A.10.b.). We again used the XTT cell viability assay as another measurement of PPTT 
effectiveness. The percentage of viable cells treated with the HSP70 siRNA as compared 
to control siRNA treated cells decreased 25% for HSC and MCF-7 cells (c). While Huh7.5 
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cells treated with the HSP70 siRNA were only 10% less viable, the control siRNA cells 
after laser treatment were only 30% viable. Similar to the apoptosis assay we did not 
observe any differences in cell viability between control siRNA treated cells after laser 
treatment and HSP70 siRNA treated cells without laser treatment. These experiments show 
that specific loss of HSP70 enhances the efficacy of PPTT against multiple cancer cell 
lines. The remaining viability after loss of HSP70 and PPTT is likely due to the expression 




Figure 2-12. HSP70 regulates cell death in response to PPTT 
(a) After immunolabeling HSP70, confocal microscopy was performed on HSC 
(human squamous carcinoma), MCF-7 (human breast cancer) and Huh7.5 (human 
hepatocellular carcinoma) cells treated with a control siRNA (Ctrl siRNA) or a 
HSP70 siRNA. Representative images and quantification are shown. Mean ± SD. *p 
< 0.05 (b) Histograms were generated from flowcytometry data of Annexin Vþcells 
after PPTT that werealso treated with a control siRNA (siCtrl) or a siRNA against 
HSP70 (siHSP70). Error bars are presented as the Mean ± SEM. *p < 0.05 (c) Cell 
viability results from an XTT assay performed on siCtrl or siHSP70 treated cells. 
Error bars are presented as the Mean ± SEM. *p < 0.05 
    If HSP70 is essential for the resistance of cancers to PPTT then AuNRs conjugated with 
inhibitors to HSP70 would make PPTT more effective. As Quercetin (QE) has been shown 
to be a promising inhibitor of HSP70 [51, 52], we conjugated AuNRs with QE. To ensure 
conjugation we measured the absorbance of AuNRs with and without QE. QE alone 
absorbed at 370 nm ( 
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Figure 2-13a). AuNRs alone did not show a peak at 370 nm before conjugation with QE, 
however after conjugation with QE AuNRs display a peak at 370 nm confirming QE 
conjugation to the AuNRs. Fluorimetry was also used to demonstrate QE attachment to 
BSA. BSA alone displays an excitation peak at 300 nm and emission peak at 360 nm. 
However, after conjugation with QE the emission intensity of BSA is dramatically 
decreased (  
Figure 2-13b) (Figure A.11.b).  Furthermore, confirming the stability of the BSA surface 
conjugation after the QE conjugation, BSA conjugated to the surface of the AuNRs still 
displayed a negative zeta potential after conjugation with QE (table A.1.).  We then tested 
the efficacy of QE conjugated AuNRs on cell viability and apoptosis after PPTT. After 
Annexin V labeling and performing flow cytometry on HSC cells we observed a 
significantly increased percentage of cells undergoing apoptosis when AuNRs were 
conjugated with QE as compared to without ( 
Figure 2-13c). We did not observe any differences in cells that did not receive AuNRs that 
received only laser treatment or received AuNRs but no laser. An XTT assay was used to 
measure cell viability in cells treated with AuNRs that were conjugated with and without 
QE. While HSC cells treated with AuNRs without QE had a 40% decrease in cell viability 
as compared to controls, HSC cells treated with AuNRs conjugated with QE displayed an 
80% decrease in cell viability as compared to controls ( 
Figure 2-13d). We did not observe any loss or differences in viability in control cells that 
did not receive AuNRs, received only laser treatment or received AuNRs but no laser. 
These results suggest that AuNRs conjugated with HSP70 inhibitors enhance the efficacy 
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of PPTT.  To test if QE is released from the AuNRs after PPTT we irradiated the particles 
in solution, centrifuged the AuNRs and compared the UV vis spectrum of AuNRs 
conjugated with QE and no laser treatment to both the supernatant and AuNRs after laser 
treatment. Like QE alone ( 
Figure 2-13a) the supernatants from QE conjugated AuNRs displays peaks at 270 nm and 
370 nm (figure A.11.b). Additionally, the UV-vis spectrum of isolated AuNRs displayed 
a loss in the absorption wavelengths of QE after PPTT.  These results suggest that after 
irradiation the AuNRs + QE, the QE is released from the AuNRs enabling it to inhibit 
HSP70 and enhance the efficacy of PPTT.  
 
Figure 2-13. Conjugation with a HSP70 inhibitor makes AuNRs more efficient at 
PPTT 
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 (A) UV-vis absorption spectra of AuNRs alone, AuNRs conjugated with Quercetin 
(QE), and QE only. (B) Excitation and emission spectra of BSA before and after 
addition of QE. (C) Histograms were generated from flow cytometry data of Annexin 
V+ HSC (human squamous carcinoma) cells under control conditions and with 
AuNRs conjugated to QE. Mean±SEM. * p<0.05 (d) Cell viability results from an 
XTT assay performed on HSC cells under control conditions and after treatments. 
Mean±SEM. * p<0.05 
    A better understanding of the molecular mechanisms of PPTT and optimization based 
on those findings represent the next steps in AuNR based cancer therapies. In PPTT AuNRs 
have the beneficial ability of being only active during laser treatment and have been seen 
to not display toxic effects otherwise (2, 39).  Additionally, AuNRs are desirable as they 
can be easily conjugated with different molecules that could enhance their function. 
Previous studies from our lab have developed enhanced PPTT strategy by increasing the 
selectivity to target cancer cells, increasing cell uptake of nanoparticles by developing 
specific surface conjugation or developing new AuNRs size that has higher efficient in 
convert light energy into heat [39, 40, 53-55]. In this work, we sought to know more about 
the mechanism of thermotolerance in different cells and develop new strategy to enhance 
the PPTT-induced apoptosis.  
    PPTT either induces cell death via apoptosis or necrosis. High doses of heating (>50oC) 
cause necrosis, which result in inflammation and is harmful to the neighboring healthy 
cells. On the other hand, lower temperature (<50oC) mainly induces apoptosis, which is 
very favorable as programing cell death is a “clean” way to remove cancer cells [56]. Our 
main target is to only trigger apoptosis during PPTT. To accomplish apoptosis at lower 
temperatures, cellular mechanisms of thermo-resistance need to be bypassed.  
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    We conducted PPTT in three different cell lines HSC, MCF-7 and Huh7.5 and correlated 
their response to PPTT to their HSP70 levels. HSP70 act as an upstream inhibitor to cell 
apoptosis by preventing cytochrome c/dATP-mediated caspase activation [37].  We 
observed that the less the initial HSP70 level, the higher percentage of cells underwent 
apoptosis after PPTT and reducing HSP70 protein levels enhanced apoptosis in all cell 
lines tested. We extended these results by conjugating AuNRs with a heat shock protein 
inhibitor that would sensitize cells to PPTT thereby promoting apoptosis as a non-
inflammatory cancer cell death (Figure 2-14). After demonstrating a successful AuNRs 
conjugation with an HSP70 inhibitor these new AuNRs were tested for their ability to 
enhance cancer cell apoptosis. Similar to siRNA based studies, HSP70 inhibitor 
conjugation enhanced the ability of AuNRs after PPTT.  
     Unlike adding HSP inhibitor directly onto cells, we used AuNRs as a drug delivery 
system. The AuNRs give an efficient delivery system to target drugs towards cancer cells 
as minor amounts of HSP inhibitor are present at the surface, eliminating side effects that 
a HSP inhibitor might cause to the non-cancerous cells. This strategy greatly enhanced the 
PPTT induced cell apoptosis in vitro. The extension of these results into in vivo models 
represents the next step to ablate cancers efficiently and with minimal side effects.  
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Figure 2-14. A model for HSP70 inhibitor optimized PPTT 
2.3.4 Conclusion and Future Look  
We undertook this work to get a deeper understanding of factors affecting photothermal 
therapy. We tested the efficacy of PPTT on different cancer cell lines and determined that 
compared to MCF7 and HSC cell lines, HuH7.5 cells were much more susceptible to PPTT. 
We correlated the levels of HSP70 to PPTT susceptibility and determined that reducing the 
amount of HSP70 in all three cancer cell lines increased the efficacy of PPTT significantly. 
Therefore, thermo-tolerance of cancers to PPTT through differences in HSPs represents a 
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2.4 Simultaneous Time-dependent Surface Enhanced Raman Spectroscopy, 
Metabolomics and Proteomics Reveal Cancer Cell Death Mechanisms 
Associated with Au-Nanorod Photo-thermal Therapy [1] 
    In cancer plasmonic photothermal therapy (PPTT), plasmonic nanoparticles are used to 
convert light into localized heat leading to cancer cell death. Among plasmonic 
nanoparticles, gold nanorods (AuNRs) with specific dimensions to absorb the near-infrared 
(NIR) laser light have been widely used. The detailed mechanism of PPTT therapy, 
however, remains poorly understood. Typically, surface enhanced Raman spectroscopy 
(SERS) has been used to detect time-dependent changes in the intensity of the vibration 
frequencies of molecules that appear or disappear during different cellular processes.  A 
complete proven assignment of the molecular identity of these vibrations and their 
biological importance have not yet been accomplished. Mass spectrometry (MS) is a 
powerful technique that can accurately identify molecules in chemical mixtures by 
observing their m/z values and fragmentation patterns. Here, we complemented the study 
of changes in SERS spectra with MS-based metabolomics and proteomics to identify the 
chemical species responsible for the observed changes in SERS band intensities. Using 
PPTT, we observed that the bands at around 1000, 1207 and 1580 cm−1 increase in 
intensity, which were assigned in the literature to phenylalanine with dispute. Our 
metabolomics results showed increased levels of phenylalanine, its derivatives and 
phenylalanine-containing peptides, providing evidence for more confident SERS peak 
assignments. To better understand the mechanism of phenylalanine, increase upon PPTT, 
we combined metabolomics and proteomics results through network analysis, which 
proved that phenylalanine metabolism was perturbed. Furthermore, several apoptosis 
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pathways were activated, via key proteins (e.g.  HADHA and ACAT1), which are 
consistent with the proposed role of altered phenylalanine metabolism in inducing 
apoptosis. In conclusion, our study shows that the integration of the SERS with MS-based 
metabolomics and proteomics can assist the assignment of signals in SERS spectra, and 
further characterize the related molecular mechanisms involved in the cellular processes 
involved in PPTT. 
 
2.4.1  Introduction 
Plasmonic nanoparticles offer a powerful means to follow dynamic changes associated 
with intracellular molecular events in real-time. [2-3] Their localized surface plasmon 
resonance (LSPR) confers these particles unique optical properties. For example, the 
electromagnetic fields on the surface of plasmonic nanoparticles are greatly increased, and 
exhibit exponential decay patterns following non-radiative (heat) or radiative (e. g. light 
scattering) processes.[4-5] Raman scattering from the molecules localized near the 
plasmonic nanoparticles’ surface is therefore enhanced by orders of magnitude, resulting 
in the well-known surface enhanced resonance (SERS) phenomenon [5-6] SERS has been 
successfully applied to single cell analysis, where plasmonic gold nanoparticles are placed 
inside the cell and the resulting SERS spectrum collected in order to record the intracellular 
microenvironment changes occurring in time near the nanoparticles.  Our group reported 
on the SERS spectral changes observed during the full cell cycle of a single cancer cell. 
The time required to kill cancer cells associated with the time taken for the SERS spectrum 
to stop changing when the cells were  given anti-cancer drugs [7] or were heated [8] was 
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also determined.  However, the molecular species associated with the observed SERS 
bands could not be confidently assigned, preventing from elucidating the molecular 
mechanisms involved in these critical cellular processes. 
Photothermal therapy has its foundation in the targeted destruction of cancerous cells via 
the heat released by gold nanorods following near IR radiation absorption. The so called 
“water wavelength window” between 700–1200 nm is widely considered to be the optimal 
spectral region for conducting PPTT [9-10], as tissue and water absorption are minimized 
in this range. Gold nanorods (AuNRs), on the other hand, readily absorb near-infrared laser 
light, resulting in effective photothermal generators, for both in vitro and in vivo 
applications. AuNRs-based PPTT has been successful at inducing cancer cell apoptosis 
[11-12] resulting in in vivo tumor removal. [12-14] 
   Despite the operational success of PPTT, the molecular mechanisms associated with 
PPTT-induced apoptosis remain largely unknown or under dispute. We observed PPTT 
induce apoptosis initiate through heat shock proteins previously, [15] while several reports 
indicate it is mediated by the mitochondrial apoptotic pathway via Bid activation and 
caspase 3 activity. Although SERS reports on the real-time biomolecular dynamics in the 
microenvironment associated with the PPTT process, [16-17] SERS spectra from cells are 
incredibly complex, reflecting overlapping signals from a variety of proteins and 
metabolites that are difficult to assign to individual species. It has been reported, for 
example, that the 1000 and 1580 cm-1 peaks showed significant increase during cell 
apoptosis [18] with great debate in their assignment. [19] According to published literature, 
the 1000 cm-1 signal has been assigned to phenylalanine, [20] while a different report 
assigned it to tryptophan. [21] Furthermore, it has been argued [7] that these SERS signals 
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reflect changes in protein structure, a topic still being intensively debated. One hypothesis 
states that the 1000 cm-1 signal is indicative of the exposure of protein hydrophobic rings 
following conformational changes, [7] while others report that the protein conformation 
change induced by adding methanol or SDS [21] or increasing temperature [8] does not 
alter the intensity of the 1000 cm-1 peak, therefore contradicting the hypothesis that this 
signal is associated with alterations in protein conformation.  
Herein, we monitored the SERS spectral signature in vitro during apoptosis as a function 
of PPTT exposure time. We also performed metabolomics and proteomic studies on cell 
lysates under the same exact PPTT conditions. Integrative multi-omics network analysis 
revealed specific alterations that explain the underlying changes in SERS spectral data, 
demonstrating the power of combining SERS with MS for studying cellular processes 
following PPTT. 
 
2.4.2 Experimental Methods  
Materials. Tetrachloroauric acid trihydrate (HAuCl4.3H2O), trisodium citrate, NaBH4, 
ascorbic acid, cetyltrimethylammonium bromide (CTAB), AgNO3, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), NaCl, sodium deoxycholate 
SDC) were purchased from Sigma-Aldrich (USA). Methoxypolyethylene glycol)-thiol 
(mPEG-SH, MW 5000) was purchased from Laysan Bio, Inc. Cell penetrating peptide 
RGD (RGDRGDRGDRGDPGC) and nuclear localization signal NLS 
(CGGGPKKKRKVGG) peptides were obtained from GenScript, Inc. Dulbecco’s 
phosphate buffered saline (PBS), Dulbecco’s modified Eagle’s medium (DMEM), fetal 
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bovine serum (FBS), antibiotic solution, 0.25% trypsin/2.2 mM EDTA solution were 
purchased from VWR. Mammalian cell protease inhibitors were purchased from Roche 
Applied Sciences, sequencing grade trypsin was purchased from Promega, and Lysyl 
endopeptidase (Lys-C) was from Wako.  
Instrumentation. Gold nanoparticles were imaged using a JEOL 100CX-2 transmission 
electron microscope (TEM) microscope and their average size was then measured by 
ImageJ software. UV−vis spectra were obtained using an Ocean Optics HR4000CG UV-
NIR spectrometer. SERS spectra were collected using a Renishaw InVia Raman 
microscope equipped with a 785-nm diode Raman excitation laser and a Leica optical 
microscope. Comprehensive metabolomics analyses were performed with ultra-
performance liquid chromatography-mass spectrometry (UPLC-MS), using a Waters 
ACQUITY UPLC H Class system fitted with a Waters ACQUITY UPLC BEH C18 
column (2.1×50 mm, 1.7 μm particle size, Waters Corporation, Milford, MA, USA), 
coupled to a Xevo G2 QTOF mass spectrometer (Waters Corporation, Manchester, UK) 
with an electrospray ionization (ESI) source. The typical resolving power and mass 
accuracy of the Xevo G2 QTOF mass spectrometer were 25,000 (FWHM) and 1.8 ppm at 
m/z 554.2615, respectively. Proteomics analysis was done on a hybrid dual-cell quadrupole 
linear ion trap - Orbitrap mass spectrometer (LTQ Orbitrap Elite, Thermo Fisher) with 
Xcalibur 3.0.63 software. Flow cytometry experiments were conducted on a BD LSR II 
Flow Cytometer (BD Biosciences). 
Synthesis, Conjugation and Characterization of AuNSs and AuNRs. Gold nanospheres 
(AuNSs) with an average diameter of 30-40 nm were synthesized using the citrate 
reduction method.22 Briefly 200 mL of 0.254 mM HAuCl4.3H2O solution was heated until 
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boiling, then reduced by adding 5 mL of 0.35% of trisodium citrate. The solution was then 
left heating until it turned wine red, followed by cooling under water flow. The citrate 
stabilized AuNSs were first centrifuged at 5000 g for 10 min and re-dispersed in deionized 
(DI) water to remove extra citrate for the next step of conjugation. Gold nanorods (AuNRs) 
with an average size of 25 x 6 nm (length x width) were synthesized using a seedless growth 
method [23]. Briefly, 5 ml of 1.0 mM HAuCl4 was added to a mixture of 5 mL of 0.20 M 
CTAB, 250 μL of 4.0 mM AgNO3 and 8 μL of 37% HCl. 70 μL of 78.8 mM ascorbic acid 
was added, then, 15 μL of 0.01M of ice-cold NaBH4 was immediate injected. The solution 
was left undisturbed for 12 h, followed by centrifugation at 21000 g for 50 min and re-
dispersed in DI water and a second centrifugation at 19000 g for 40 min to remove the 
extra CTAB. TEM was used to measure the sizes and homogeneity of the nanoparticles. 
AuNSs and AuNRs were then conjugated according to previous work. 8 First, mPEG-SH 
(1 mM) was added to the nanoparticles for overnight to achieve about 1000 ligands on each 
particle. Then, the PEGylated nanoparticles (1 nM) were treated with RGD (1 mM) and 
NLS (1 mM) to achieve 104 and 105 molar excess, respectively. The number of the bounded 
ligands to the AuNPs, were about 25% of the added ligands. evaluated based on Ellman’s 
protocol. 24 The solution was then allowed to shake overnight at room temperature. Excess 
of ligands were removed by centrifugation. UV-vis spectrometer and zetasizer was used to 
test the conjugation. Surface modification causes red shift of UV-vis spectra due to the 
change in the dielectric constant of the surrounding environment of AuNSs.  
Cell culture, AuNPs incubation and Plasmonic photothermal therapy. Human oral 
squamous cell carcinoma (HSC-3) cells were grown in DMEM medium containing 10% 
(v/v) fetal bovine serum and 1% (v/v) antibiotic solution. Cells were kept at 37 oC in a 
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humidified incubator under 5% CO2.  HSC-3 Cells were left under overnight incubation 
with 2.5 nM AuNRs in complete media, and then were exposed to a CW laser (808 nm 5.8 
W/cm2) for different time course. The concentration of nanoparticles was carefully chosen 
to avoid cytotoxicity or perturbation to the cell cycle. 
In vitro SERS measurement. Time dependent SERS spectra were collected throughout 
the NIR laser exposure period to monitor molecular changes in the plasmonic nanoparticle 
microenvironment during photothermal heating of the AuNRs. The Raman laser was 
directed into a microscope, after focusing on the sample by a 50×/0.75 N.A. objective, 
forms a 1-2 μm spot size. Spectra of molecules in the single cell were measured with a 
1200 lines/mm grating and collected by a CCD detector in the range of 400−1800 cm−1 
using a Renishaw InVia Raman spectrometer. Spectrum baseline was removed using R 
Package Baseline (version 1.2-1). Dark field images were taken by a Lumenera Infinity2 
CCD camera. For SERS studies, the cells were seeded on glass coverslips in complete 
growth medium for 24 h to achieve a 40 % final confluence before SERS study. Then, the 
cells were incubated with 0.05 nM PEG/RGD/NLS-functionalized AuNSs in supplemented 
DMEM cell culture medium for 24 h. [25] Six hours before the SERS examination, the cell 
media (with AuNSs) were removed and 2.5 nM of AuNRs suspended in supplemented 
medium was added to the cells to perform PPTT.  
Apoptosis/necrosis assay. HSC-3 cells were cultured in 12-well plates for 24 h and then 
treated with 2.5 nM of AuNRs@NLS for 24 h. After AuNRs incubation, PPTT was applied 
for different time periods. Before the apoptosis/necrosis assay, the cell culture media was 
removed and cells were collected after trypsinization, followed by washing with cold PBS 
twice. Then, cells were dispersed in 493 ml of Annexin V binding buffer, and 5 μL of 
 122 
Annexin V FITC (BioLegend) and 2 μL of propidium iodide PI (BioLegend, 100 µg / mL) 
were added to the cell suspension and incubated for 15 min at room temperature. [26] The 
cells were then filtered and subjected to flow cytometry analysis using a BSR LSR II flow 
cytometer (BD Biosciences).  A 488-nm laser was applied for excitation, and FITC was 
detected in FL-1 using a 525/30 BP filter while PI was detected in FL- 2 using a 575/30 
BP filter. Standard compensation using unstained and single-stained cells was done before 
performing actual experiments. FlowJo software (Tree Star Inc.) was used for analysis of 
the viable, apoptotic and necrotic cells from at least 10000 events. 
Sample preparation for metabolomics experiments. Cells were cultured in 60 mm petri 
dishes. The culture media was removed and cells were washed 3 times with PBS, followed 
by a wash with deionized water for 2 s and immediate removal of the wash solution. Seven 
mL of metabolite extraction solvents (HPLC grade methanol: acetonitrile: 0.5 M formic 
acid, 2:2:1 v/v, -20 oC) was added immediately for quenching and lysing the cells. 26 Cells 
were then scraped down, and the cell suspension was transferred to centrifuge tubes, 
followed by vortexing and sonication in ice water bath and incubation on ice for 15 min 
for metabolite extraction. The cell suspension was then centrifuged at 20,400 g at 4 oC for 
15 min. Solvent in the sample was evaporated using a CentriVap Vacuum Concentrator 
until dryness. The dried samples were kept at -80 °C until analysis. [26] 
Sample preparation for proteomics experiments. Cells were cultured in 60 mm Petri 
dishes. Ice-cold lysis buffer (50 mM HEPES, pH 7.8, 150 mM NaCl 0.1% SDS (optional) 
0.5% sodium deoxycholate 1% Triton X 100 or NP-40, phosphatase inhibitors) was added 
directly to the cells after washing with PBS twice. The cells were then scraped down and 
the obtained mixtures homogenized with sonication and vortexing. Cell debris was then 
 123 
removed by centrifugation at 18,000 g for 20 min at 4 °C. Four volumes of ice-cold 
acetone/ethanol/acetic acid (v/v/v = 50/50/0.1) was added to the supernatant to precipitate 
the proteins at -20 °C overnight. After centrifugation, the protein pellet was re-dissolved 
in denaturing buffer (pH 8.0) containing 8 M urea and 50 mM HEPES, and the protein 
concentration was tested using a Bradford assay. The disulfide bonds in the protein solution 
were reduced by 2 mM dithiothreitol (DTT) at 37 °C for 2 h and subsequently alkylated by 
adding 6 mM iodoacetamide (IAA) and kept in darkness at room temperature for 40 min. 
[27] 
Ultra-Performance Liquid Chromatography (UPLC)-MS Metabolomics Analysis. 
Before analysis, ultrapure water was added to each dried sample to obtain a final biomass 
concentration of ~50,000 cells/ μL. Samples were further vortexed and then centrifuged at 
15,000 rpm for 10 min at 4 °C. The supernatant of each biological sample was transferred 
to autosampler vials for UPLC-MS analysis. Gradient elution was employed in the 
chromatographic separation method using 0.1% acetic acid in water (mobile phase A) and 
acetonitrile (mobile phase B), with the following program: 0-1 min, 98% A, 1-3 min 98%-
70% A, 3-8 min 70%-50% A, 8-10 min 50%-5% A, 10-15 min 5% A. The flow rate was 
constant at 0.3 mL min-1. After each sample run, the column was re-equilibrated to the 
initial conditions in 6 min. The injection volume was 5 μL. The column and auto sampler 
tray temperatures were set at 35 and 5 °C, respectively. The mass spectrometer was 
operated in negative ion mode with a probe capillary voltage of 2.2 kV and a sampling 
cone voltage of 45.0 V. The source and desolvation gas temperatures were set to 120 and 
350 °C, respectively. The nitrogen gas desolvation flow rate was 650 L/h. The mass 
spectrometer was calibrated across the range of m/z 50-1200 using a 0.5 mM sodium 
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formate solution prepared in 2-propanol/water (90:10 v/v). Data were drift corrected during 
acquisition using a leucine encephalin (m/z 554.2615) reference spray (Lock Spray) 
infused at 3 μL min-1. Data were acquired in the range of m/z 50-1200, and the scan time 
was set to 1 s. Technical duplicates were acquired in all cases. Tandem MS experiments 
were carried out by fast data dependent acquisition (fast DDA) or MS/MS in negative 
polarity and resolution mode. Targeted ions for MS/MS were entered in an include list. A 
0.2 s continuum MS survey scan was collected from 50 to 650 Da until the intensity of an 
individual precursor ion raised above 5000, then switched to MS/MS acquisition, in which 
a 0.1s continuum scan was collected from 30 to 650 Da. The MS/MS scan switched off 
once the accumulated total ion current reached 100,000 or after 0.25 s. A collision energy 
profile of 15, 25 and 35 V was applied to the trap cell for ion fragmentation. For the MS/MS 
method, a scan time was 1s and collision voltages between 8 to 30 V were applied to the 
trap cell.  Data acquisition and processing were performed with Masslynx v4.1.  
LC-MS/MS Analysis for proteomic experiments. Purified and dried peptide samples 
were dissolved in a 10 μL solution containing 5% ACN and 4% formic acid (FA), and 3 
μL was loaded onto a micro capillary column packed with C18 beads (Magic C18AQ, 3 
μm, 200 Å, 100 μm x 16 cm, Michrom Bioresources) by a Dionex WPS-3000T PLUS auto 
sampler (UltiMate 3000 thermostatted Rapid Separation Pulled Loop Well Plate Sampler). 
Peptides were separated by reverse-phase chromatography using an UltraMate 3000 binary 
pump with a 110-min gradient of 8-38% ACN (with 0.125% FA) for the triplicates. 
Peptides were detected with a data-dependent Top 20 method (the 20 most abundant ions 
were selected for MS2), [28] in a hybrid dual-cell quadrupole linear ion trap – Orbitrap 
mass spectrometer (LTQ Orbitrap Elite, Thermo Fisher, with Xcalibur 3.0.63 software). 
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For each cycle, each full MS scan (resolution: 60,000) in the Orbitrap at 106 AGC target 
was followed by up to 20 MS/MS for the most intense ions in the LTQ. The selected ions 
were excluded from further analysis for 90 seconds. Ions with singly or unassigned charge 
were not sequenced. For each full MS scan, the maximum ion accumulation time was 1000 
ms and the one for MS/MS scans was 50 ms. Mass spectra Raw files were converted into 
mzXML format, then searched using the SEQUEST algorithm (version 28). [29] Spectra 
were matched against a database containing sequences of all proteins in the UniProt Human 
(Homo sapiens) database (downloaded in February 2014). The search was performed using 
following parameters: fully digested with trypsin; up to 3 missed cleavages; fixed 
modifcations: carbamidomethylation of cysteine (+57.0214); variable modifcations: 
oxidation of methionine (+15.9949). False discovery rates(FDR) of peptide and protein 
identifications were controlled by the target-decoy method. [30] Linear discriminant 
analysis (LDA) was used to control the quality of peptide identifcations using parameters 
such as Xcorr, precursor mass error, and charge state.  [31] Peptides fewer than seven amino 
acid residues in length were deleted. Furthermore, peptide spectral matches were filtered 
to <1% FDR.  
Data analysis. For metabolomics, spectral features (retention time (Rt), m/z pairs) were 
extracted from UPLC-MS data using Progenesis QI version 2.0 (Nonlinear Dynamics, 
Waters Corp.). The data preprocessing procedures included retention time alignment, peak 
picking, integration, and de-convolution to group the adducts derived from the same 
compound.  
Raw data from metabolomics were normalized using supervised normalization of 
microarray. [32] In the SNM procedure, variances due to biological and technical replicates 
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were adjusted by setting them as variables in the model. Variance explained by different 
experimental treatments (control, AuNRs@NLS, and AuNRs@NLS/PPTT) was fitted as 
a biological variable in the model. Clustering analysis on similarity matrix of metabolomics 
data was carried out to verify the reproducibility of metabolomics experiments. 
Hierarchical clustering was done with JMP software (JMP®, Version 9. SAS Institute Inc., 
Cary, NC.). Metabolomics data were log2 transformed before analysis of variance 
(ANOVA) which was used to detect differential levels of metabolites between control and 
treatment groups. We fitted models with treatment conditions as fixed effects. A 
Benjamini-Hochberg 5% false discovery rate (FDR) correction was used to select 
differential metabolites. For identified differential metabolites perturbed by PPTT, we used 
the Mummichog program for network-level metabolites annotation. [33] The MS mode 
considered in Mummichog was negative ion in order to compute isotopic and adduct 
species. The metabolites identified as being affected by PPTT were subjected to pathway 
analysis using the MetaCore pathway analysis software (“MetaCore from Thomson 
Reuters”).  
For proteomics, raw data were also normalized using SNM. Clustering analysis on the 
similarity matrix of data was also carried out to show the reproducibility of the 
experiments. Hierarchical clustering was done with JMP software (JMP®, Version 9. SAS 
Institute Inc., Cary, NC). The identified proteins were subjected to pathway analysis using 
the MetaCore pathway analysis software (“MetaCore from Thomson Reuters”) to study the 
effect of PPTT.  
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2.4.3 Results and Discussion  
Formulation of AuNRs and cell uptake 
To perform PPTT inside human oral squamous cell carcinoma (HSC-3) cells, AuNRs 
were used to efficiently convert NIR light into heat. The AuNRs were synthesized using a 
seedless method [34] with an average size of 25 x 6 nm as shown in Figure 2-15b (TEM 
figure) which has an absorption maximum at about 800 nm (as shown in the UV-Vis 
spectrum in Figure 2-15c). This particle size is favorable in conducting PPTT as it has 
better conversion of light into heat efficiency. [35] 
For formulation of AuNRs@NLS, we first used methoxypolyethylene glycol thiol 
(mPEG-SH) to modify the surface of AuNRs to gain better biocompatibility. [36] The 
PEGylated particles were then functionalized with Arg-Gly-Asp (RGD) peptides (known 
to bind to Rvβ6 integrin on the surface of cancer cells to enhance the receptor-mediated 
endocytosis of the nanoparticles) [37] and nuclear localization signal (NLS) peptides 
(peptide sequences that are recognized by importin and translocate near the nucleus [38]) , 
as shown in Figure 1a. Successful surface modification of AuNRs@NLS is evident in the 
red-shift of the plasmon peak of AuNRs to longer wavelengths, from 800 nm for the as-
synthesized AuNRs to 825 nm AuNRs@NLS (Figure 2-15c). The zeta potentials of the 
AuNRs at different stages were measured (Table A.2.) to confirm surface modifications. 
The as-synthesized CTAB-coated AuNRs had highly positive surface charges as imparted 
by the CTAB cationic surfactant. Following PEG modification, the AuNRs became 
negatively charged (-10.2 ± 6.73 mV). The zeta potential of the AuNRs became positive 
again after further modification of the RGD and the NLS peptides. 
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The uptake of AuNRs was first monitored by dark-field (DF) microscopy. The HSC cells 
were incubated with 2.5 nM of AuNRs for 24 h. For AuNRs@NLS, as shown in the DF 
image (Figure 2-10d), clear internalization of AuNRs@NLS was observed compared with 
cells not exposed to AuNRs and cells exposed to AuNRs without targeting agents. The DF 
image shows AuNRs@NLS accumulated in nuclear regions. In addition, the UV-Vis 
spectra of culture media with AuNRs before and after incubation with cells were also 
collected (Figure 2-10e), which showed the decrease of the peak intensity that, gives the 
portion of AuNRs being uptaken by the cells. Differential interference contrast (DIC) 
microscopy image also confirmed the cellular internalization of AuNRs@NLS (Supporting 
Figure A.12.). In summary, AuNRs were successfully formulated and then introduced into 
cells with good cell uptake. The cell viability and apoptosis were tested under different 
concentrations of AuNRs. The results indicate that the concentration of the AuNRs utilized 
in this study is much lower than that affecting cell viability or inducing apoptosis 
(Appendix Figure A.13.). 
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Figure 2-15. Characterization of conjugated AuNRs and measurement of HSC-3 
(human squamous carcinoma) cell endocytosis with AuNRs: 
 (A) Schematic showing the surface conjugation of the AuNRs with PEG, followed by 
RGD and NLS. (B) Transmission Electron Microscope (TEM) image of conjugated 
nanorods (AuNRs). Scale bar = 100 nm. (C) UV-Vis absorption spectra of the 
unconjugated AuNRs (black spectrum), AuNRs conjugated with NLS (red spectrum). 
(d) The dark field images of control HSC-3 cells (not exposed to AuNRs), cells exposed 
toAuNRs@PEG and cells exposed to AuNRs@NLS for 24 h. Scale bar = 20 nm. (e) 
UV-Vis absorption spectra of the AuNRs@NLS dispersed in culture media before 
(black spectrum) and after (red spectrum) incubation with cells.  
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SERS of cancer cells undergoing AuNRs-based photothermal therapy 
The AuNRs with dimensions (25×6 nm) [24] and concentration (2.5 nM) was selected for 
use of heat generation. After incubation with AuNRs for 24 h, a CW 808 nm NIR laser 
with power of 5.8 W/cm2, [1, 39-40] was used for irradiation of the cells for different time 
intervals. The laser wavelength overlapped with the longitudinal SPR peaks of the AuNRs. 
The temperature rose to 45 °C after 2 min of laser exposure. The effect of PPTT was 
confirmed using a cell viability assay and apoptosis/necrosis assay. The cell viability 
results showed a significant decrease in the percentage of viability (∼40%) for the HSC 
cells incubated with AuNRs (2.5 nM) after exposure to the 808 nm NIR laser for 3 min 
(Appendix Figure A.14.). In the apoptosis/necrosis assay, cells were labeled with Annexin 
V and propidium iodide (PI), and the fluorescent signals were examined by flow cytometry. 
As shown in Figure A.14, the number of apoptotic cells significantly increased after 
applying PPTT.  The decrease of cell viability and increase of apoptosis indicated the 
efficacy of PPTT. 
For real-time SERS measurement, spectra were collected at a single spot of cells to avoid 
the variation due to changing location. A 785 nm laser was focused on a single cell and 
spectra were recorded. As our AuNRs have weak SERS signals (due to their small size), to 
enhance the signals, 40 nm gold nanosphers (AuNSs) with the same surface modification 
as AuNRs were used to assist the detection. [37] The detailed information of AuNSs@NLS 
characterization and cellular uptake was in Appendix Figure A.15. The introduction of 
AuNSs does not affect AuNRs uptake or SERS spectra shapes during PPTT process due to 
their small amount and not absorbing NIR light (Appendix Figure A.16. and A.17.a). SERS 
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spectra of HSC cells without PPTT were comparable with our previous publications [41-
42] with the possible assignment of each peak in Appendix Table A.3. Upon NIR laser 
exposure, the band around 1000 cm−1 increased in intensity due mainly to the benzene ring 
breathing of phenylalanine as mentioned before. [7] Though most of the publications assign 
this band to phenylalanine, some debate is still going on regarding its assignment 21Further, 
we observed that the enhancement of the 1000 cm-1 peak was accompanied by the 
enhancement of the 1207 and 1580 cm−1 bands (Figure 2-16a), which are attributed to the 
in-plane CH stretching vibrations and side chain vibration coupled with the in-phase 
motion corresponding to phenylalanine.43-44 The same experiment was repeated 3 times 
and the same trend of peak intensity changes of 1000, 1207 and 1580 cm-1 was obtained 
(Figure 2-16b and Appendix Figure A.18.). SERS data of cells 12 hours after PPTT has 
also been performed to confirm that the signal remains altered (Figure A.19.).  On the other 
hand, a control experiment was conducted on cells without laser exposure. No obvious 
SERS spectral change was observed during the NIR laser control.  (Appendix Figure 
A.17.b). This gave us more evidence of the phenylalanine increase after the PPTT process. 
Generally, we can rule out the possibility of tryptophan contributing to the 1000 cm-1 signal 
since side-chain vibrations in its SERS spectrum appear at 758, 869, 1011, 1357, 1410, 
1546 and 1602 cm-1, corresponding to the counterparts at 756, 874, 1009, 1358, 1423,1558 
and 1619 cm-1 in the solid Raman spectrum.45 However, our SERS data didn't show 
obvious increase of these above peaks. Therefore, our SERS results support the conclusion 
that the phenylalanine increases in the microenvironment around nanoparticles during 
PPTT. 
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In addition to the phenylalanine bands we also observed a 750 cm-1 band whose intensity 
increases during PPTT (Figure 2-16), which has been assigned to the pyrrole breathing 
mode ν15 in cytochrome c. [46-47] This result suggested the increase of apoptotic cells 
during thermal heating through cytochrome c-mediated apoptosis.  This result is in 
agreement with our flow cytometry data (Appendix Figure A.14.) indicating that PPTT 




Figure 2-16. SERS spectra: 
(A) collected from single HSC-3 cell under NIR laser exposure of (808 nm diode laser 
5.8 W/cm2) at 1 and 2 minutes’ delays. The 750, 1000, 1207, and 1580 cm-1 bands are 
shown in red and placed in red boxes in (A) and shown in the bar graphs in (B) Raman 
bands associated with bio-molecules located within the AuNP plasmonic field. 
 
Metabolomics and proteomics experiments confirming perturbation of phenylalanine 
metabolism during AuNRs-PPTT 
    For metabolomics experiments, we analyzed the metabolites of cells using liquid 
chromatography-mass spectrometry (LC-MS).  Two biological replicates and two technical 
replicates were conducted. A total of 1122 tentative features (retention time, m/z pairs) 
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were detected in metabolite extracts, corresponding to 152 metabolites with detectable 
([M-H]-) primary ion. Hierarchical clustering analysis on the similarity matrix of 
metabolomics data was carried out to verify the reproducibility of the experiments 
(Appendix Figure A.20.b). Among these, 238 metabolomics features were differentially 
expressed in the AuNR@NLS-treated group when compared to the control group 
(FDR=0.05, corresponding to p=0.015) (Appendix Figure A.20.e); 483 metabolomics 
features were differentially expressed in the AuNR@NLS/PPTT group in contrast to the 
control group (FDR=0.05, corresponding to p=0.015) (Appendix Figure A.20.f). 
Specifically, many of these features corresponded to an increase in the relative amount of 
phenylalanine (Figure 2-17a) and related species after PPTT (Figure 2-17b-d, Appendix 
Figure A.21.). Phenylalanine derivatives and phenylalanine-containing short peptides, 
such as glutamylphenylalanine (Figure 2-17b), asparaginyl-phenylalanine (Figure 2-17c), 
histidinyl-phenylalanine (Figure 2-17d) were amongst those altered, explaining the trends 
observed in the SERS data. Tandem MS experiments confirmed the identity of the species 




Figure 2-17. Metabolite perturbations observed in HSC-3 cells treated with AuNRs-
PPTT (NLS conjugated particles): 
(A-D) Bar graphs showing the normalized abundance of phenylalanine-related 
metabolites altered following PPTT. Normalized abundances of metabolites following 
AuNRs@NLS without PPTT are also given for comparison. (A) L-Phenylalanine. The 
result was confirmed by MS/MS (shown in figure 3e). (B) Glutamylphenylalanine. (C) 
Asparaginyl-Phenylalanine. (D) Histidinyl-Phenylalanine.  (E) Product ion spectrum 
obtained under data dependent acquisition (DDA) conditions for the precursor ion at 
m/z 164.0710. Matching of this mass spectrum to the Metlin database MS/MS 
reference spectrum of phenylalanine (10 V collision energy) is shown with mass 
accuracies indicated for each ionic species detected. 
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    Furthermore, we also conducted a label-free quantitative proteomics experiment for 
studying alterations in protein abundances and seeking possible evidence for, and 
understanding of the mechanisms responsible for the phenylalanine concentration increase. 
A test experiment was done to measure the accuracy of our proteomics workflow using the 
reported method, [27] where 99% of the proteins have shown accurate quantification 
(Appendix Figure A.22.). In our proteomics experiment, two biological replicates and 
three technical replicates were conducted. Clustering analysis (Appendix Figure A.20.a) 
indicated good reproducibility for the proteomics experiments. In total, 1341 proteins were 
identified. Among these, 326 proteins were differentially expressed in the AuNR@NLS-
treated group compared to the trol group (Appendix Figure A.20.c); 278 proteins were 
differentially expressed in the AuNR@NLS/PPTT-treated group in contrast to the control 
group (Appendix Figure A.20.d).   
Proteomics results were integrated with metabolomics for a more holistic understanding of 
the biological processes involved. Integrated pathway analysis showed that the 
phenylalanine metabolism pathway was significantly perturbed by PPTT (Appendix 
Figure A.23. and A.24.). Approximately half of the metabolites in the phenylalanine 
metabolism pathway were identified as changes, including 2-phenyl-acetamide (increase), 
phenylpiruvate (decrease), 2-hydroxy-3-phenyl-acrylic acid (decrease), 3-oxobutanoate 
(increase), fumarate (increase), phenylacetaldehyde (increase), L-tyrosine (decrease), 4-
fumarylacetoacetate (decrease) and 4-maleylacetoacetate (decrease). These alterations 
were accompanied by perturbations in several key proteins in the phenylalanine 
metabolism pathway.  
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Elevated levels of phenylalanine are known to induce apoptosis, [44-45] which is consistent 
with the apoptotic phenotype observed in PPTT-treated cells. An overview of pathways 
identified as being related to phenylalanine-induced apoptosis is schematically shown in 
Figure 2-13A. Two proteins in the phenylalanine metabolism pathway have been 
previously associated with apoptosis. Mitochondrial acetyl-CoA acetyltransferase 
(ACAT1) has been shown to be involved in the development of doxorubicin resistance to 
decrease cell apoptosis.48 Another mitochondrial protein, hydroxyl-coenzyme A 
dehydrogenase/3-ketoacyl-coenzyme A thiolase/enoyl-coenzyme (HADHA), has been 
shown to prevent chemically-induced apoptosis in cancer treatment. [49] In our 
experiments, both proteins were observed to be down-regulated following PPTT treatment, 
suggesting that the anti-apoptotic protection was turned off resulting in enhanced 
vulnerability to apoptosis (Figure 2-18b, c).  
In addition to the phenylalanine metabolism pathway, three possible mechanisms of 
phenylalanine-induced apoptosis were suggested by the results. Firstly, increased 
phenylalanine was shown to induce apoptosis by involvement of the Fas receptor (FasR)-
mediated cell death receptor pathway.50 In this study, two proteins (Lamin B1 and PAK1) 
in the Fas/Fas ligand death receptor pathway were identified. These two proteins have been 
previously demonstrated to be associated with apoptosis. Lamin B1, as the major 
component of the nuclear lamina underlying the nuclear membrane, plays an important role 
in maintaining nuclear membrane integrity. Destruction of nuclear membrane integrity 
being a hallmark of apoptosis. During apoptosis, Lamin B1 mRNA level have been shown 
to decrease, [51] which could result from induction of either p53 or pRB tumor suppressor 
pathways. [52-53] Literature results also show that the Fas/Fas ligand complex downstream 
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effector PAK1 is required to prevent apoptosis by limiting the expression of pro-apoptotic 
proteins or modulating post-translational modifications on effectors. [54-56] In this study, 
both proteins were down-regulated, suggesting a cellular shift towards apoptosis, and 
reduced anti-apoptotic protection (Figure 2-18d,Figure 2-18e).  
Phenylalanine has also been shown to activate mitochondria-mediated apoptosis through 
the Rho/ROCK pathway. [56] In this study, we identified down-regulation of the myosin 
phosphatase targeting subunit 1 (PPP1R12A) in PPTT-treated cells, this being a 
downstream effector of ROCK (Figure 4f) that would contribute to the apoptotic phenotype 
following PPTT. In apoptotic cells, PPP1R12A is cleaved, with the cleaved PPP1R12A 
inhibiting myosin II binding, which results in membrane blebbing and apoptosis. [57]  
A third mechanism of phenylalanine-induced cell death involves a component in Granzyme 
B signaling-mediated apoptosis, known as lysosome-associated membrane protein 2 
(LAMP2). This protein was down-regulated following PPTT treatment (Figure 2-18g).  
LAMP2 is critical to maintain lysosome integrity and normal cellular function, and lower 
levels of LAMP proteins have been positively associated with apoptosis. [55] It is not yet 
conclusively established, however, whether decreased LAMP2 levels are also directly 




Figure 2-18. (A) Schematic diagram explaining the molecular apoptosis mechanisms 
involved in altering phenylalanine metabolism as induced by PPTT 
   (B-G) Bar graphs showing the normalized abundance of key proteins contributing 
to apoptosis involved in altering phenylalanine metabolism following PPTT. 
Normalized abundances of key proteins following AuNRs@NLS without PPTT are 
also given for comparison. (B) HADHA. (C) ACAT1. (D) Lamin B1 (LMNB1). (E) 
PAK1. (F) PPP1R12A. (G) LAMP2. 
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    Time-dependent SERS has recently enabled to probe molecular changes in single 
(cancer) cells in time during the full cell cycle, or as the cell dies from exposure to drugs 
or from heat treatment. SERS accurately follows changes in cellular and subcellular 
environments during the onset and progression of processes such as apoptosis and mitosis 
7 in real-time and at a single cell level. Cells present several active molecular Raman bands 
associated with bio-molecules located within the AuNP plasmonic field.  
    Herein, we coupled SERS measurements with metabolomics and proteomics 
experiments performed on the same set of samples, aiming to study the change of the 
subcellular microenvironment around AuNRs during the PPTT process. Our SERS data 
showed that the 1000, 1207 and 1580 cm-1 bands increased during PPTT, which suggested 
an increase of phenylalanine and its derivatives. These findings were confirmed with whole 
cell metabolomics experiments using high resolution mass spectrometry. We observed an 
increase of free phenylalanine, together with an increase of its derivatives and 
phenylalanine-containing peptides. Integrative analysis of proteomics and metabolomics 
data also showed that the proteins and metabolites in the phenylalanine metabolism 
pathway related to apoptosis were perturbed in apoptosis direction. Elevated levels of 
phenylalanine have been implicated in mitochondria-mediated apoptosis through 
Rho/ROCK pathway and Fas/Fas ligand mediated apoptosis. [50,58] In this study, both 
pathways were changed in favor of apoptosis in PPTT where level of phenylalanine was 
increased. In addition, the results suggested that during phenylalanine-induced apoptosis, 
lysosome integrity may have been perturbed, which may further contribute to cell death. 
This hypothesis was further strengthened by the observation of an increasing pattern of 
pyrrole breathing mode ν15 in cytochrome c shown in the SERS spectra (750 cm
-1), which 
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suggests the increase of apoptotic cells during thermal heating through cytochrome c-
mediated apoptosis, which agrees with flow cytometry data (Appendix Figure A.14.). 
Meanwhile, some other apoptosis pathways were revealed by proteomics in Appendix 
Figure A.25.  
Further investigations into the mechanism of how PPTT treatment increases phenylalanine 
levels in cells focused on the fact that phenylalanine can be converted to L-tyrosine. [59-
60] Metabolomics data indicated that after PPTT treatment, the level of L-tyrosine was 
decreased (Appendix Figure A.23.).  Based on our results, the channel allowing for the 
conversion from phenylalanine to L-tyrosine could have contributed to the accumulation 
of phenylalanine, which further induced mitochondria-mediated apoptosis. 
We observed in our result that several metabolites/proteins change abundance in the 
presence of AuNRs even without light exposure, which is possibly due to the gold 
nanoparticles alone could perturbed apoptosis pathways of the biological system, which is 
reported previously. [61] This effect, however, comparing to the effect of PPTT treatment 
on apoptosis pathways, is to a much smaller extend, and did not cause actual apoptosis 
(Appendix Figure A.13.). 
Besides phenylalanine dependent process, we further identified significantly perturbed 
pathways by integrative analysis of proteomics and metabolomics (Appendix Figure 
A.24.). Other amino acids metabolism pathways are enriched, including methionine-
cysteine-glutamate, and lysine metabolism, which are very essential for the basic survival 
of the cells. Interestingly, we also found clues on the perturbation of pathways related to 
lipid metabolism and ketone body metabolism. [62-63] 
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2.4.4 Conclusion and Future Outlook 
 By integrative analysis of Raman spectroscopy profiles, metabolomics and proteomics 
mass spectrometric data, we discovered that free phenylalanine and associated metabolites 
are significantly perturbed by PPTT, leading to cell apoptosis. We therefore propose that 
phenylalanine measurements by SERS can be developed as a sensitive and convenient 
readout for non-invasive direct apoptosis characterization. 
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CHAPTER 3. APPLYING THE PLASMONIC PHOTOTHERMAL 
THERAPY IN XENOGRAFT MICE AND NATURAL 
MAMMARY GLAND TUMORS 
3.1 The Long-Term Effects of Gold Nanorods in a Mouse Model: Circulation, 
Biodistribution, and Toxicity [1] 
    Gold nanorods (AuNRs) have great potential in plasmonic photothermal therapy (PPTT) 
for the treatment of cancer. However, there is limited knowledge regarding their 
biodistribution, long-term fate, and systemic toxicity. Herein, we examine the long-term 
toxicity (15 months) of AuNRs size (72 x 19 nm), the surface coating (polyethylene glycol 
(PEG) in BALB/c mice. Our results demonstrate that the density of PEG on the surface of 
AuNRs greatly decreases, while increasing tumor accumulation of AuNRs. More 
importantly, we observed no organ morphology changes after exposure to AuNRs for 15 
months. In conclusions: To our knowledge, this is longest duration systemic toxicity and 
biodistribution study of AuNRs to date and these results suggest that AuNRs are safe and 
viable as anti-cancer agents. 
 
3.1.1 Introduction 
    Owing to their absorption in the near infrared region, gold nanorods (AuNRs) have 
demonstrated great potential for use in plasmonic photothermal therapy (PPTT) of cancer, 
[2-4] as well as diagnostic imaging and biosensing. [5,6] However, there is insufficient 
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knowledge of their long-term fate, systemic toxicity and biodistribution with respect to 
surface coating (including tumor targeting ligands) and particle size.  
    The use of gold nanoparticles in in vitro cancer diagnosis and treatment [2,3,7] has 
drawn considerable attention to their potential in vivo toxicity profile, which remains 
largely undefined [8]. While one study has reported that citrate-capped AuNPs do not 
demonstrate significant cytotoxicity [9], other studies report that their presence in dermal 
fibroblasts results in actin stress, thus inducing major adverse effects on cell viability. [10] 
Some studies have shown that PEG-coated spherical AuNPs induce apoptosis and 
inflammation in a mouse liver, indicating the possibility of acute toxicity induced by other 
types of AuNPs. [11] While several other studies have reported that there is no significant 
short-term toxicity of AuNPs. [20,19, 21] The preservation of AuNPs, without significant 
clearance from the body for over six months, has been reported for spherical AuNPs.5 Such 
accumulation of metallic AuNPs within the body, over a long-time, raises significant 
concerns regarding their long-term safety. Toxicity is also reported to be largely dependent 
on the size, shape, structure, and surface properties of the AuNPs.[15, 17] A comprehensive 
investigation of the organ uptake, biodistribution, long-term fate, and toxicity of AuNRs, 
based on size and surface chemistry, is essential to the fundamental understanding of in 
vivo biological interactions of these nanoparticles.[18, 19] Polyethylene glycol (PEG) is 
known to safeguard against plasma protein adsorption in vivo and has thus been widely 
used as a biocompatible stabilizing agent of AuNPs, enabling passive tumor targeting via 
the enhanced permeability and retention (EPR).[9, 18, 22-27] However, it is not fully 
understood whether PEG molecular weight and additional conjugation of tumor targeting 
ligands affects biodistribution or toxicity in vivo. In the present study, we have synthesized 
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AuNRs with the size of 72 x 19 nm (width x length). We modified the particle surface with 
varying densities of PEG (500, 1000 and 10000 PEG ligands/AuNR), and further 
conjugated the AuNRs with a head and neck squamous cell carcinoma targeting peptide 
(HNSCP-1). We have determined the biodistribution and the associated toxicities of these 
AuNRs in a BALB/c xenograft mouse model of squamous cell carcinoma of the head and 
neck squamous cell carcinoma (SCCHN). In addition, the short-term and long-term fate 
(up to 15 months) of the different AuNRs were also investigated. Our results suggest that 
AuNR-based agents provide a promising approach for the treatment of head and neck 
cancer.  
 
3.1.2 Experimental Methods 
 
3.1.2.1 AuNRs (72 X 19nm) Synthesis by Seed-Mediated Growth Method [27] 
    AuNRs of 72 nm length were synthesized at 25°C using the seed-mediated growth 
method where a seed solution consisting of 0.2 M CTAB, 1.0 mM HAuCl4 and 0.01 M 
NaBH4 was prepared and added to a growth solution containing 1.0 mM HAuCl4, 0.2 M 
CTAB, 4.0 mM silver nitrate and 78.8 mM ascorbic acid. The aspect ratio and a surface 
plasmon resonance (SPR) of the AuNRs were obtained by adjusting the amount of silver 
nitrate added to the growth solution, and the large CTAB stabilized AuNRs were purified 
by centrifugation and redispersed in DI H2O.  
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3.1.2.2 Functionalization of AuNRs 
     AuNRs were conjugated with a thiol-modified PEG (M.wt 5000) at varying surface 
coverages;  500, 1000 and 10000 PEG/AuNR while small AuNRs were conjugated with 
1000, and 10000 PEG/AuNR. The PEG bounded to the surface has been calculated by the 
measuring the difference between the concentration of the original PEG before addition to 
the AuNRs and the one that left in the supernatant (with free -SH group) using Elman’s 
reagents by calculating the molarity of (-SH) groups in the assay find the absorbance and 
divide by 13600 M-1 cm-1 (the extinction coefficient of the reagent).29 It was observed that 
AuNRs’ stability increased with increasing surface coverage of the PEG ligands. PEG-
modified AuNRs were purified with centrifugation and redispersed in DI H2O. In order to 
confirm nanoparticle functionalization, the hydrodynamic diameter (HD) and the size of 
the AuNRs were measured via dynamic light scattering (DLS) and transmission electron 
microscope (TEM). 
 
3.1.2.3 Blood Clearance Properties of AuNRs 
     These experiments were carried out in BALB/c mice (male), 6 weeks of age. The 
animals were injected via the tail vein with AuNRs. At specified time points of 5 min, 30 
min, 2 h, 4 h, 6 h, 8 h, 24 h and 48 h, blood was collected from the retro-orbital sinus in 
pre-weighed heparinized capillary tubes. The blood samples were dissolved with 70% 
nitric acid and assayed for Au using ICP-MS. Blood clearance was analyzed with a two-
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compartmental model using WinNonlin 5.0.1 software. In Figure 7, the blood half-lives 
were compared for the different AuNRs tested. 
 
3.1.2.4 Short-term and Long-Term Uptake Fate of PEG-coated AuNRs 
    BALB/C mice (male), 6 weeks of age, were injected via the tail vein with 200 μl solution 
of AuNRs (0.18mg/kg). At specified time points of 1, 3, 7, 14, 30, 60, and 90 days and 15 
months, the mice were euthanized by pressurized CO2 asphyxiation, 3 mouse each group. 
Organs including the liver, spleen, kidney and lung were collected, rinsed with distilled 
water and dried. The dried tissues were dissolved and assayed for Au using ICP-MS, and 
parts of the organs (liver, spleen, kidney, lung) and muscle (under skin from mouse right 
flank, ~20 mg) were collected and fixed in 10% (v/v) neutral buffered formalin for further 
pathology tests. After AuNRs injection, mice were monitored for clinical signs of toxicities 
including ruffled fur, impeded movement, clear sign of abnormal constitution, aberrant 
behavior, obvious loss of weight, ocular or nasal discharge, and respiratory distress, the 
inability of the animals to walk and diarrhea. [16, 31]   
 
3.1.2.5 Peripheral Blood Analysis 
     Following the treatment, the mice were sacrificed by CO2. One ml of blood was 
immediately harvested in a heparinized tube. Blood hematology analyses were performed 
using an automatic hematology analyzer which included complete blood count (CBC), 
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hemoglobin (Hb), platelet (Plt), LDH (lactate dehydrogenase), and white blood cell count 
with differentials (neutrophil, lymphocytes and eosinophils). Serum samples were 
subjected to chemical analyses of glutamic pyruvate transaminase (GPT), glutamic 
oxaloacetic transaminase (GOT), blood urea nitrogen (BUN), and creatinine (CRE) levels 
using Theoretical Tests Per Kit, on the P-Modular Analytics System manufactured by 
Roche Diagnostics Inc. (Indianapolis, IN). 
    The blood clearance properties of the targeted AuNRs were examined in a healthy mouse 
model using the same procedure as described above. For tumor uptake studies, Tu212 cells 
were subcutaneously planted into the right flank of nude mice (Charles Rivers, Portage, 
MI), 6-7 weeks of age, 3 mice per group, and were allowed to grow to approximately 250 
mm3. AuNRs and a control with saline alone in PBS buffer were injected into mice 
bloodstream via the tail vein. After 2 h, 8 h, 24 h, 48 h and 72 h, the mice were euthanized 
by pressurized CO2 asphyxiation based on IACUC guidelines, and blood, tumor, liver, 
spleen, kidney, lung, brain, bladder and muscle were collected and assayed for Au content 
using ICP as described above.    
 
3.1.2.6 Histopathology Evaluation 
    As described above, the liver, spleen, kidney and lung were dissected from the mice for 
histopathological analysis. The tissues were embedded in paraffin and cut at a 5 μm 
thickness. The tissues were stained with hematoxylin and eosin (H & E) to assess 
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pathology.  The detailed pathologic evaluation of all organs at different time points was 
conducted by American Board Certified Pathologist (HJCS). 
 
3.1.2.7 Nude Mice Bearing Human HNC Xenograft Tumor Model 
     For the tumor uptake studies, the tumors were inoculated by injection of 1x106 HNC 
Tu212 cells subcutaneously into the right flank of nude mice (Charles Rivers, Portage, MI), 
6-7 weeks of age, 3 mice per group, and were allowed to grow to approximately 250 mm3 
(calculated by ab2/2, with a, b representing tumor length and width respectively).  
 
3.1.2.8 Statistical Analysis 
    Paired t-test was conducted to compare differences in the values of same outcome 
variables (Au concentration, body weight change) from the same samples at two different 
time points. Two sample t-test were used for different samples. One-way analysis of 
variance (ANOVA) was employed to test the overall significance across multiple groups. 
We further evaluated pair-wise differences by using Tukey’s method when the overall 
difference was significant at a p value of 0.05. The SAS statistical package (SAS Institute, 
Inc.) was used for all data management and analyses. 
 
 158 
3.1.3  Results and Discussion 
    AuNRs with a surface plasmon resonance at approximately 800 nm (typically prepared 
for use as plasmonic photothermal contrast agents) were achieved (Figure 3-1a). The 
surface of the AuNRs was modified via conjugation with PEG (see Methods section). The 
effect of PEG density on the AuNR surface was studied in terms of circulation half-life, as 
well as uptake, distribution, and clearance in the main organs. Figure 3-1 shows that 
increasing the density of PEG ligands on the AuNR surface (500 ligands/AuNR versus 
1000 ligands/AuNR) prolongs the circulation half-life (8.7 hr versus 14.7 hrs, respectively). 
In addition to circulation half-life, we also compared the uptake, distribution, and clearance 
of AuNRs in the main organs, including the liver, spleen, lungs, and kidney for up to 15 
months after intravenous administration of PEG-conjugated AuNRs at 0.18 mg Au/kg 
(dose comparable to that reported previously).[32]  The concentration of Au remaining in 
organ tissue was also quantified via ICP-MS. Figure 3a and b displays the concentration of 
Au (ng/mg dry tissue) in the RES organs (i.e. liver and spleen, respectively). PEG-
conjugated AuNRs (500 and 1000 PEG ligands/AuNR) accumulate in the RES organs with 
no significant differences observed with increasing or decreasing PEG density on the 
AuNR surface.  The majority of injected PEG-AuNRs were still localized in the liver and 
spleen after 15 months without any adverse morphology changes observed in these organs. 
Additionally, PEG-AuNRs were detected in mouse feces, but not urine (Figure 3-3d), 
suggesting that the PEG-AuNRs were primarily eliminated via bile secretion. 
    To complement the circulation half-life, biodistribution, and organ uptake of PEG-
AuNRs, complete blood count (CBC), hemoglobin (Hb), platelet (Plt), LDH (lactate 
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dehydrogenase), and white blood cell count with differentials (neutrophil, lymphocytes and 
eosinophils) were tested at different time points following intravenous administration of 
PEG-AuNRs, showing no significant changes.  To test for additional adverse effects, body 
weight (Figure 3-4a), blood urea nitrogen levels (BUN, Figure 3-4b), and creatinine levels 
(CRE, Figure 3-4c) were also measured. PEG-AuNRs had no significant effect on body 
weight, nor was there any observed effect on BUN or CRE levels, suggesting that 
intravenous administration of these AuNRs has a minimal impact on renal function. In 
addition, serum glutamic pyruvate transaminase (ALT) and glutamic oxaloacetic 
transaminase (AST) levels were quantified to evaluate the effects on hepatic function after 
administration of PEG-AuNRs of treated mice. Both ALT and AST levels did not change 
significantly in the treated groups compared with the control group (Figure 3-4d).  
    To further characterize the accumulation of the PEG-AuNRs in the RES organs (i.e. liver 
and spleen), transmission electron microscopy (TEM) was utilized to visually observe 
particle uptake and organ tissue microstructure. no adverse changes were observed in the 
liver and spleen tissue microstructure for up to 15 months following intravenous 
administration of AuNRs (Figure 3-3a) PEG-AuNRs. This finding could be significant, 
especially since our previous studies have shown that the AuNRs exhibit greater potential 
as photothermal contrast agents in PPTT, suggesting their enhanced utility in cancer 
therapeutics.  
    Our previous studies, as well as that of other researchers in the field, have demonstrated 
the great success of AuNR-assisted PPTT in the ablation of head and neck tumor 
xenografts, indicating their strong potential as plasmonic photothermal contrast agents for 
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the treatment of cancer in the clinic. That being said, we also realize the limited knowledge 
available regarding several characteristics of this new generation of cancer treatment 
agents, including their biodistribution, long-term fate, toxicity, tumor affinity, and how 
these properties are influenced by tuning the particle size, and surface coating. Toxicity of 
PEGylated spherical AuNPs, specifically inflammation in the liver, has been observed in 
other studies, suggesting the potential for adverse effects with other AuNP-based treatment 
platforms. (32) Our present study suggests that the long-term effects of AuNRs (up to 15 
months in a mouse model) are minimal, in terms of toxicity to major organs. Increasing 
PEG density on the surface of AuNRs can prolong circulation half-life, while addition of a 
tumor targeting peptide (HNSCP-1) increases tumor uptake of AuNRs. Overall, our long-
term study suggests that AuNP-based therapeutics do not exhibit significant toxicities, and 




Figure 3-1 Characterization of AuNRs 
(A) TEM of large rpods (Length 72±7 x Width 19±4 nm), (B) UV-Vis absorbance 
spectra of the large (Length 72 nm, black) CTAB-stabilized AuNRs. The SPR peaks 
of the large and small AuNRs were 767 nm.  



























                                            
 
Figure 3-2: Blood half-life of PEG-conjugated AuNRs 
 (A) 500/AuNR and (B) 1000/AuNR. (C) TEM images shown that the 72 nm AuNRs 
showed no remarkable change in size or shape in the liver 15 months after systemic 







Figure 3-3. Au concentrations are shown in liver 
(A) and spleen (B) of Balb/c mice at different time points after IV injection of a single 
dose of AuNRs (Au: 0.18mg/kg, 3 mice per group). Total Au concentrations in Balb/c 
mice (C) at different time points after IV injection of a single dose of AuNRs (Au: 






Figure 3-4 Toxicity 
Body weight (A), renal (B, C) and liver (D) function changes in mice at different time 





Figure 3-5. TEM images at tow time points AuNRs 
 (Au: 0.18mg/kg, 3 mice per group). 10000 PEG/AuNR (indicated by arrow) found in 
the liver and spleen without morphology changes (up to 15 months) when treated with 
AuNRs (72 nm length). 
 
3.1.4 Conclusion and Future Look 
   This work gives the results of extensive long time study on the bio distribution and 
toxicity effect of gold nanorods (AuNR)s used in the plasmonic photothermal therapy of 
cancer in the xenograft mice. We tested the long-term toxicity and biodistribution of 
AuNRs in different mice organs. No toxicity was observed in the mouse model up to 15 
months after injection of gold nanorods. The long-term safety profile of the AuNRs 
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3.2 Gold Nanorods-assisted Plasmonic Photothermal Therapy of Cancer; Efficacy, 
Toxicity and Mechanistic Studies in vivo [1] 
Gold nanorods (AuNRs)-assisted plasmonic photothermal therapy (AuNRs-PPTT) is a 
promising strategy for combating cancer, in which AuNRs absorb near infrared (NIR) light 
and convert it into heat, causing cell death mainly by apoptosis and/or necrosis. Developing 
a valid PPTT that induces cancer cell apoptosis and avoids necrosis in vivo and exploring 
its molecular mechanism of action is of great importance. Furthermore, assessment of the 
long-term fate of the AuNRs after treatment is critical for clinical usage. We first optimized 
the size, surface modification (rifampicin (RF) conjugation), and concentration (2.5 nM) 
of AuNRs and the PPTT laser power (2 W/cm2) to achieve maximal induction of apoptosis. 
Second, we studied the potential mechanism of action of AuNRs-PPTT using quantitative 
proteomic analysis in mouse tumor tissues. Several death pathways were identified, mainly 
involving apoptosis and cell death by releasing neutrophil extracellular traps (NETs) 
(NETosis), which were more obvious upon PPTT using RF-conjugated AuNRs 
(AuNRs@RF) than with polyethylene glycol thiol (PEG)-conjugated 
AuNRs.  Cytochrome c and p53-related apoptosis mechanisms were identified as 
contributing to the enhanced effect of PPTT with AuNRs@RF. Furthermore, Pin1 and 
IL18-related signaling contributed to the observed perturbation of the NETosis pathway by 
PPTT with AuNRs@RF. Third, we report for the first time a 15-month toxicity study that 
showed no long term toxicity of AuNRs in vivo. Together, these data demonstrate that our 
AuNRs-PPTT platform is effective and safe for cancer therapy in mouse models. These 




Plasmonic photothermal therapy (PPTT) has recently drawn considerable attention for 
cancer treatment, as plasmonic nanoparticles can effectively convert absorbed near infrared 
light into heat that ultimately kills cancer cells [2-5]. Gold nanorods (AuNRs) show unique 
physicochemical properties compared to other gold nanoparticles [6-7], in that they absorb 
and scatter NIR radiation (650−900 nm) strongly, and have suitable aspect ratios (length 
divided by width). AuNRs have been found to be one of the most effective photothermal 
contrast agents [8, 21, 9]. PPTT can induce cell death mainly via two pathways: necrosis 
and apoptosis [10]. During necrosis, the heat induced by PPTT (if above 50 oC) could 
disrupt the plasma membrane, causing the cellular components to leak out and cause 
inflammation, metastasis [11], and harm to surrounding normal tissues. Apoptosis is a 
programmed cell death pathway that triggers cancer cell death [12-13], attenuates 
inflammatory activities, and is regarded as a “cleaner” process of cell elimination. Skewing 
the response toward apoptotic cell death rather than necrotic death will minimize 
inflammatory responses that may promote the damage or destruction of healthy tissues. 
Therefore, modulating PPTT to trigger apoptosis would be more favorable in clinical 
settings [8, 14] It has been reported that different intracellular locations or shapes of 
nanoparticles potentially regulate the switch between necrosis and apoptosis [15]. In this 
study, we aimed to optimize the conditions of AuNRs-PPTT to trigger apoptosis rather 
than necrosis and examined the molecular impact of AuNRs-PPTT in vivo using western-
blot analysis and mass spectrometry-based proteomics.  
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To optimize the efficacy of apoptosis induction, several aspects of the fabrication of 
AuNRs were considered, i.e. the size, dose and surface modifications of AuNRs, in order 
to enhance the internalization of AuNRs and the generation of heat. Effective 
internalization of AuNRs in tumor tissue is a significant challenge [16-
19]_ENREF_12_ENREF_13. To increase the uptake of AuNRs, surface modification with 
ligands that assist endocytosis or block exocytosis has been used, aiming at greater 
nanoparticle retention inside cancer cells [20]. We have previously developed rifampicin 
(RF)-conjugated AuNRs for enhancing the internalization of AuNRs in tumor cells. RF 
was shown to enhance the entry of AuNRs into cells and decrease exocytosis from the cells 
[21]. However, detailed mechanisms of the behavior of RF-coated AuNRs in vivo have yet 
to be explored. Heat generation and dose of the AuNRs must also be considered [22].  
 
To better understand the cellular responses to PPTT, more systematic studies in vivo are 
required. Most previous reports concerning the mechanism of PPTT were only conducted 
in vitro [15] and focus on a single protein or pathway. Several mechanisms have been 
proposed in vitro.  Ali et al proposed heat shock protein 70 as a major player [14]. Pérez-
Hernández et al reported that apoptosis during PTT using gold nanoprisms is mediated by 
proteins Bak and Bax, through the activation of protein Bid [15]. To better understand the 
mechanisms involved, systematic analysis such as mass spectrometry (MS)-based 
proteomics is necessary.  
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The safety profile of AuNRs remains largely undefined [23]. Gold is a chemically inert 
material. Therefore, it is generally considered biocompatible and has been used in some 
routine clinical practices for many years, e.g. in treating rheumatoid arthritis. Several 
studies have reported no significant short term toxicity of AuNPs (1 day to 3 months) [24-
26]. You et al., [27]  ENREF [29] have reported a lack of both acute and chronic toxicity 
over 3 months following multiple injections of PEGylated hollow gold nanospheres in 
mice. _ENREF_23_ENREF_23However, other studies have contradictorily reported that 
the presence of nanoparticles causes cytotoxicity such as actin stress [28], induces 
apoptosis, or causes inflammation in mouse livers [29]. Some studies have explored how 
gold nanoparticle exposure (aside from any heat-induced effects) impacts cells at the 
molecular level, affects pathways such as mitochondrial oxidative phosphorylation, and 
causes oxidative stress [30]. The dose-dependent effects of gold nanoparticles on biological 
systems have been widely recognized [31]. A high dose of NPs or the desorbed surfactants 
from their surface could result in “toxic” behavior [32, 33] Of concern for AuNRs is the 
incomplete purification of surfactant CTAB, which may cause cytotoxicity34. Therefore, 
the optimal dose and purification of AuNRs is of great importance in minimizing toxic 
effects. The preservation of spherical AuNPs without complete clearance over six months 
has been reported [35]. You et al., [27] also reported slow clearance of gold nanoparticles 
from the body during the 3-month period. Such body deposition of metallic NPs over a 
long-period raises significant concerns regarding their long-term safety. Therefore, a 
comprehensive investigation of the organ uptake, biodistribution, longer-term fate and 
toxicity of AuNRs is essential to fundamentally understand their in vivo biological 
interactions and to use this knowledge to minimize their toxicity [25].  
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Here, we report for the first time the long-term in vivo fate of AuNRs 15 months after the 
initial administration, their biodistribution and associated toxicity in a BALB/c mouse 
model, and their efficacy in a head and neck squamous cell carcinoma (HNSCC) xenograft 
model. Our findings add to the current knowledge of AuNRs-PPTT in vivo in regulating 
apoptosis signaling and in providing an effective and safe potential new treatment. This 
study provides a strong framework for the translation of this approach to the clinic. 
 
3.2.2 Experimental Methods 
AuNRs synthesis, conjugation, and characterization: A seedless growth method was used 
for the synthesis of gold nanorods (AuNRs) with an average size of 25 ± 3 nm × 5.5 ± 0.8 
nm (length x width) [36]. Briefly, HAuCl4 (5.0 mL, 1.0 mM) was added to 5.0 mL of 0.2 
M cetyltrimethylammonium bromide (CTAB) at room temperature. Then, 250 μL of 4.0 
mM AgNO3, 8 μL of 37% HCl and 70 μL of ascorbic acid (78.8 mM) was successively 
added and the solution was gently mixed. Immediately afterwards, 15 μL of 0.01 M ice-
cold NaBH4 was injected into the unstirred growth solution and allowed to react for 12 hrs. 
The synthesized AuNRs were then centrifuged at 21000 rcf for 50 min and re-dispersed in 
DI water, followed by a second centrifugation at 19000 rcf for 40 min to remove the extra 
CTAB. A seed-mediated growth method was used for the synthesis of AuNRs with an 
average size of 72 ± 7 nm × 16 ± 4 nm: where 4.0 mM of silver nitrate and 78.8 mM of 
ascorbic acid were added to a growth solution consisting of 0.2 M CTAB, 1.0 mM of 
HAuCl4 and 0.01 M of NaBH4.  Then, CTAB stabilized AuNRs were purified by 
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centrifugation (10000 rcf for 50 min) and redispersed in DI H2O, followed by a second 
centrifugation at 7000 rcf for 30 min. For AuNRs conjugated with PEG, we added mPEG-
SH (1 mM) to the nanoparticles overnight to achieve about 20,000 ligands on each particle. 
For AuNRs conjugated with RF, we first added 50 ml of 0.5 mM bovine serum albumin 
(BSA) (Sigma-Aldrich, USA) to 1 nM AuNRs solution, which was then incubated for 3 h 
at room temperature. Then, 300 μL of 5 mM RF was added to the AuNRs solution and 
incubated for 3 hrs. After conjugation, the particles were centrifuged to remove the extra 
ligands. Transmission electron microscopy (TEM) was used to examine particle size and 
homogeneity. UV-Vis spectrometer and ZetaSizer 3000 (Malvern Instruments) were used 
to examine if the conjugation was successful. For BSA fluorescent quenching experiments, 
excitation and emission measurements were carried out on a Quanta Master™ 300 — 
phosphorescence/fluorescence spectrofluorometer. BSA was used at a concentration of 10-
4 M. The number of RF molecules per AuNRs was calculated according to Ali et al, 37based 
on the UV-Vis spectra. The dose of AuNRs were presented as molar concentration. For 
comparison with other studies, 5 nM = 1 O.D. (optical density) [36]. 
Dark-field images: MDA686TU cells were seeded on glass coverslips in complete growth 
medium for 24 h to achieve 40% final confluence. Cells were incubated with 2.5 nM 
AuNRs with RF or PEG conjugation in supplemented DMEM cell culture medium for 24 
h. Dark field images were taken using an inverted microscope equipped with a dark field 
condenser and Lumenera Infinity2 CCD camera. 20 X objective lens was used to collect 
scattered light from the samples to produce dark field images. 
Differential interference contrast (DIC) microscopy: MDA686TU cells were seeded on 
glass coverslips in complete growth medium for 24 h, then incubated with 2.5 nM AuNRs 
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with RF or PEG conjugation in supplemented DMEM cell culture medium for 24 h. For 
DIC imaging, an inverted Nikon Eclipse Ti-E microscope equipped with Perfect Focus 
System (PFS, 25 nm z-axial resolution) was used for imaging and z-stacks acquisitions 
under DIC microscopy. The DIC mode utilized a DIC polarizer and analyzer pair, a high 
resolution 100×I-R DIC slider, a high numerical aperture (N.A., 1.40) oil immersion 
condenser lens, a Nikon CFI Apo TIRF 100× (N.A., 1.49) oil immersion objective, and a 
12 V/100 W halogen lamp as light source. Appropriate bandpass filters were placed in the 
light path. Z-stack movies were taken by a Hamamatsu ORCA-Flash 4.0 V2 CMOS camera 
(C11440-22CU, pixel size: 6.5 µm × 6.5 µm) with Camera Link interface using Micro-
Manager and analyzed using NIH ImageJ and reconstructed in Amira. Fixed Hey cells on 
22 mm × 22 mm glass coverslips were rinsed with DPBS at pH 7.4 and fabricated into a 
sandwiched chamber with two pieces of double-sided tape and a cleaned glass slide. PBS 
solution was added into the chamber to fill the space and the chamber was sealed with clear 
nail polish. The sample slide was then placed under the microscope for observation. Z-
stacks were acquired using the Multi-Dimensional Acquisition function in Micro-Manger. 
DIC optical sectioning (shown as a video in Supporting Information) through the whole 
cell thickness was achieved by moving the objective on the motorized nosepiece using PFS 
at 65 nm/step at 33 ms (30 fps) exposure time. 
Cell lines: Information and primary sources of HNSCC cell lines MDA686TU, Fadu, 
SqCC/Y1 were described elsewhere [38]. UD-SCC2, UM-SCC-47 cell lines were obtained 
from Dr. Ferris (University of Pittsburg Cancer Center). Cells were maintained in 
DMEM/F12 (1:1) medium supplemented with 10% heat-inactivated FBS in a 37C, 5% 
CO2 humidified incubator.  
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Cell viability assay: Sulforhodamine B (SRB) assay was used for cell viability 
determination 39. Cells were seeded (5103 cells/well) in a 96-well plate. 24 hrs later cells 
were treated with AuNRs for 24 hrs and exposed to laser for 2 min. Cells were fixed after 
another 24 hrs. Plates were stained with SRB and bound SRB was dissolved to assess OD 
at 492 nm using a microplate reader. The percentage of surviving cells was calculated based 
on the absorbance values relative to the non-treated samples.  
Apoptosis assay: Apoptotic cells were identified and measured as described elsewhere 
[40]. Briefly, cells were collected and stained with Annexin V-phycoerythrene and 7-AAD 
(BD PharMingen) for 15 min at room temperature. Samples were measured using a 
fluorescence-activated cell sorting (FACS) caliber bench-top flow cytometer (Becton 
Dickinson). FlowJo software (Tree Star) was used for apoptosis analysis. 
Western blot analysis: Western blot was incubated with primary followed by secondary 
antibodies and detected using enhanced chemiluminescence system as described [40]. 
Primary antibodies were anti-phospho-Akt, anti-total Akt, anti-phospho-Erk, anti-total Erk, 
anti-caspase3, anti-caspase3, anti-PARP from Cell Signaling, MA; anti-p21 from Santa 
Cruz Biotech, CA; and anti-β-actin from Sigma Aldrich. Secondary antibodies were from 
Santa Cruz Biotech. Western band quantification was performed using Image-Quant TL 
software (GE/Amersham Biosciences, Piscataway, NJ). 
Nude mice bearing human HNSCC xenograft tumor model: Based on protocols approved 
by the Institutional Animal Care and Use Committee of Emory University, female nude 
mice (athymic nu/nu) aged 4–6 weeks were purchased from Taconic. Each mouse was 
injected with 5×106 MDA686TU cells subcutaneously in the right flank, and tumor volume 
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was monitored (volume = 0.5×L×W2). Mice were randomized into groups once the tumors 
reached 70 mm3. Mice were injected intratumorally with PBS or different concentrations 
of AuNRs, and exposed to different powers of NIR laser for 2 min (5 mice/group). Tumors 
were monitored every other day and mice were sacrificed on the 25th day after cancer cell 
transplantation. Tumors and organs were collected, measured and processed for paraffin 
embedding. 
Immunohistochemistry: Upon deparaffinization and rehydration, tissue sections were 
permeabilized with 0.25% Triton-X-100/PBS for 5 min. Tissue sections were blocked with 
2.5% horse serum for 30 minutes. To detect intracellular localization and expression levels 
of Ki67 proteins, we used mouse anti-human Ki-67 antibody (prediluted; Invitrogen, 
Carlsbad, CA) then counterstained cell nuclei using 4,6-diamidino-2-phenylindole (DAPI, 
Invitrogen, Carlsbad, CA). Mouse and rabbit IgG were used as negative controls. 
Sample preparation for proteomics: 5×106 MDA686TU cells were injected into the right 
flank of nude mice. We injected a single dose of AuNRs@PEG (2.5 nM) or AuNRs@RF 
(2.5 nM) intratumorally followed by 2 min of 2 W/cm2 NIR laser exposure when the tumors 
had reached 150 mm3. 24 hours later we collected tumors for proteomics analysis. Each 
experiment was repeated twice. Mouse tumor tissues were homogenized, followed by 
ultrasonic tissue ablation with ice-cold lysis buffer (50 mM HEPES, pH 7.8, 150 mM NaCl 
0.1% SDS, 0.5% sodium deoxycholate 1% Triton X 100 or NP-40, phosphatase inhibitors). 
The cells were then scraped down and the obtained mixtures homogenized with sonication 
and vortexing. Cell debris was removed by centrifugation at 18,000 g for 20 min at 4 °C. 
Four volumes of ice-cold acetone/ethanol/acetic acid (v/v/v = 50/50/0.1) was added to the 
supernatant to precipitate the proteins at -20 °C overnight. After centrifugation, the protein 
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pellet was re-dissolved in denaturing buffer (pH 8.0) containing 8 M urea and 50 mM 
HEPES, and the protein concentration was tested using a Bradford assay. The disulfide 
bonds in the protein solution were reduced by 2 mM dithiothreitol (DTT) at 37 °C for 2 h 
and subsequently alkylated by adding 6 mM iodoacetamide (IAA) and incubation in 
darkness at room temperature for 40 min [41]. Purified peptides were labelled with 6-plex 
TMT reagents (Thermo) following the manufacturer’s protocol. Briefly, lyophilized 
peptides were dissolved in 100 μL of 100 mM triethylammonium bicarbonate (TEAB) 
buffer, pH= 8.5. Each channel of the TMT reagents was dissolved in 41 μL of anhydrous 
ACN and transferred into the peptide tube. The reaction was performed at room 
temperature for 1 h then was quenched by adding 8 μL of 5% hydroxylamine. Peptides 
from all six tubes were then mixed, desalted again using a tC18 Sep-Pak cartridge, and 
lyophilized overnight. For protein analysis, the peptide mixture was separated by high pH 
reversed-phase high-performance liquid chromatography (HPLC) into 20 fractions with a 
40-min gradient of 5-55% ACN in 10 mM ammonium acetate (pH=10). 
LC-MS/MS analysis and database search: After TMT labeling and purification, 
lyophilized peptide samples were dissolved in 10 μl solvent of 5% ACN and 4% FA, and 
4 μl of the dissolved sample were loaded onto a microcapillary column packed with C18 
beads (Magic C18AQ, 3 μm 200 Å, 100 μl x 16 cm, Michrom Bioresources) by a Dionex 
WPS-3000TPLRS autosampler (UltiMate 3000 thermostatted Rapid Separation Pulled 
Loop Wellplate Sampler). Peptides were separated by reversed-phase chromatography 
using an UltiMate 3000 binary pump with a 90-min gradient of 4-30% ACN (in 0.125% 
FA). Peptides were detected with a data-dependent Top15 method [42] in a hybrid dual-
cell quadrupole linear ion trap – Orbitrap mass spectrometer (LTQ Orbitrap Elite, 
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ThermoFisher, with Xcalibur 3.0.63 software). For each cycle, one full MS scan 
(resolution: 60,000) in the Orbitrap at 106 AGC target was followed by up to 15 MS/MS 
for the most intense ions. The selected ions were excluded from further analysis for 90 
seconds. Ions with single or unassigned charge were discarded. MS2 scans were performed 
in the orbitrap cell by activating with high energy collision dissociation (HCD) at 40% 
normalized collision energy with 1.2 m/z isolation width. All MS2 spectra were converted 
into mzXML format, and then searched using the SEQUEST algorithm (version 28) [43]. 
Spectra were matched against a database containing sequences of all proteins in the UniProt 
Human (Homo sapiens) database. The following parameters were used during the search: 
20 ppm mass tolerance; fully digested with trypsin; up to 3 missed cleavages; fixed 
modifications: carbamidomethylation of cysteine (+57.0214), TMT modification of lysine 
(+229.1629) and N-terminus (+229.1629); variable modifications: oxidation of methionine 
(+15.9949). False discovery rates (FDR) of peptide and protein identifications were 
evaluated and controlled by the target-decoy method [44]. Each protein sequence was listed 
in both forward and reversed orders. Linear discriminant analysis (LDA), which is similar 
to other methods in the literature [45], was used to control the quality of peptide [46]. 
Peptides fewer than seven amino acid residues in length were discarded. Furthermore, 
peptide spectral matches were filtered to <1% FDR. An additional protein-level filter was 
applied in each dataset to reduce the protein-level FDRs (<1%). 
Proteomics data analysis: For proteomics analysis, each experiment was repeated twice. 
The mean expression level of each protein was used for downstream analysis. Raw data 
were normalized using supervised normalization of microarray (SNM) [47]. Variance due 
to biological replicates was adjusted by setting them as variables in the model. Variance 
 181 
explained by different experimental treatments (control, AuNRs@PEG-PPTT, and 
AuNRs@RF-PPTT) was fitted as a biological variable in the model. Hierarchical 
clustering was performed with statistical software R. Proteins identified as being affected 
were subjected to pathway analysis using the MetaCore from Thomson Reuters. 
Short-term and long-term uptake fate of PEGylated AuNRs: BALB/C mice (male), 6 
weeks of age, were injected via the tail vein with 200 μl solution of Au NRs (0.18mg/kg). 
At specified time points of 1 day, 3, 7, 14, 30 days and 15 months, mice were euthanized 
by pressurized CO2 asphyxiation, 3 mouse each group. Liver, spleen, kidney and lung were 
collected, rinsed with distilled water and dried. The dried tissues were dissolved and 
assayed for Au using ICP-MS. 
Histopathology evaluation: Liver, spleen, kidney and lung tissues were embedded in 
paraffin and cut at 5 um thickness. The tissues were stained with hematoxylin and eosin 
(Sigma) to assess histological alterations via microscopy. 
Statistical Analysis: All results represent the average of at least three separate experiments 
and are expressed as mean +/- standard deviation or standard error. Statistical analysis was 
conducted using t test. P-value less than 0.05 was considered statistically significant. 
 
3.2.3  Results and Discussion 
Efficacy of AuNR@RF/PPTT in cellular growth inhibition in vitro (HNSCC cells) and 
in tumor growth reduction in a MDA686TU xenograft model 
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AuNRs were synthesized using a seedless growth technique [36]. AuNRs were conjugated 
with bovine serum albumin (BSA) as a protein carrier and linker to rifampicin (RF), as 
shown in schematic Figure 1A. Detailed descriptions of AuNRs synthesis, conjugation, 
cellular uptake and cytotoxicity measurements are in the supporting information. Briefly, 
transmission electron microscope (TEM) images (Figure B.1.A) show the average size of 
AuNRs (for small AuNRs: 25 (± 3) nm × 5.5 (± 0.8) nm (length × width); and for big 
AuNRs: 72 (± 7) nm × 16 (± 4) nm) and UV-Vis spectrum shows an absorbance centered 
near 800 nm, corresponding to the longitudinal surface plasmon resonance band of AuNRs 
(Figure B.1.B). Successful conjugation of BSA/RF molecules to the surface of AuNRs 
(AuNRs@BSA@RF) was proven by red-shift of the plasmon peak of AuNRs in the UV-
Vis spectrum (Figure B.1.B), fluorimetry (Figure B.1.C) and zeta potential (Figure B.1.D). 
Successful uptake of AuNRs@RF was observed by 3-dimensional scanning differential 
interference contrast (DIC) microscopy (Figure 1B and B.3.), dark field images (Figure 
B.1.E) and UV-Vis absorbance (Figure B.1.F). After applying PPTT to AuNRs@RF, the 
release of RF molecules from the surface of AuNRs, as shown in schematic Figure 1A, was 
demonstrated by UV-Vis spectra (Figure B.1.B). After PPTT, the RF peaks of the particles 
(330 nm and 470 nm) disappeared, accompanied with the increased concentration of RF in 
the supernatant, indicating the release of surface RF. The number of RF molecules per 
AuNRs was calculated according to a previous study [37]. From the calculation, we found 
657 rifampicin molecules present on each AuNRs@BSA, most of which was released after 
PPTT as shown in Figure B.1.B by the loss of RF peaks on AuNRs. Furthermore, DIC 
images (Figure 1B) show increases in the sizes of nanoparticle aggregates after PPTT, 
further supporting the release of surface ligands after PPTT (shown in Figure 1A) which 
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causes the particles to more easily aggregate. Similarly, AuNRs@PEG were also prepared, 
and their detailed characterization is described in supporting data (Appendix Figure B.2.). 
The effectiveness of PPTT in the regulation of cell viability was examined in five HNSCC 
cell lines, MDA686TU, Fadu, UD-SCC2, UM-SCC-47, and SqCC/Y1. We applied 
different concentrations of AuNRs@PEG with 2 W/cm2 laser to optimize the AuNRs 
concentration. We found inhibition of cell viability (~30-50%) following treatment with at 
least 2.5 nM AuNRs@PEG compared to non-treated cell lines after 72 h (Appendix Figure 
B.4. A). Furthermore, we compared the effectiveness of AuNRs@RF and AuNRs@PEG 
in MDA686TU cells. Interestingly, we observed that AuNRs@RF/PPTT reduced cell 
viability more efficiently than AuNRs@PEG/PPTT (Figure B.4.B). We also observed that 
treatment with both AuNRs@RF and AuNRs@PEG mainly induced apoptosis without 
obvious necrotic death (Appendix Figure B.4.C). These observations prompted us to 
further investigate the mechanistic details of AuNRs@RF action. In MDA686TU cells 
treated with AuNRs@PEG or AuNRs@RF followed by laser treatment, RF-conjugated 
AuNRs induced approximately twice as much apoptosis when compared to 
AuNRs@PEG/PPTT alone (Figure 1C) (Appendix Figure B.4.B). Western blot analysis 
revealed that AuNRs-PPTT induced apoptotic signaling molecules such as cleaved caspase 
3 (effector caspase), followed by cleavage of substrate poly ADP-ribose polymerase 
(PARP) (Figure 1D). In addition, we observed that AuNRs@RF/PPTT reduced cell 
viability and proliferation, evidenced by reduction of Akt and Erk activation and 
upregulation of the cell cycle inhibitor protein, p21 (Figure 1D). 
 
 184 
To optimize AuNRs concentration and laser power and assess anti-cancer therapeutic 
potential in vivo, we established a MDA686TU xenograft model. We applied three 
concentrations of AuNRs (conjugated with PEG or RF), 2.5, 5 and 10 nM; along with three 
different powers of laser, 0.5, 1 and 2 W/cm2. In addition, we compared two different sizes 
of AuNRs@PEG (the characterization of big AuNRs is shown in Figure B.5.) due to their 
different heat conversion capacity. Nanoparticles (100 µL) were injected intratumorally 
and laser treatment was performed once on day 1. We included three control groups: PBS, 
AuNRs (without laser), and laser alone. Tumor progression data over 25 days in mice from 
each treatment group are presented in Figure 1E and supplementary Figure B.6. and B.7., 
with the corresponding mice shown in Figure 1F. We observed promising tumor growth 
inhibition with smaller-sized AuNRs@PEG. Over 25 days, tumor growth was reduced 
significantly in mice treated with AuNRs@PEG at all three concentrations only when the 
laser power was 2 W/cm2 (Figure 1E). We observed that treatment with 10 nM and 5 nM 
AuNRs@PEG with 2 W/cm2 laser reduced tumor growth by many fold compared to the 
control groups (PBS, laser only and AuNRs only) (Figure 1E) [control groups (PBS, Laser, 
AuNRs) vs treated groups (2.5, 5, 10 nM AuNRs@PEG-PPTT), p<0.01]. However, we 
observed skin wounding effects in mice at these concentrations (Figure 1F). Treatment 
with 2.5 nM AuNRs@PEG-PPTT had a moderate wounding effect, however, tumor 
growth increased after 20 days (Figure 1E). In comparison with 2.5 nM small 
AuNRs@PEG (25 nm length), treatment with 2.5 nM large (72 nm length) AuNRs@PEG-
PPTT had no obvious effect on tumor inhibition (Figure 3-6E). Since AuNRs@RF-PPTT 
showed the most efficient apoptosis in vitro (Figure 3-6C), we were interested to see the 
effect in vivo in comparison to AuNRs@PEG-PPTT. We found that 2.5 nM AuNRs@RF-
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PPTT efficiently reduced tumor growth to the same extent as 10 nM AuNRs@PEG-PPTT 
without any skin wounding (Figure 3-6E, F) [control groups (PBS, Laser, AuNRs) vs 
treated group (2.5 nM AuNRs@RF-PPTT), p<0.01]. All mice were sacrificed on day 25 
and tumors were collected. Tumor weight was significantly reduced in mice treated with 
all concentrations of small AuNRs with 2 W/cm2 laser (Figure B.6.) [control (PBS, Laser, 
AuNRs) vs treated groups, p <0.01], while large AuNRs (Figure B.6.) or lower laser power 
was unable to reduce tumor growth (Figure B.7.). The mice were monitored during and 
after tumor cell and nanoparticle injections. Movement, diet, and vital signs (ruffled fur, 
weight loss, and normal activity) were observed throughout the experiments. We did not 
observe any abnormalities other than the skin wounding effect at higher concentrations of 
AuNRs. IHC of mouse tumor tissues for the cell proliferation marker Ki67 (Figure 3-6G) 
suggested that AuNRs@RF (25 nm length) with 2 W/cm2 laser significantly reduced cell 






Figure 3-6. Efficacy of AuNRs@RF in vivo and in vitro 
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 (A) Schematic showing the characterization and conjugation of AuNRs@Rifampicin, 
and the release of surface ligands after PPTT; (B) DIC images of optical sectioning of 
control sample (without nanoparticles), cells incubated with AuNRs@RF, and cells 
after PPTT. All scale bars are 10 µm; white arrows indicate AuNRs aggregates. (C) 
Comparative apoptosis analysis in MDA686TU HNSCC cells treated with AuNRs or 
AuNRs@RF and PPTT after 72h (error bars are mean ±SD, n=3); (D) Western 
blotting for the indicated proteins in MDA686TU HNSCC cell line after treatment 
with AuNRs@PEG-PPTT and AuNRs@RF-PPTT. A representative blot of three 
independent experiments is presented; (E) MDA686TU HNSCC tumor xenograft 
growth (tumor volume = 0.5×l×w2) progression in groups: PBS, 2 W/cm2 Laser, 10 
nM small AuNRs@PEG as control groups; 5 nM, 10 nM small AuNRs@PEG with 
2W/cm2 Laser; 2.5nM small and large AuNR@PEG with 2W/cm2 Laser; 2.5 nM 
AuNRs@RF with 2W/cm2 laser. First and only dose was given on Day 1 (tumor 
volume ~ 70 mm3) and tumor growth was monitored until Day 25 (endpoint of tumor 
volume 1800 mm3) (error bars are mean ±SEM, n=5). Statistical analysis (t-test) 
between control groups (PBS, Laser, AuNRs@PEG) vs treated groups (2.5, 5, 10 nM 
AuNRs@PEG-PPTT, 2.5 nM AuNRs@RF-PPTT) was p< 0.01 (F) Representative 
mouse from each of the indicated groups presented; (G) Ki67 expression detected in 
xenograft tissue by IHC analysis. Representative images shown from indicated 
groups (brown stain for Ki67 and nuclei were counterstained by hematoxylin, blue; 
magnification X200). For comparison with other studies, 5 nM = 1 O.D. (optical 
density) for small AuNRs36. 
 
AuNRs@RF-PPTT induces stronger perturbation of apoptosis and cell death by 
releasing neutrophil extracellular traps (NETs) (NETosis) pathway:  
We conducted quantitative proteomics experiments using tandem mass tags (TMT) to 
study alterations in protein expression levels in tumor tissues, identify the mechanisms 
responsible for the induction of apoptosis by AuNRs@PEG-PPTT and AuNRs@RF-
PPTT, and explore why AuNRs@RF-PPTT was much more effective. Two biological 
replicates were conducted for AuNRs@PEG-PPTT-treated, AuNRs@RF-PPTT-treated, 
and control groups. Differentially expressed proteins identified in each experiment 
(AuNRs@PEG-PPTT and AuNRs@RF-PPTT) were compared (Figure 3-7A). In total, we 
measured 5222 proteins. For proteomics analysis, we set +/-0.5 as a threshold for fold 
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change (log 2) detection (Figure 3-7B). Following AuNRs@PEG-PPTT treatment, 532 
proteins were decreased and 600 proteins were increased. AuNRs@RF-PPTT treatment 
led to downregulation of 558 and upregulation of 644 proteins (Figure 3-7C). Overlap in 
altered proteins (increased or decreased) is shown in Figure 3-7D.  
Pathway analysis identified apoptosis-related pathways that were significantly regulated 
by AuNRs@RF-PPTT and AuNRs-PPTT compared to the control group (Figure 3-7F), 
including Granzyme B signaling, BAD phosphorylation, caspase cascade, and others. 
These pathways and associated increased proteins (Figure 2E and Table S1) may provide 
a mechanistic explanation for the apoptosis promoting effect of PPTT with AuNRs. 
Apoptosis-related proteins are listed in Figure 3-7E and a schematic illustration is shown 
in Figure 3-7G. A greater increase in cytochrome c and Apaf-1 protein expression was 
identified following AuNRs@RF-PPTT versus AuNRs@RF treatment. Cytochrome c and 
Apaf-1 form a complex leading to the activation of caspase-9, which activates caspase-3, 
inducing caspase-3 mediated apoptosis [48, 49]. In addition, we observed the activation of 
upstream signaling of p38alpha, which leads to ROS generation [50, 51] that can result in 
mitochondrial dysfunction-triggered apoptosis. We also observed increased levels of 
FANCD2, p53 and PTEN. FANCD2 is required for the maintenance of chromosomal 
stability, which is involved in the repair of DNA double-strand breaks [52, 53]. DNA 
damage can affect FANCD2 via FANCL [54, 55], whereas FANCD2 can further interact 
with BRCA1 [56, 57]. BRCA1 then activates CHK1 [58], which activates p53 [59]. 
Activated p53 then promotes apoptosis [60]. PTEN can also induce apoptosis via 
PI3K/AKT dependent and independent pathways [61] or other pathways [62-63]. We 
observed stronger apoptosis promotion, i.e., greater upregulation of apoptosis-related 
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proteins, with AuNRs@RF-PPTT compared to AuNRs@PEG-PPTT treatment (Figure 
3-7E). These observations at the molecular level are in agreement with the phenotypic 
study showing that AuNRs@RF-PPTT is more effective than AuNRs@PEG-PPTT in vivo 
and in vitro.  
Interestingly, our proteomics analysis also revealed that treatment with AuNRs@RF-PPTT 
induced changes in the levels of several proteins involved in the NETosis pathway more 
strongly than AuNRs@PEG-PPTT (Figure 3-7F). NETosis refers to a specific form of 
neutrophil cell death caused by pathogen infection, which releases neutrophil extracellular 
traps (NETs). It has been recently reported that small NPs activate the NETosis pathway 
[64]. NETosis can be triggered by two pathways: directly by IL-18 [65-67] or by chromatin 
decondensation [68-71]. In this study, proteomics analysis identified nine proteins in the 
NETosis pathway. Specifically, a clear elevation of histone H2, histone H4, IL-18, and 
Pin1 were observed following AuNRs@RF-PPTT treatment; therefore, both pathways 
leading to NETosis were altered (Figure 2G). Since NETosis is related to endocytosis, we 
speculate that AuNRs@RF may be better taken up by cells resulting in enhanced NETosis. 
In summary, from proteomics analysis, we determined that AuNRs@RF-PPTT can induce 





Figure 3-7 Quantitative proteomics 
(A) Comprehensive heatmap showing the proteome perturbed by AuNRs@PEG-
PPTT and AuNRs@RF-PPTT compared to control group; (B) Distribution of fold 
changes in proteins perturbed by AuNRs@PEG-PPTT and AuNRs@RF-PPTT 




increased and decreased  in each group; (D) Venn diagram showing the differentially 
expressed proteins identified in each group; (E) Heatmap for proteins related to 
apoptosis and NETosis contributing to the better efficacy of AuNRs@RF-PPTT 
compared to AuNRs@PEG-PPTT. The values of protein fold change are listed in 
Table S1; (F) Identified significant pathways related to apoptosis and NETosis; (G) 
Simplified pathway map of NETosis and apoptosis. 
 
Long term effects of AuNRs on biodistribution and toxicity:   
    Treatment with AuNRs enhanced PPTT in Balb/C mice with a low dose of NIR light 
(Figure 3-6E), indicating their strong clinical potential. However, there is limited 
knowledge regarding several features of this new generation of AuNRs, including their 
biodistribution, long-term fate and toxicity. To assess toxicity, the histopathology of tissues 
from the liver, spleen, lung and kidney of mice was evaluated by a pathologist 1 month and 
15 months after single intravenous (iv) injection of AuNRs@PEG. We did not observe any 
histopathological abnormalities in any of the mouse organs (Figure 3-8A). Furthermore, 
we monitored mice every week for 15 months following AuNRs@PEG injection and did 
not observe any clinical signs of toxicity including ruffled fur, impeded movement, signs 
of abnormal constitution, aberrant behavior, loss of weight, ocular or nasal discharge, 
respiratory distress, inability to walk, or diarrhea. TEM was utilized to visually observe 
AuNRs@PEG particle uptake and organ tissue microstructure. As seen in Figure 3-8B, 
AuNRs@PEG remained inside the cells without any structural changes. Measurement of 
Au levels in the tissues demonstrated that AuNRs@PEG were present mostly in the spleen 
and liver of mice (Figure 3-8C, D), and to a lesser extent in the kidney and lung (Figure 
3-8E, F). To measure any gold excretion, we tested the amount of Au in the feces of mice 
at three different time points (1, 14 and 30 days) (Figure B.8.). We found that a very small 
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portion of injected Au was excreted whereas the major portion of Au accumulated mainly 
in the spleen and liver and was sustained without any structural modification over a long 
period (observed: up to 15 months). Au accumulated in mouse organs from the first day of 
treatment and remained in these tissues even 15 months later, without any evidence of 
toxicities. 
AuNRs-PPTT is widely recognized as a promising strategy for combating cancer. 
Developing a valid PPTT in vivo that triggers cancer cell apoptosis (avoiding necrosis) and 
exploring its molecular mechanism of action is of great importance. In addition, exploring 
the long-term fate of the AuNRs after treatment is critical for clinical usage. In this 
systematic in vivo study, we 1) optimized the conditions of AuNRs-PPTT to induce 
apoptosis, 2) explored the molecular mechanisms of action of AuNRs-PPTT, and 3) 
revealed the long-term (15 month) fate of AuNRs, which indicated their lack of toxicity in 
mouse models. To optimize PPTT conditions to maximize tumor apoptosis, we evaluated 
the size, surface modification, and concentration of AuNRs and the PPTT laser power both 
in vitro (five HNSCC cell lines) and in vivo (MDA686TU xenograft mice model). Cell and 
tumor growth inhibition and apoptosis were clearly observed in vitro and in vivo. It is worth 
noting that among the 5 HNSCC cell lines, we have used UM-SCC-47, which is an HPV 
positive cell line. Our findings suggest that AuNRs-PPTT is equally effective against viral 
and non-viral derived tumors. Histopathological analysis of mice tissue revealed that a 
lower concentration (2.5 nM) of AuNRs@RF-PPTT significantly reduced cancer cell 
viability as shown by decreased Ki-67. Past attempts to induce apoptosis in vitro have 
applied a moderate hyperthermia [72] or targeted different cellular locations [8, 73-74]. 
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Herein, by adjusting the surface modification and heat generation, we were able to generate 





Figure 3-8. Effect of AuNRs on organ toxicity and accumulation 
 (A) Histopathological images of the liver, spleen, kidney and lung of Balb/c mice at 
different time points after IV injection of a single dose of AuNRs (Au: 0.18mg/kg, 3 
mice per group); (B) TEM images at two time points AuNRs (Au: 0.18mg/kg, 3 mice 
per group). 10,000 PEG/AuNR (indicated by arrow) were found in the liver and 
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spleen without morphology changes (up to 15 months) when treated with 25 nm length 
AuNRs. (C-F) Accumulation of AuNRs in different organs over 15 months. Au 
concentrations are shown in the liver (C), spleen (D), kidney (E) and lung (F) of Balb/c 
mice at different time points after IV injection of a single dose of AuNRs (Au: 
0.18mg/kg, 3 mice per group) (Error bars are mean ±SEM). 
In our study we have optimized our treatment dose based on the tumor volume using very 
low doses (in nMs with 100 uL AuNPs injection volume) and intratumoral injection, which 
is more realistic for the clinical application of PPTT. In contrast, most earlier studies have 
injected the nanoparticles intravenously, at doses based on animal body weight 
(nanoparticle amount in mg/Kg body weight) [75-77]. Compared to other studies, we used 
a moderate laser intensity and low exposure time (0.5 to 2 W/cm2 for 2 minutes)[78]. 
 
The effect of heat shock (hyperthermia) on the induction of cell apoptosis has been known 
for centuries. The mechanism of hyperthermia-induced apoptosis has been largely unclear 
until recently [79]. PPTT is not simply heat shock; instead, it could be regarded as a 
synergistic effect between nanoparticles and hyperthermia. We observed that both 
apoptosis and NETosis pathways were significantly affected after treatment with PPTT, 
especially AuNRs@RF-PPTT, which demonstrated a much stronger molecular impact on 
these pathways. Cytochrome c and p53-related apoptosis mechanisms were identified as 
contributing to the enhanced effect of PPTT with RF-conjugated AuNRs. Furthermore, 
Pin1 and IL18-related signaling contribute to the observed perturbation of the NETosis 
pathway by PPTT with RF-conjugated AuNRs. Upregulation of Pin1 has been shown to 
induce ROS production through phosphorylation of NADPH oxidase regulatory subunits 
p47-phox and p67-phox [68-70]. ROS production further leads to the release of PERM. 
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Histone H4 and histone H2 are subsequently degraded leading to chromatin 
decondensation, which is further enhanced by PERM. Eventually the integrity of the 
nuclear envelope is disrupted, resulting in cell rupturing [71]. The greater effect of 
AuNRs@RF-PPTT on NETosis may result from better uptake of AuNRs into the cells 
when conjugated with RF. It has been reported recently that cells entrap nanoparticles via 
formation of NETs, which are formed immediately following rapid damage to plasma 
membranes and instability of the lysosomal compartment induced by nanoparticle 
stimulation [64]. The significant effects observed in our study of AuNRs@RF-PPTT on 
the NETosis pathway may account for the greater efficacy of the RF conjugate.  
 
After PPTT, we observed the aggregation of AuNRs@RF around cell nuclear membranes 
as shown by DIC microscopy (Figure 1B). Our proteomics study identified greater 
upregulation of nuclear lamin proteins (Figure 2E), which are responsible for nuclear 
shape and structure. Therefore, AuNRs@RF may harm nuclear membrane integrity 
through intrinsic cell defense mechanisms. On the other hand, lamins are known to impede 
cancer cell migration and invasion [80, 81] Lamin promotes cell-matrix adhesion and plays 
an important role in apoptosis by loosening epithelial cell contact with the extracellular 
matrix [82]. Lamins are targets for degradation in the apoptotic process, and accordingly 
are often used as markers for apoptosis [83]. 
 
There is to date limited knowledge regarding the biodistribution, long-term fate and 
toxicity of AuNRs. Thus, our studies of the toxicity of AuNRs are important to develop 
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safer treatments. To the best of our knowledge, this is the first report of a 15-month toxicity 
study of AuNRs in mice.  Based on our findings, we can conclude that these AuNRs have 
great potential to be used in PPTT for the local treatment of cancers, supporting the efficient 
translation of AuNRs into clinical settings. 
 
3.2.4 Conclusion and Future Outlook  
We have optimized the efficacy and studied the molecular mechanisms of AuNRs-assisted 
plasmonic photothermal therapy, and examined the 15-month toxicity and fate of AuNRs 
in a mouse model. Together, these data demonstrate that our AuNRs-PPTT is highly 
effective and safe for local therapy for cancers. These findings provide a strong framework 
for translation of this approach to the clinic. 
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3.3 Treatment of Natural Mammary Gland Tumors in Canines and Felines Using 
Gold Nanorods-Assisted Plasmonic Photothermal Therapy to Induce Tumor 
Apoptosis [1] 
Plasmonic photothermal therapy (PPTT) is a cancer therapy in which gold nanorods are 
injected at the site of a tumor before near-infrared light is transiently applied to the tumor 
causing localized cell death. Previously, PPTT studies have been carried out on xenograft 
mice models. Herein, we report a study showing the feasibility of PPTT as applied to 
natural tumors in the mammary glands of dogs and cats, which more realistically represent 
their human equivalents at the molecular level. We optimized a regime of three low PPTT 
doses at 2-week intervals that ablated tumors mainly via apoptosis in thirteen natural 
mammary gland tumors from seven animals. Histopathology, X-ray, blood profiles, and 
comprehensive examinations were used for both the diagnosis and the evaluation of tumor 
statuses before and after treatment. Histopathology results showed an obvious reduction in 
the cancer grade shortly after the first treatment and a complete regression after the third 
treatment. Blood tests showed no obvious change in liver and kidney functions. Similarly, 
X-ray diffraction showed no metastasis after 1 year of treatment. In conclusion, our study 
suggests the feasibility of applying the gold nanorods-PPTT on natural tumors in dogs and 
cats without any relapse or toxicity effects after 1 year of treatment. 
 
3.3.1 Introduction 
Plasmonic nanoparticles (NPs) exhibit unique physical and chemical properties that can be 
utilized for both cancer treatment and diagnosis. In plasmonic photothermal therapy 
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(PPTT), NPs such as gold nanorods (AuNRs) absorb near-infrared (NIR) light resulting in 
hyperthermia, thereby inducing tumor ablation. In PPTT, cancer cells show a much higher 
uptake of NPs than normal cells. Although many traditional cancer therapies with drugs or 
radiation cause side effects due to their toxicity to normal cells, PPTT has fewer side effects 
mainly because of its selectivity to cancer cells. In PPTT, two selective targeting methods 
can be applied: 1) active targeting and 2) passive targeting. In active targeting, specific 
surface modifications (ligands) of NPs can recognize and bind to the receptors on the 
surface of cancer cells. On the other hand, in passive targeting, NPs are usually injected 
directly to solid tumor and accumulate inside the tumor mainly via the enhanced 
permeability and retention effect. The enhanced permeability and retention effect has been 
regarded as a primary rationale for the delivery of NPs due to the leaky tumor blood 
vasculature. Then, the tumor will be irradiated with laser, causing localized heat for killing 
cancer cells [2–6] These attributes of PPTT make it a superior alternative in cancer 
treatment. 
Among all plasmonic gold NPs, three types have shown the greatest potential for use in 
cancer PPTT: gold nanocages, gold nanoshells (AuNSs), and AuNRs.7-9 These three types 
of NPs have been synthesized with specific sizes and shapes designed to enable absorption 
of NIR radiation and allow for subsequent heat transmission. Due to the toxicological 
properties that could result from the presence of unused silver (Ag) on the interior of the 
nanocage during its synthesis, the widespread use of  gold nanocages for the treatment of 
cancer is not likely to occur.10 The AuNSs plasmon wavelength is dependent on the ratio 
of the thickness of the shell to the core diameter.1 Thus far, the use of AuNSs has been 
limited to the US Food and Drug Administration-approved use of the AuNSs AuroLase® 
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(Nanospectra Biosciences, Inc., Houston, TX, USA) for PPTT clinical trials of head and 
neck cancer.1 One challenge of using AuNSs is the difficulty of synthesizing them with a 
uniform ratio of shell to core radii. AuNRs exhibit a longitudinal NIR surface plasmon 
resonance band that is directly proportional to its aspect ratio (length/width). Among all 
plasmonic gold NPs, AuNRs are regarded as one of the most feasible options for absorbing 
NIR laser radiation. 11-14 For example, a recent publication compared the efficacy of 
AuNRs with that of AuNSs and found that AuNRs intrinsically have greater absorption 
efficacy per gram of gold and longer circulation half-life in vivo.15 Additionally, PPTT-
AuNRs studies have shown encouraging results with no significant toxicological side 
effects in vivo (xenograft mice model).16-19 
PPTT can induce cell death primarily by two pathways: necrosis and apoptosis [20]. During 
necrosis, the heat induced from PPTT disrupts the plasma membrane causing the 
cytoplasmic components to leak out and inflammation to occur within the cell. However, 
apoptosis is a highly regulated cell death pathway and would thus be a cleaner way for 
eliminating cancer cells. Therefore, modulating PPTT to trigger apoptosis would be more 
favorable in clinical studies. It has been reported that different intracellular locations or 
shapes of NPs regulate the switch between necrosis and apoptosis [21, 22].  In this study, 
we were able to cause cancer cell apoptosis in vitro and in vivo by adjusting the laser 
exposure time. 
The primary novelty of this study was the extension of AuNRs-assisted PPTT to natural 
tumors in animals larger than ones used in any previous study. Mammary gland tumors of 
epithelial origin are very common neoplasms of canines and felines. The similarity of 
molecular and biological machinery of canines/felines and that of humans suggests the 
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suitability of using mammary tumors of these animals as a model for the study of human 
mammary tumors [23-25]. The second novelty was the optimization of AuNRs-PPTT’s 
conditions to generate tumor apoptosis as a favorable cell death mechanism (rather than 
necrosis) [12, 26-27]. Herein, we directly injected the PEGylated AuNRs to the mammary 
tumors of each canine/feline as opposed to intravenous injection, as our previous study 
showed a better efficacy for intratumoral injection than intravenous injection,1 although 
the latter could be helpful for some applications (especially for tumors that are not 
accessible for direct injection of AuNR) [8].  We tested PPTT on canine and feline natural 
mammary gland tumors. To minimize side effects, we optimized PPTT dosages to enable 
a slow cancer cell apoptosis. Using our optimized protocol, adjusting the photothermic 
temperature to 44°C, we could ablate 100% of tumors in seven animals without any relapse 
or toxicity effect after 1 year from the tumor treatment. 
 
3.3.2  Experimental methods  
Synthesis and surface modification of AuNRs 
AuNRs were prepared according to the literature [28]. Briefly, HAuCl4 (5 mL, 1 mM; 
Sigma-Aldrich, St. Louis, MO, USA) was added to 5 mL of cetyltrimethylammonium 
bromide (CTAB, 0.20 M; Sigma-Aldrich). AgNO3 (250 μL, 4 mM; Sigma-Aldrich) was 
then added and the pH of the solution adjusted to 1–1.15. Around 70 μL of ascorbic acid 
(78.8 mM; Sigma-Aldrich) was added to the solution until the solution became clear. Ice-
cold NaBH4 (15 μL, 0.01 M; Sigma-Aldrich) was injected into the unstirred growth 
solution immediately and then allowed to react for 6 hours. The resulting AuNRs had 
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dimensions of approximately 25×5 nm (see “Formulation and characterization of the 
AuNRs” section, Figure 1). AuNRs were concentrated by centrifuging at 19,745 rcf for 15 
minutes. The pellet was redispersed in water and centrifuged at 19,745 rcf for an additional 
15 minutes. Then methoxy polyethylene glycol (PEG) thiol (m-PEG-Th, PEG; Laysan Bio, 
Arab, AL, USA) was added to the CTAB-conjugated AuNRs and was incubated overnight 
in a shaker. A final ratio of about 20,000 PEG molecules per NP was achieved after 
centrifugation to remove unconjugated PEG. 
Characterization of AuNRs 
The characterization of AuNRs was carried out using a Cary 500 UV–Vis Spectrometer 
(Agilent Technologies, Santa Clara, CA, USA) for the spectroscopic measurements, and a 
JEOL 100 CX transmission electron microscope (TEM) (JEOL Ltd., Tokyo, Japan) was 
used to image the samples. Zeta potentials were measured using a ZetaSizer 3000 HAS 
(Malvern Instruments, Worcestershire, UK). Zeta potential was tested to characterize the 
surface conjugation with PEG. Ellman’s reagents (react with free -SH group; Sigma-
Aldrich) were used to quantify the number of PEG molecules bound to the surface of the 
AuNRs [29] Ellman’s reagent reacts with free -SH group and can be measured 
calorimetrically at 412 nm. By subtracting the absorbance of the residual PEG, in the 
supernatant solution after PEG conjugation and centrifugation, from the original 
absorbance of the solution before adding to AuNRs, we can calculate the number of PEG 
molecules on the surface of AuNRs by Beer’s law. The results of characterization are 
described below (see “Formulation and characterization of the AuNRs” section). 
Animal diagnosis, ultrasonography, and X-ray examination 
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The animals were admitted to the clinic of Department of Surgery, Faculty of Veterinary 
Medicine, Cairo University. All pets’ owners claimed that their animals did not receive any 
treatment before their arrival at the university. Histopathology tests were used to diagnose 
the tumors as adenocarcinoma without any skin invasion, except for one tumor (Case 1, 
Tumor 6). Seven animals were included in this study, five canines (females) and two felines 
(females), and the total number of tumors was thirteen. All animals were handled in 
accordance with Association for Assessment and Accreditation of Laboratory Animal Care 
and Office of Laboratory Animal Welfare guidelines under the direction of the Institutional 
Animal Care and Use Committee. Ultrasonography examination was performed with a 
real-time Toshiba medical company ultrasound system (Toshiba, Tokyo, Japan), using 
multifrequency probes (7 microns convex and 7 MHz linear probe) with displayed depth 
of 4–6 mm. The scans and photographs were taken on Polaroid in both longitudinal and 
transverse scans. At the tumor site, the animal’s hair was clipped and shaved, and 
subsequently, sonographic gel was applied to the skin of the animals. Radiographic 
recordings were taken with an X-ray machine (Fischer, Berlin, Germany). The 
radiographic setting factors were 58 to 70 kVp, 10 mAs, and 90 cm focal spot–film 
distance. The radiographic exposures were conducted, dorsoventrally and right laterally. 
The tumor dimensions were measured using calipers and confirmed with sonar. 
Performing PPTT in animals 
Each animal was subjected to three sessions of PPTT treatment in 2-week intervals using 
an 808 nm diode laser with a power of 5.8 W/cm2 and a spot size of around 5.6 mm2. An 
effective dose of AuNRs solution (7.5 nM AuNRs) for each 100 cm3 was used, and the 
amount used was scaled up based on the volume of the tumor and injected directly into the 
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tumor. Five minutes after injection, the entirety of the tumor was irradiated with the laser. 
The AuNRs concentration was decreased by 50% for each subsequent treatment. The 
temperature increase of a tumor during the laser irradiation was measured by placing a 33-
gauge hypodermic thermocouple (OMEGA Engineering, Inc., Stamford, CT, USA) needle 
directly inside the tumor (42°C–44°C). The results of PPTT in animals, histopathology 
evaluation (see “Histopathology evaluation for animals” section), blood analysis (see 
“Blood analysis” section), X-ray (see “Animal diagnosis, ultrasonography, and X-ray 
examination” section) are discussed in “Applying PPTT to animals” and “The 
physiological status of animals after 1 year from treatment” sections. 
Histopathology evaluation for animals 
The detailed pathologic evaluation of tumors was conducted by the members of the 
pathology department, Faculty of Veterinary Medicine, Cairo University. 
Histopathological analysis was performed on 5 µm sections from tumor tissue that were 
fixed in 10% buffered formalin. The samples were stained with hematoxylin and eosin to 
assess pathology. 
Blood analysis 
Blood analyses tests for examining the liver and kidney functions of the animals were 
conducted before and after treatment. The tests were performed according to the 
manufacturer’s instructions using diagnostic kits of the StatLab Spectrum Diagnostics in 
Egypt. Absorption spectrometry with six light-emitting diodes as optical light source was 
used. The kits were purchased from Egyptian Company for Biotechnology (Obour city 
industrial area, Egypt). 
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Cell culture and PPTT optimization in vitro and in vivo 
To examine the in vitro efficacy of PPTT and optimize the treatment condition (see 
“Optimization of PPTT toward generating cancer cell apoptosis” section), MCF-7 breast 
cancer cells (human adenocarcinoma; American Type Culture Collection, Manassas, VA, 
USA) were cultured in Dulbecco’s Modified Eagles’ medium (Corning Incorporated, 
Corning, NY, USA) supplemented with 10% v/v fetal bovine serum, 1% 
penicillin/streptomycin at 37°C in a 5% CO2 humidified atmosphere. For incubation, the 
growth media was removed from the cell cultures that had NPs and replaced with identical 
media containing PEGylated AuNRs (2.5 nM) overnight, and an 808 nm diode laser 
(power: 5.8 W/cm2; spot size around 5.6 mm) was used on the cells. The level of cell 
ablation was related to the time of PPTT. Two time scales were used: 2 and 5 minutes. 
For optimizing the PPTT condition in vivo, we applied PEGylated AuNRs (2.5 nM) for 
two different time periods (2 and 5 minutes) using an 808 nm diode laser (power: 5.8 
W/cm2; spot size around 5.6 mm). The result of optimization is shown in Supplementary 
material. 
Apoptosis/necrosis assay in vitro 
MCF-7 cells (human breast cancer cells) were washed with phosphate-buffered saline and 
then trypsinized (Clonetech, Mountain View, CA, USA).29 After trypsinization, cells were 
centrifuged and washed with phosphate-buffered saline. Cells were then resuspended in 
493 µL 1× annexin binding buffer (Invitrogen, Thermo Fisher Scientific, Waltham, MA, 
USA) with 2 µL working propidium iodide (PI; BioLegend, San Diego, CA, USA) 100 
µg/mL and 5 µL annexin-V–fluorescein isothiocyanate (BioLegend) and then incubated at 
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room temperature for 15 minutes. Subsequently, cells were filtered and subjected to flow 
cytometry using a BSR LSR II flow cytometer (BD Biosciences, San Jose, CA, USA). 
Samples were excited with a 488 nm laser, and fluorescein isothiocyanate was detected in 
FL-1 by a 525/30 BP filter, whereas PI was detected in FL-2 by a 575/30 BP filter. FlowJo 
software (Tree Star Inc., Ashland, OR, USA) was used to count annexin V+ cells from at 
least 10,000 events. 
 
3.3.3 Results and Discussion 
Formulation and characterization of the AuNRs 
Based on our previous study in vitro, AuNRs with average length × width (26×5 nm) 
showed enhanced efficacy of PPTT, which was driven from the high ratio of the absorbed 
light to scattered light, [30-32] we synthesized AuNRs with similar dimensions using our 
reported method, [28] and these AuNRs are shown in the TEM image (Figure 3-9A). To 
absorb the near-IR laser light for performing PPTT, AuNRs were generated with an aspect 
ratio of about 5 and with a surface plasmon resonance wavelength of ~800 nm (Figure 1B). 
The approximate length and width were 26±3 nm and 5±0.8 nm, respectively, which was 
obtained by counting the length and width distributions of 100 particles (Figure 3-9C and 
D). After synthesis, AuNRs were successfully coated with mPEG-Th as shown by their 
zeta potential of −17.1±7.83 mV (Figure 3-9F), while as-synthesized AuNRs had a 
positive zeta potential (Figure 3-9E) because of positively charged CTAB. The number of 
PEG molecules per particle was observed to be approximately 20,000 PEG/AuNR. 
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Figure 3-9. Characterization of PEGylated AuNRs rods (length 26±3 nm, width 5±0.8 
nm): 
(A) TEM image with 100 nm scale bar. (B) UV–Vis absorbance spectra showing the 
SPR peaks of AuNRs. (C) Corresponding histograms of the lengths of the 100 AuNRs 
particles counted. (D) Corresponding histograms of the widths of the 100 AuNRs 
particles counted. (E) Zeta potential data of the as-synthesized rods. (F) Zeta potential 
data of PEGylated AuNRs. 
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Optimization of PPTT toward inducing cancer cell apoptosis. We developed a mild PPTT 
strategy that induced cell apoptosis using a reduced laser exposure time. We conducted 
PPTT in vitro (MCF-7 cells) and in vivo (mammary gland tumor) by irradiating the tumors 
for 2 or 5 minutes. The control sample that incubated with AuNRs but without laser 
treatment were shown in Appendix Figure B.9. B. After 2 minutes of laser irradiation, 
42.7% and 2.89% of the population underwent apoptosis or necrosis, respectively (Figure 
B.9.C), whereas 5 minutes of laser irradiation caused 20.17% and 15.5% of apoptosis or 
necrosis, respectively. The data demonstrates that a 5-minute irradiation time 
predominantly leads to necrosis (heating up to about 52°C), while on the other hand, a 2-
minute irradiation time mainly results in apoptosis (Appendix Figure B.9. D, heating up 
to 42°C –44°C). This result is very comparable with the former study which showed that a 
low dose of heat induces apoptosis, whereas a high dose (heating above 50°C) induces 
necrosis.21 For thermal damage of cells, Sapareto et al 33 proposed “cumulative equivalent 
minutes at 43°C (CEM43) apop” as a method to calculate the thermal dose applied. Using 
their methods, we calculated that the CEM43 of 5-minute irradiation is more than 500 times 
that of 2-minute irradiation. When laser was applied without AuNRs injection, no obvious 
temperature increase was observed. 
Then, we used a preliminary optimal laser time on a single mammary gland tumor in a dog. 
We applied PPTT with two different irradiation times (2 and 5 minutes) to both sides of a 
single tumor. It was concluded that 2 minutes of irradiation caused a gentle change within 
the tumor, whereas 5 minutes of irradiation caused a very severe burning (Figure B.9.E). 
We related our thermal dosage to the average temperature that arose from the animal or 
cells after a 2-minute irradiation. In both cases, the temperatures are similar (42°C–44°C). 
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Based on these preliminary experiments, we selected the 2-minute irradiation time as the 
optimal irradiation time for complete tumor treatment for all tumor groups. 
Applying PPTT to animals 
After establishing the dosage of an effective laser application time, the PPTT optimized 
conditions were conducted multiple times (0, 2, and 4 weeks) and tumor volumes evaluated 
every 2 weeks until complete regression, as shown in Figure 3-10. Before any PPTT 
treatment, tumors of all the animals showed variant growth, and after PPTT, obvious tumor 
regression was observed. All thirteen tumors with variant volumes regressed with an 
average half-life of about 2 weeks and completely disappeared within 6–8 weeks. Images 
of tumor change and relevant histopathology in Case 7(feline) show the tumor regression 
process (Tumor 6: open tumor and Tumor 10: close tumor). Although both tumors have 
different malignancy stages (Table 1: Blood profile for each case before treatment and 1 
year after cure), the images indicate that both tumors respond positively to the treatment, 
and no tissue burning was seen after gentle treatments. Histopathological examinations 
were carried out on tumors to investigate the malignancy of the tumors before and after 
PPTT. Photographic images (Figure 3-11), and also complete images of the case (Figure 
B.10.), showed the tumor statuses before, during, and after treatments. As shown in Figure 
3-11A, before treatment, Case 7 (Tumor 6) was diagnosed with well-differentiated and 
highly malignant adenocarcinoma according to histopathology. Figure 3-11A showed that 
the cells were arranged either in tubular pattern or solid masses, in which the acini were 
arranged in groups and surrounded by fibrous connective tissue stroma. The stroma was 
infiltrated with inflammatory cells, mainly macrophages and lymphocytes. The acini were 
lined by secretory cells without a basement membrane, and the nucleus appeared to be 
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deeply basophilic with an enlarged, clear nucleolus. Poorly undifferentiated neoplastic 
mass characterized by a cluster of neoplastic cells with deeply basophilic cytoplasm and a 
vesiculated nucleus was observed. The tumor mass appeared highly cellular with low 
fibrous connective tissue stroma and loss of Grade IV acinar pattern (solid carcinoma). 
Two weeks after the second treatment and before the third treatment, histopathology 
showed absence of epithelial lining of acini and basement membrane, indicating a decrease 
in malignancy. Also, it revealed the atrophy of acini with dense fibrous connective tissue 
proliferation. The mammary lobule appeared as involution stage Grade I (Figure 3-11B). 
Finally, after the third treatment, there was complete regression of the tumors. 
Additionally, 1 year after the third treatment, no relapses were observed for Case 7 (feline) 
(Figure 3-11C and E). 
Furthermore, in Case 2 (canine), X-ray image showed there was no metastasis in the 
internal organs, and ultrasound image showed the tumor location, shape, and dimensions 
(Figure B.11.). Tumor statuses before, during, or after treatments are seen in Figure 3-12, 
and other photographs for Case 2 are shown in Figure B.12. For the tissue sections, 
moderately undifferentiated tumor mass characterized by basophilic cells with condensed 
nuclear chromatin lining the acini are observed (Figure 3-12A). The connective tissue 
stroma was infiltrated with mononuclear cells of mainly lymphocyte and macrophage 
origin but also contained some multinucleated giant tumor cells (Grade III). On the other 
hand, after treatment (Figure 3-12B) histopathology revealed some necrosis of acini 
accompanied with cellular stroma (Grade 0). No metastasis was observed based on X-ray 
diffraction images (Figure 3-13). Similarly, Case 3 has been explained in the 
Supplementary material, along with photographic images taken before treatment, 2 weeks 
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after treatment, and 1 year after treatment (Figure B.13., photographs). Histopathology 
images for Case 3 before treatment shows the tumor grade change from Grade III before 
treatment to Grade 0 after the treatment (Figure B.14.). Furthermore, the X-ray images 
before and after treatment show there is no metastasis in both statuses (Figure B.15.). 
Images of tumor change and relevant histopathology in Case 7 (feline) show the tumor 
regression process (Tumor 6: open tumor and Tumor 10: close tumor). Although both 
tumors have different malignancy stages (Table 1), the images indicate that both tumors 
responded positively to the treatment, and no tissue burning appeared after the gentle 
treatments. The regression curve as shown in Figure 3-10 shows a dramatic tumor 
regression with normal hair growth. Furthermore, 1 year after the completion of treatment, 




Figure 3-10. Regression curves of 13 tumors of variable volumes from multiple PPTT 
treatment (labeled with “arrow”). 




Figure 3-11. Photographs for Case 7 (feline) with two tumors (Tumor 6: anterior 
thoracic opened tumor; and Tumor 10: caudoinguinal tumors) 
Histopathology images (Tumor 6) showing the tumor regression before and/or after 
each treatment. Notes: After 1 year of treatment, no relapse is observed (E). After 1 
year, the tumors completely disappeared, thus we were unable to take histopathology 
data for the animals. Magnification of histopathology images stained with H&E: (A) 
and (D) ×100; (B) ×200.  Abbreviation: H&E, hematoxylin and eosin. 
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Figure 3-12. Photographs for Case 2 (canine; Tumor 4: left caudothoracic and Tumor 
9: right abdominal mammary gland) and histopathology images (Tumor 4) showing 
the tumor status before treatment (A) and after regression (B). 
Notes: Magnification of histopathology images stained with H&E: ×100. 
Abbreviation: H&E, hematoxylin and eosin. 
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Figure 3-13 X-ray lateral exposure for Case 7 (feline) 
(A) and Case 2 (canine) (B). Notes: Left: 2 weeks after third treatment and right: 1 
year after third treatment showing that there is no metastasis.  The physiological 







Short-term toxicity of AuNRs-PPTT was regarded as minimal because of the normal 
behavior and the animal’s activity, diet, body weight, and appearance. In addition, the study 
of AuNRs toxicity on mice models has proved its short-term safety.15,20 For long-term 
safety, a complete blood profile picture for all the cases was examined at two different 
times: once before the treatment and once1 year after treatment. The objective was to 
follow-up the animals 1 year after their final treatment and check for any changes in 
anatomical function (liver and kidney) as well as their overall health (eg, body weight, 
physical activity, and body skin). No significant change was observed in liver (alanine 
transaminase and aspartate transaminase) and kidney (urea and creatinine) functions when 
comparing before treatment and 1 year after treatment, although some animals in did have 
abnormal initial blood analysis results before treatment, which might be due to their 
different health or diet conditions (Table 1). In summary, this result suggests no obvious 
change in liver and kidney functions and that PPTT is safe even after 1 year. 
Our data suggests that administering AuNRs in conjunction with very low photothermal 
conditions of 42°C–44°C for 2 minutes to canines and felines with natural tumors triggers 
apoptosis, which is more favorable for tumor treatment than necrosis. We tracked the 
animals after treatment for 1 year and found no tumor relapse or metastasis, or any negative 
physiological changes, indicating that there is no toxicity when using optimized AuNRs-
PPTT conditions. We did not observe changes in liver and kidney function 1 year after 
treatment. In addition, the normal behavior and animal’s activity, diet, body weight, and 
appearance indicate no biotoxicity of AuNRs. To our knowledge, this is the first study 
supporting the efficacy and safety of AuNRs-PPTT applied to natural mammary tumors in 
canines and felines. 
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A previous study has reported that AuNRs-PPTT can induce cell apoptosis following the 
common mitochondrial alternative pathway, reactive oxygen species production, Ca2+ 
release, mitochondrial membrane potential change, cytochrome C release, and the 
subsequent activation of the caspase family.34-38 Besides this, other potential mechanisms 
of PPTT-induced apoptosis have been reported, such as initiating Golgi apparatus–
endoplasmic reticulum dysfunction by albumin-conjugated gold NPs [39-42] and nuclear 
damage by harming the de novo RNA biosynthesis [43]. Further studies are needed to gain 
a better understanding of the mechanism of NP-based photothermal therapy. 
Most cancer therapeutic strategies target a tumor’s microenvironment, such as 
inflammatory tumor–associated macrophages (TAMs) and cancer-associated fibroblasts 
(CAFs), as they are considered to be key players in promoting tumorigenesis [21] It has 
been published that TAMs and CAFs have high uptake toward gold NPs [44-46]. Our 
results showed complete clearance of the tumor with no relapse or metastasis. Therefore, 
we expect that PPTT has a significant effect on a tumor’s microenvironment, which is most 
likely related to the high uptake of AuNRs and therefore consistent with the higher 
photothermal response for CAFs and TAMs in the tumor microenvironment [47-48]. 
Further studies will be conducted to examine the effect of AuNRs-PPTT on changing a 
tumor’s microenvironment.
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3.3.4  Conclusion and Future Look 
We developed a three PPTT treatment regime with 2-week intervals to gradually suppress 
the natural tumors of dogs and cats without causing any burning of the tumor or affecting 
the nearby healthy cells. The results show a complete tumor regression in the seven animals 
(thirteen tumors). Furthermore, 1 year after the completion of treatment, no signs of relapse 
or effects of toxicity were observed. This evidence shows not only the efficacy of AuNRs-
PPTT as a proposed treatment, but also its viability as a safer alternative to conventional 
treatments. All animals were subjected to AuNRs-PPTT and showed no relapse , toxicity 
or metastasise  effect even 1 year after treatment. 
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CHAPTER 4. GOLD NANOPARTICLES INHIBIT CANCER 
CELL MIGRATION 
Moustafa Ali and Yue Wu have equally contributed to designing, performing, analyzing, 
and writing the research in this chapter. 
 
4.1 Nuclear membrane-targeted gold nanoparticles inhibit cancer cell migration 
and invasion  
If we can prevent cancer cell migration (i.e. stops metastasis), not too many people would 
die of cancer. Recent studies have showed that gold nanoparticles (AuNPs) can suppress 
metastasis by slowing down the migration speed of cancer cells. Since nuclear stiffness of 
the cell largely decreases cell migration, our hypothesis is that targeting AuNPs to the cell 
nucleus region could enhance nuclear stiffness, and therefore inhibit cell migration. Our 
results show that upon nuclear targeting of AuNPs, the ovarian cancer cell motilities 
decrease more significantly than non-targeted AuNPs. Furthermore, using atomic force 
microscopy, we observed an enhanced cell nuclear stiffness. In order to understand the 
mechanism of cancer cell migration/invasion inhibition, firstly, the exact locations of the 
targeted AuNPs were clearly imaged using a high-resolution three-dimensional imaging 
microscope, which showed that the AuNPs were trapped at the nuclear membrane. 
Meanwhile, we observed a greatly increased expression level of lamin A/C protein, which 
is located in the inner nuclear membrane and functions as a structural component of the 
nuclear lamina to enhance nuclear stiffness. We propose that the AuNPs that are trapped 
at the nuclear membrane both: 1) add to the mechanical stiffness of the nucleus and 2) 
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stimulate the overexpression of lamin A/C located around the nuclear membrane, thus 
increasing nuclear stiffness and slowing cancer cell migration and invasion.  
 
4.1.1  Introduction  
Metastasis, a process in which cancer cells migrate to other locations of the human body, 
is responsible for most cancer-related mortality. It usually begins with local invasion to the 
surrounding tissues, followed by intravasation into the lymph and blood microvasculature 
before the cancer cells finally colonize within the microenvironment of other locations in 
the patient’s body. [2, 3] Many treatments for inhibiting metastasis are based on drugs that 
target specific proteins that promote the cell migration process; however, past attempts to 
develop anti-metastasis drugs have not been efficacious in clinical trials.[4] Moreover, in 
many cases, the anti-cancer drugs that target specific proteins might lose their efficacy after 
several months of treatment due to protein mutations, thus conferring drug resistance to 
cancer cells,[5] and could also cause side effects on healthy tissues.[6] 
Recent advances in nanomedicine provide us with a great opportunity to avoid the 
drawbacks of current drugs. [5-11] Nanoparticles have been widely used in cancer 
diagnosis and cancer therapy thanks to their intrinsic chemical, physical and optical 
properties. [10, 12-14] Nanoparticles with proper surface modifications can target tumors 
selectively, [8, 15-18] and their effects on cancer cell migration or metastasis have drawn 
attention from many researchers. [19-22] In 2013, Murphy et al. reported that gold 
nanoparticles (AuNPs) with different surface charges and sizes can affect cancer cell 
migration. [19] In 2014, Chor Yong Tay et al. [21] found that after incubation with nano-
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ceramics, such as titania, silica and hydroxyapatite, cells showed significantly impaired 
wound healing capability by disruption of the intracellular microtubule assembly. In the 
same year, Zhou et al. [22] showed that gold nanorods (AuNRs) coated with bovine serum 
albumin (BSA) exhibited reduced cell migration and invasion by impairing ATP synthesis, 
which subsequently inhibits the F-actin cytoskeletal assembly and decreases cancer cell 
migration.[22] Arvizo et al. used non-specific targeted gold nanospheres (AuNSs) to inhibit 
cancer cell migration by abrogating MAPK signaling and reversing the epithelial-
mesenchymal transition.[16] For most of the related works, non-specific targeted 
nanoparticles have been used, for instance, Zhou et al.[22] used BSA coated AuNRs that 
showed inhibitory effects on cancer cell migration, but the high concentration of AuNRs 
(50-200 µM) that they used might be an obstacle for clinical usage.  To maintain the 
nanoparticle effect on slowing the cancer cell migration with a minimized amount of 
nanoparticles, the intracellular locations of nanoparticles could be an important factor to 
consider. It is thus promising to design nanoparticles that can target specific intracellular 
regions to enhance the inhibition of cancer cell migration.  
Mechanical stiffness of cancer cells has been shown to grade metastatic potential in patient 
tumor cells, [23] as well as in cultured cancer cell lines. [24, 25] Lower stiffness is related 
to more invasive cells. [26] In eukaryotic cells, the nucleus contains most of the cell's 
genetic material and controls cell activities by transcriptional regulation. It is the largest 
and stiffest organelle in most cells and largely determines the cell migration ability. [27-
29] Lamin A/C (LMNA) proteins are an important factor in nuclear stiffness. They form a 
dense protein network that connects the nuclear membrane and chromatin structures on the 
interior of the nuclear membrane. Recent studies have shown that nuclear lamin A protein 
 242 
scales with tissue stiffness [30] and generate a barrier to cells migrate through three-
dimensional (3D) environments. [31] It is shown that lamin A/C deficiency hampers cell 
mechanics, polarization, and migration. [32, 33] 
Here, targeted AuNPs were used to locate the AuNPs to the cells, because of their specific 
physical and chemical properties and better biocompatibility than other nanomaterials such 
as nano-ceramics or silver nanoparticles. [18, 34] By targeting and locating the AuNPs to 
the cell in a manner to modulate the stiffness of its nucleus, we could improve the inhibition 
effect on cell migration. In our experiment, we used three ligands, methoxy-polyethylene 
glycol thiol (PEG) for increasing the biocompatibility of AuNPs, RGD 
(RGDRGDRGDRGDPGC) peptides for binding to the surface integrin of cancer cells and 
enhancing endocytosis, and nuclear localization signal (NLS, CGGGPKKKRKVGG) 
peptides for targeting the AuNPs to the nucleus. Cell migration or invasion abilities have 
been measured, and the results show a clear decrease in these functions after the nuclear 
targeting of the nanoparticles. For studying the cell mechanical response, atomic force 
microscope (AFM) showed that the two types of AuNPs (i.e. AuNRs and AuNSs) both 
significantly enhanced the nuclear stiffness. A high-resolution 3D optical imaging system 
showed the exact location of the nanoparticles, which were trapped at the nuclear 
membrane. The levels of lamin A/C were found to be elevated upon nanoparticle 
incubation, which could be an explanation for the observed enhanced nuclear stiffness 
causing inhibition of cell motility upon gold nanoparticle treatment. 
 
4.1.2  Experimental Methods  
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Gold nanoparticle synthesis, conjugation and characterization: Gold nanospheres 
(AuNSs) with an average diameter of 35 nm were synthesized using the citrate reduction 
method. [35] Briefly, 100 mL of 0.254 mM HAuCl4.3H2O solution was heated till boiling, 
and then reduced by adding 2.5 mL of 0.35% of trisodium citrate. The solution was then 
left heating until it turned wine red, followed by cooling under water flow. The citrate 
stabilized AuNSs were centrifuged under 5000 g for 10 min and redispersed in deionized 
(DI) water to remove extra citrate and be ready for conjugation.  
Gold nanorods (AuNRs) with an average size of 25 x 6 nm (length x width) were 
synthesized using a seedless growth method. [36] Briefly, 5 ml of 1.0 mM HAuCl4 was 
added to a mixture of 5 mL of 0.20M CTAB, 250 ul of 4.0 mM AgNO3 and 8 μL of 37% 
HCl. For reduction, 70 μL of 78.8 mM ascorbic acid was added, followed by immediate 
injection of 15 μL of 0.01M of ice-cold NaBH4. The solution was left undisturbed for 12 
hrs, then centrifuged at 21000 rpm for 50 min and redispersed in DI water followed by a 
second centrifugation at 19000 rpm for 40 min to remove the extra CTAB. TEM was used 
to measure the sizes and homogeneity of the nanoparticles. 
AuNSs and AuNRs were then conjugated according to previous work, [37, 16] to achieve 
nuclear and cytoplasmic targeting. For nuclear targeting, first, mPEG-SH (1 mM) was 
added to the nanoparticles for overnight to achieve about 1000 ligands on each particle. 
Then, the PEGylated nanoparticles (1 nM) were treated with RGD (1 mM) and NLS (1 
mM) to achieve 104 and 105 molar excess, respectively. The solution was then allowed to 
shake overnight at room temperature. Excess ligands were removed by centrifugation. For 
preparing BSA conjugated nanoparticles, BSA (4.5 mM) was added to the nanoparticles 
and left for 3 h to incubate. UV-vis spectrometer and zetasizer was used to test the 
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conjugation. Surface modification causes red shift of UV-vis spectra due to the change in 
the dielectric constant of the surrounding environment of Au nanoparticles. 
Cell culture and AuNPs incubation: The ovarian cancer HEY A8 cell lines were grown 
in RPMI-1640 media supplemented with 10% FBS and 1% antibiotic-antimycotic solution 
(R10 medium). Cells were kept in a humidified incubator at 37 oC and under 5% CO2. 
After achieving 50% confluence, the cells were incubated with functionalized AuNSs or 
AuNRs in supplemented DMEM cell culture medium for 24 h. The concentration of 
nanoparticles was carefully chosen to avoid cytotoxicity or perturbation to the cell cycle. 
[38] 
Apoptosis/necrosis assay: The HEY A8 cells were collected by trypsinization and washed 
with cold PBS twice. Then, cells were the dispersed in 493 mL of Annexin V binding 
buffer before labeling by 5 μL of Annexin V FITC (BioLegend) and 2 μL of PI (BioLegend, 
100 μg/ mL). The mixture was then incubated for 15 min at room temperature. The cells 
were subjected to flow cytometry analysis using a BSR LSR II flow cytometer (BD 
Biosciences). For excitation, a 488 nm laser was applied. FITC and PI were detected in FL-
1 and FL-2 using 525/30 and 575/30 BP filters, separately. Standard compensation using 
unstained and single-stained cells was conducted before performing actual experiments. 
FlowJo software (Tree Star Inc.) was used for data analysis. At least 10 000 events were 
collected for each experiment. [57] 
Cell motility assay: HEY cells were seeded on uncoated 24-well plate at a sub-confluent 
density for 24 hours. Then the cells were treated with nanoparticles of varying shapes and 
conjugated motifs before returning them to incubator for 12 hours to facilitate particle 
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uptake. After the incubation period, cells were stained with nuclear dye Hoechst 33342 
(dilution 1: 10,000) for 30-60 minutes. Cells were maintained at 37°C and 5% carbon 
dioxide throughout the experiment using an environmental cell chamber (InVivo 
Scientific). For observation, a Nikon Eclipse Ti inverted epifluorescent microscope was 
used and both bright field (BF) and DAPI images were taken at multiple xy positions at 12 
minute time interval for 6-8 hours at 10x magnification. The locations of cell nuclei, 
segmented from fluorescent images, were tracked in MATLAB to define cell traces. The 
cell migration coefficients and directional velocities were determined by fitting the traces 
to the persistent random walk model. Briefly, mean square displacements were calculated 
from the two-dimensional tracking data and was used for fitting the following equation, 
⟨d2(τ)⟩ = 4μ{t − P[1 − e−t/P]} 
Where P= persistence time and μ=migration coefficient. 
Trans-well invasion assay: The Cultured 24 Well BME Cell Invasion Assay kit 
(Trevigen) was used according to the manufacturer’s instructions. For these studies, HEY 
cells were seeded and grown in a 6 well plate to 60-80% confluency before treating with 
nanoparticles in serum free media for 24 hours. Cells were then detached, spun down and 
re-suspended in serum free media.  We also counted the cell number at this time to adjust 
the density to 500,000 cells/mL. Then 50,000 cells (100 μL) were added for each condition 
to the top surface of transwell inserts with 8 μm membrane pores coated with basement 
membrane matrix (BME). Cells were allowed to migrate toward the 10% FBS containing 
media in bottom chamber acting as the chemo attractant for a period of 32 hours. After the 
desired incubation time, non-migratory cells were gently removed from the top of each 
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transwell using q-tips and the migrated cells at the bottom surface were detached using 
detaching buffer and incubated with Calcein AM. A plate reader was used to measure the 
fluorescence intensity, which is positively related to the number of trans-well cells. 
Atomic Force Microscopy: AFM mechanical measurements [39, 40] of HEY A8 cells 
were obtained using an MFP 3-D AFM (Asylum Research, Santa Barbara, CA) on a 
vibration isolation table (Herzan, Laguna Hills, CA). A silicon nitride cantilever (Bruker, 
Camarillo, CA) was used for the experiments. The pyramidal tip had a half angle of 35° 
and the radius of curvature of the point of the tip was 20 nm. Measurements were performed 
on cells plated to the glass bottom of the Fluorodish and in culture media at room 
temperature. For eliminating the effect of the overlapping neighboring cells on the 
stiffness, single cells were measured. Thermal calibration [41] yielded the cantilever spring 
constant, k=28.01pN/nm. A measurement rate of 0.39 Hz was used. The 5 nN force trigger 
resulted in indentations of approximately 4 𝜇m for typical cells. Cells were optically 
located using a Nikon Eclipse Ti microscope (Nikon, Melville, NY). Force-displacement 
curves were recorded to obtain the Young’s modulus of each cell. Two distinct sets of 
measurements were performed with the AFM. The first investigated changes in mean cell 
stiffness between populations treated with AuNPs@NLS and an untreated control 
population. The second set of measurements investigated subcellular elasticity of nucleus. 
For the first set of measurements, the cantilever probe was positioned over the individual 
cells for indentation and measurement. For the second set, the probe was positioned over 
the perinuclear region.  
Cell Imaging Using DIC Microscopy: An inverted Nikon Eclipse Ti-E microscope 
equipped with Perfect Focus System (PFS, 25 nm z-axial resolution) was used for imaging 
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and z-stacks acquisitions under differential interference contrast (DIC) microscopy. The 
DIC mode utilized a pair of DIC polarizer and analyzer, a high resolution 100×I-R DIC 
slider, a high numerical aperture (N.A., 1.40) oil immersion condenser lens, a Nikon CFI 
Apo TIRF 100× (N.A., 1.49) oil immersion objective, and a 12 V/100 W halogen lamp as 
light source. Appropriate bandpass filters were placed in the light path. The z-stack movies 
were taken by a Hamamatsu ORCA-Flash 4.0 V2 CMOS camera (C11440-22CU, pixel 
size: 6.5 µm × 6.5 µm) with Camera Link interface using Micro-Manager and analyzed 
using NIH ImageJ and reconstructed in Amira. Fixed HEYA8 cells on 22 mm × 22 mm 
glass coverslips were rinsed with DPBS at pH 7.4 and fabricated into a sandwiched 
chamber with two pieces of double-sided tape and a cleaned glass slide. PBS solution was 
added into the chamber to fill the space and the chamber was then sealed by clear nail 
polish. The so-formed sample slide was then place under the microscope for observation. 
Z-stacks were acquired using the Multi-Dimensional Acquisition function in Micro-
Manger. More specifically, the DIC optical sectioning through the whole cell thickness 
was achieved by moving the objective on the motorized nosepiece using PFS at 65 nm/step 
at 33 ms (30 fps) exposure time. 
Scratch assay: The scratch assay has been performed according to former report. [42] 
Cells were cultured in a 6 well plate to a confluent monolayer. A p200 pipet tip was used 
to scrape the cell monolayer in a straight line to create an empty gap. The debris was then 
remove by washing the cells once with culture medium and then replace with 2 ml of fresh 
medium. Then the cells were imaged shortly after and 12 hours after scratch. 
Western blot: Briefly, cells were lysed in RIPA buffer (20 mM Tris pH 7.4, 150 mM NaCl, 
2 mM EDTA, 2 mM EGTA, 0.1% Sodium Deoxycholate, 1% Triton X-100, 0.1% SDS) 
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containing protease inhibitors (Sigma-Aldrich). BCA assay (Pierce) was performed to 
measure the protein concentration and equal amounts of protein were loaded on a SDS-
PAGE gel. After SDS-PAGE, the resulting gels were transferred to PVDF membranes 
(Millipore) overnight. Afterwards, the gel was blocked with 5% milk in TBS (20 mM Tris, 
150 mM NaCl). A rabbit polyclonal antibody to Lamin A/C was used as the primary 
antibody (Bethyl Laboratories, Inc.) overnight in 4 °C with shaking. A goat anti rabbit HRP 
labeled antibody was used as the secondary antibody (Jackson Immuno Research 
Laboratories). Blots were washed 3 times for 20 m in TBS after primary and secondary 
antibodies. Konica Minolta developer and Hyglo enhanced chemiluminescence (Denville) 
were used to develop the immunoblots. 
Immunofluorescence labeling and confocal microscopy: Cells were cultured on 
confocal chamber slides (MATECH Co. USA). After gold nanoparticle treatment, [18] 
cells were fixed in 4% Paraformaldehyde/0.1% Glutaraldehyde for 10 min at room 
temperature the wash with PBS. Cells were then permeabilized with 0.1% Triton X-100 
for 5 min at room temperature. Cells were then blocked with 5% BSA and incubated with 
the primary antibody as stated in the Western-blot method for overnight. Cells were then 
incubated for 1 h with an Alexa Fluor 488 secondary antibody (Invitrogen) for 1 h before 
mounting with Prolong Gold (Invitrogen). Lastly images were taken with a Zeiss LSM 
700-405 confocal microscope and the fluorescence intensity was quantified in Image J. 
Data: To determine the Young’s modulus, IGOR Pro software (Wavemetrics, Portland, 
OR) was used to apply the Hertzian contact model [43-45] from 10-90% of the maximum 
indentation of the extension force-displacement curve. Due to the unequal sample size and 
heteroscedasticity of the AFM data, overall statistical significance of differences in mean 
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cell stiffness and nuclear stiffness between cells treated with AuNPs@NLS was tested 
using Welch’s analysis of variance (ANOVA). Post-hoc analysis was performed using the 
Games-Howell test. The analyses were performed with the alpha type error set at 0.05.  
 
4.1.3 Results and Discussion 
Au nanoparticles synthesis, conjugation, cellular uptake and cytotoxicity 
measurement 
The AuNRs with an average size of 25 (± 2)  5 (± 0.5) nm were synthesized using a 
seedless method, [36] as shown in Figure 1a (TEM figure) and a surface plasmon 
resonance (SPR) peak centered ~ 800 nm (UV-Vis spectrum in Figure 1d). The AuNSs 
with an average size of 35 ± 2 nm that absorb at 535 nm wavelength of light were 
synthesized using citrate reduction method were shown in Figure 4-1b and Figure 4-1e 
(TEM and UV-Vis spectrum).  
Gold nanoparticles (AuNPs) were functioned with three ligands, methoxy-polyethylene 
glycol thiol (PEG), RGD (RGDRGDRGDRGDPGC) peptides and nuclear localization 
signal (NLS, CGGGPKKKRKVGG) peptides, as shown in schematic Figure 4-1c. In 
details, first, we conjugated the PEG to the surface of the AuNPs surface in order to 
enhance the biocompatibility. [46] Then, the second ligand, RGD binds to surface integrins 
which are highly expressed on the surface of the cancer cells than the normal ones to 
enhance the receptor-mediated endocytosis of the nanoparticles selectively to the cancer 
cells. [47] The third ligand, which is NLS, a peptide sequences that recognized by importin 
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and translocate into the nucleus. [48] Successful surface modification of 
AuNRs@PEG@RGD/NLS (AuNRs@NLS) is evident in the red-shift of the plasmon peak 
of AuNRs to longer wavelengths, from 800 nm for the as-synthesized cetyl-trimethy 
ammonium bromide (CTAB) coated AuNRs to 805 nm for PEGylated AuNRs, and finally 
to 825 nm for the RGD and NLS modified AuNRs (Figure 4-1d). Similarly, the surface 
plasma peak of AuNSs@PEG@RGD/NLS (AuNSs@NLS) was also red-shifted (Figure 
4-1e), which is in agreement with our former publication. [37]  
Furthermore, the zeta potential of the AuNRs at the different conjugating stages of the three 
ligands were measured (Table C.1.) to confirm the surface modifications.  In details, the 
as-synthesized CTAB coated AuNRs has highly positive surface charge (50.9 ± 7.97 mV) 
as CTAB is a highly cationic surfactant. After PEG modification, the AuNRs become 
negatively charged (-13.6 ± 11.8 mV). The zeta potential of the AuNRs becomes positive 
again (14.9 ± 3.13 mV) after further modification with RGD and NLS peptides (Table S1). 
Also, the zeta potential of the AuNSs@NLS proved their successful surface modification 
(Appendix Table C.1.), similar to the previous studies. [37] 
To examine the cytotoxicity of the AuNPs, the XTT cell proliferation assay was conducted 
and no significant change of the cell viability was observed for nanoparticles at frequently 
used concentrations 0.5, 2.5 and 5 nM (for AuNRs) [18, 49] (Figure 4-2a and Figure 
4-2b), and 0.05, 0.1 and 0.2 nM concentrations (for AuNSs). [37, 50] Apoptosis/necrosis 
assay was also conducted for 5 nM of the AuNRs or 0.2 nM of the AuNSs (Figure 4-2c, 
Figure 4-2d and Figure 4-2e) using flow cytometry. Therefore, the results indicate that 
the concentrations of the AuNRs used in this study are lower than that affecting cell 
viability or inducing apoptosis.  
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The uptake of AuNPs@NLS was monitored using dark-field (DF) microscopy and UV-
Vis absorption. The HEY A8 cells, which were previously identified to be highly invasive 
cell line, [51] were incubated with 2.5 nM of AuNRs@NLS or 0.05 nM of AuNSs@NLS 
for 24 hrs. As shown in the DF image (Appendix Figure C.1. a and b), clear 
internalization of both AuNPs (AuNRs@NLS and AuNSs@NLS) was observed. 
Furthermore, for evaluating the AuNPs uptake to the HEY A8 cells, the UV-Vis spectra 
have been collected for the AuNPs in culture media before incubation with cells, compared 
with the ones after 24 h cell incubation (Appendix Figure C.1. c and d), which showed 
the decrease of peak intensity that, indicate the portion of AuNRs being uptaken by cells.   
Non-targeted AuNPs with bovine serum albumin (BSA) coating were also fabricated. 
Successful surface modification of AuNPs@BSA (both AuNRs@BSA and AuNSs@BSA) 
is evident in the red-shift of the surface plasmon peak of AuNPs to longer wavelengths 
(Appendix Figure C.2. a and b).  Zeta potential of AuNRs after BSA modification became 
negatively charged (-19.6 ± 9.89 mV, Table C.1.) due to the negative charge of BSA, while 
the as-synthesized CTAB coated AuNRs has highly positive surface charge (50.9 ± 7.97 
mV, Appendix Table C.1.). The AuNSs@BSA also has a negative zeta potential of -15.2 
± 12.5 mV (Appendix Table C.1.). No toxicity effect of AuNPs@BSA was observed, as 




Figure 4-1. Characterization of Au nanoparticles 
 (A) Transmission Electron Microscopic (TEM) image of gold nanorods (AuNRs) and 
(B) TEM image of gold nanospheres (AuNSs), Scale bar = 100 nm. (C) Schematic 
figure of Au nanoparticle conjugation with PEG, RGD and NLS peptides. (D) UV-Vis 
extinction spectra of the unconjugated AuNRs (black spectrum), AuNRs@PEG (red 
spectrum), and AuNRs@PEG@RGD/NLS (green spectrum), (E) UV-Vis extinction 
spectra of the unconjugated AuNSs (black spectrum), AuNSs@PEG (red spectrum), 




Figure 4-2. Au nanoparticles cytotoxicity measurements and cellular uptake 
(A) Cell viability measurement (XTT assay) of HEY-A8 cells after 24 h incubation 
with AuNSs@NLS at concentrations 0.05 nM (light blue), 0.1 nM (medium blue) and 
0.2 nM (dark blue). (B) Cell viability (XTT) assay for cells after 1.5 nM (light blue), 
2.5 nM (medium blue) and 5 nM (dark blue) of AuNRs@NLS incubation with HEY-
A8 cells for 24h. (C, D, and E) Flow cytometry experiment for apoptosis/necrosis 
assay (C, Ctrl; D, cells incubated with 0.2 nM of AuNSs@NLS ; (E) cells incubated 











Nuclear targeting gold nanoparticles inhibit cancer cell migration and invasion 
To test the cell motility, HEYA8 cells were incubated with AuNPs for 12 hours before 
staining with fluorescent nuclear dye. Cells were then placed on an inverted epi-fluorescent 
microscope equipped with a cell culture chamber for continuous bright field and 
fluorescence imaging. The cell migration coefficients were then determined from the 
images. As shown in Figure 3a, both nuclear-targeted AuNRs and AuNSs inhibit the 
motility of HEY A8 cells. The average migration coefficient of the cells decreases from 3 
x 10-10 by a factor of 3-10. (Figure 4-3a and Supporting Video Information for motility). 
We conducted a control experiment of non-targeted AuNPs coated with BSA, 
(AuNPs@BSA, characterization information in the Supporting Information and Figure 2).  
The motility assay shows that there is no apparent inhibition of AuNRs@BSA or 
AuNSs@BSA on cell migration (Figure 4-3b). The scratch assay was conducted to 
evaluate the migration ability. Results (Figure 4-3c) indicate that the control cells had a 
completely healed “wound” after 12 h following AuNPs incubation, while the ones treated 
with AuNRs@NLS and AuNSs@NLS were not completely healed after 12 h.  
In order to examine the invasion ability of HEY A8 cells after their treatment with the 
nuclear membrane-targeted AuNPs, the trans-well invasion assay was performed. The cells 
that invaded the basement membrane extract (BME) after 32 h were dissociated and stained 
with Calcein AM, a fluorescent dye that labels living cells. A control experiment has been 
performed to eliminate the possibility that gold nanoparticles could quench the 
fluorescence from Calcein AM (Appendix Figure C.3.). A significant decrease in 
fluorescence intensity was observed in the AuNPs treated groups, indicating the inhibition 
of the invasion ability of HEY A8 cells particles (Figure 3d). In general, the cell migration, 
 255 
and invasion abilities of HEY A8 cells were inhibited effectively by both AuNRs@NLS 
and AuNSs@NLS.  
 
Figure 4-3. Effect of AuNPs (2.5 nM AuNRs@NLS and 0.1 nM AuNSs@NLS if not 
mentioned) on motility and invasion of HEY A8 cells 
Cell migration study was performed to determine the effects of both AuNRs@NLS 
and AuNSs@NLS (A), and AuNRs@BSA (5 nM) and AuNSs@BSA (0.1 nM) (B) on 
the HEY A8 cells motility (error bar SEM). (C) Scratch assay of cells incubated with 
AuNRs@NLS and AuNSs@NLS displayed arrested healing/closing of the scratch. (D) 
Invasion assay of cells without AuNPs or with AuNRs@NLS and AuNSs@NLS 
treatment (error bar  SD). *P < 0.05, **P < 0.01, ***P<0.001. 
 
Nuclear targeting gold nanoparticles enhance nuclear stiffness 
Next, we tested our hypothesis that the nuclear-targeted AuNPs can enhance nuclear 
stiffness. Cell stiffness as quantified by the Young’s modulus has been used as a biomarker 
of the metastatic potential of cancer cells. [19] For AFM measurements (Figure 4-4a), a 
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beaded cantilever was lowered on top of the individual cells, producing an indentation in 
those cells and corresponding deflection of the AFM cantilever, which allowed for the 
measurement of cell stiffness. An overhead image of AFM cantilever tip next to HEY A8 
cells with nanoparticles was shown in Figure 4-4b. The distribution of Young’s moduli of 
individual cells, as well as that of the cell nucleus, from different nanoparticle treatments 
and the control is depicted in Figure 4-4c and Figure 4-4d. In our study, both 
AuNSs@NLS and AuNRs@NLS exhibit significant increase in the cell stiffness (Figure 
4-4c), which is similar to previous observations that nanoparticles could increase cell 
stiffness. [52, 53] For the nuclear stiffness, as shown in Figure 4d, the mean nuclear 
Young’s modulus of the cells treated with AuNPs (AuNRs and AuNSs) were also 
significantly higher than the mean nuclear Young’s modulus of the untreated cells, in 
agreement with the results of the overall cell stiffness.  In addition, we observed the 
increase of gold nanoparticle amount could increase the nuclear stiffness, as shown in 
Appendix Figure C.4. 
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Figure 4-4.  Stiffness distribution of cells: 
 (A) Schematic of measurements on cells with AFM; δ is indentation, Δx is cantilever 
deflection. To measure bulk cellular stiffness, a beaded cantilever was used to increase 
cell-probe surface area. (B) Overhead image of AFM cantilever tip next to HEY A8 
cells with nanoparticles (C) Box-and-whisker plots of stiffness of single cells for 
different nanoparticles treatment, the percentiles are 10%, 25%, 50%, 75%, and 
90%. Overall difference between means is significant (p-value calculated from 
ANOVA); (D) Box-and-whisker plots of nuclear stiffness. *P < 0.05, **P < 0.01, 
***P<0.001. 
 
AuNPs accumulate at nuclear membrane resolved by three-dimensional microscopy 
Resolving the exact localizations of AuNPs regarding the nuclear membranes [54, 55] is a 
crucial, yet highly challenging, step in our attempt to understand the effects of AuNPs on 
the inhibition of cell migration.  Most commonly used optical microscopy methods, such 
as confocal fluorescence microscopy and dark field (DF) microscopy, do not offer the 
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accurate locations of the nuclear membranes and AuNPs simultaneously, and they usually 
suffer from high background. On the other hand, TEM, despite its high resolving power, is 
limited by the high costs and tedious sample preparation to gain the full 3D distribution of 
AuNPs inside the cells. To circumvent these challenges, we employed a recently-developed 
differential interference contrast (DIC) microscopy-based 3D imaging method to visualize 
and locate plasmonic AuNPs inside the cells. [56-58] As shown in Figure 4-5a, the cells 
were placed in a sandwiched chamber. DIC optical sectioning was performed on the whole 
cell thickness. The arrow indicates the scanning optical sectioning of the cell, directed from 
layer 1 (close to the surface of the cover glass) to layer 2 (middle of the cell) and to layer 
3 (top of the cell) (Figure 4-5 and Appendix Figure C.5-6, and Videos in the Supporting 
Information). The DIC microscope, which was equipped with a set of high numerical 
aperture (NA = 1.4), oil-immersion condenser and objective, features a shallow depth of 
field in optical sectioning of a 3D specimen to generate sharply focused images. More 
importantly, the nuclear membranes are clearly visible under the DIC microscope to allow 
the determination of the relative positions of the nuclear membranes and AuNPs.  
Figure 4-5b to Figure 4-5d shows the AuNSs@NLS locations inside the HEY A8 cells. 
The black spots in the figures are the nanoparticle aggregates, which are shown clearly 
surrounding the nucleus from difference optical sections. Similarly, Figure 4-5e to Figure 
4-5g shows a similar distribution of AuNRs@NLS inside HEY A8 cells. Both 
AuNRs@NLS and AuNSs@NLS aggregates were located predominantly on the nuclear 
membranes, while the internalization of nanoparticles inside the nucleus was rarely found, 
which was likely due to the large sizes of the nanoparticles and their aggregates compared 
to the nuclear pores (around 9~12 nm [59]).  
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Figure 4-5. Locations of AuNPs inside the HEYA8 cell (up) and lamin A/C protein 
location/expression (down) inside the HEY A8 cell 
 (A) Scheme of the cell sample in sandwiched chamber for 3 dimensional DIC 
microscope imaging. Z-axis scanning step is 65 nm from the bottom (close to the 
attached glass surface) to the top of the cell.  Three layers from the bottom, middle, 
and the top of the cell, for cells incubated with 0.1 nM of AuNSs@NLS (B-D) and 2.5 
nM of AuNRs@NLS (E-G) were imaged, corresponding to frame 75, 235, and 395 
(AuNSs@NLS) and frame 49, 179, and 285 (AuNRs@NLS) of the movies in the 
Supporting Information. (H) Western-blot results of lamin A/C, with beta-actin as 
reference protein. (I, J and K) Lamin A/C localization by confocal microscope of (I) 






Nuclear targeting gold nanoparticles cause lamin A/C protein increase 
Lamins, especially lamin A/C, are intermediate filament proteins found at nearly all cell 
nuclei and contribute to nuclear stiffness and stability. (60), (61) Nuclear lamins interact 
with the membrane-associated proteins to form the nuclear lamina (30-100 nm thick), 
which is located in the interior of the nuclear membrane. It has been reported that lamin 
A/C-deficient cells exhibit severely reduced nuclear stiffness. [30, 61] To further 
understand the biological mechanism for why nuclear membrane-targeting AuNPs increase 
nuclear stiffness and inhibit cancer cell migration, we measured the expression level of 
lamin A/C in Western-blots (Figure 4-5h) and confocal microscopy imaging after immuno-
staining (Figure 4-5). The results indicate a clear overexpression of lamin A/C after 
incubation with AuNSs@NLS or AuNRs@NLS. As shown in Figure 4-5i, Figure 4-5j 
and Figure 4-5k, the fluorescence signal from lamin A/C was increased as a circle-
surrounding the nucleus, which is in agreement with the location of nuclear lamina.  
AuNPs conjugated with a nuclear localization signal were thought to be able to internalize 
into the nucleus. [54, 62] In our study we clearly observed most of the NLS conjugated 
gold nanoparticles aggregated around the nuclear membrane. Western blot experiment 
showed that the endocytosis and nuclear transportation has been activated upon 
nanoparticle incubation (Appendix Figure C.7.), due to the increased expression level of 
dynamin protein (a GTPase responsible for endocytosis in the eukaryotic cell) and GTP-
binding nuclear protein Ran (involved in the transport into and out of the cell nucleus). 
Since the cellular and nuclear transportation are all activated, the trapping of AuNPs at the 
nuclear membrane was most likely due to the large size of the gold nanoparticles aggregates 
compared to the nuclear pores.  
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It has been widely reported that following the entry of nanoparticles, they traffic through 
early endosomes to late endosomes and lysosomes (endolysosomal trafficking). [63, 64] 
To achieve nuclear membrane targeting, nanoparticles need to escape from the endosome 
and/or lysosomes. There are several well-established mechanisms explaining the cytosolic 
release of the NPs from endosomes or lysosomes. One of the most popular mechanism is 
through the charge interactions. The cationic nanoparticles could interact with the 
negatively charged phosphor lipid membrane, followed by “proton sponge” effect, causing 
endosomal membrane rupturing [65, 66] and nanoparticle escaping. In our study, the 
positively charged AuNRs@NLS. [67] could have the similar mechanism to escape from 
the endosome. In our results, most of the nanoparticles finally locates surrounding the cell 
nucleolus after incubation with cells overnight (Figure 4-5b toFigure 4-5g and Supporting 
movies HEYA8_AuNSs@NLS.avi and HEYA8_AuNSs@NLS.avi), indicating a good 
efficacy that gold nanoparticles escape from the endosome/lysosomes and target the 
nuclear membrane. Meanwhile, the above results show that the effect of endosome 
degradation [68] of the surface conjugated peptides might be very minor.  
Coincident with the increased nuclear stiffness by the AuNPs is the aggregation of the 
AuNPs at the nuclear membrane and the increase of the Lamin A/C expression, which is 
located at the inner side of nuclear membrane. Lamin A/C is known to maintain the 
mechanical strength of the nucleus, [69] and is thus consistent with an inhibited cell 
migration. In our results, a clearly increased expression level of Lamin A/C was observed. 
Thus, we propose that the increase of nuclear stiffness not only due to the mechanical 
contribution of the presence of gold nanoparticles, but could also due to the increase of 
Lamin A/C. How AuNPs increase Lamin A/C is not yet well explored in literature. Figure 
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Figure 4-5c shows AuNPs closely contact with the nuclear membrane, which could 
potentially disturb the membrane integrity. Therefore, we propose it could be a cellular 
defense mechanism as lamin is known to remain the mechanical strength of nucleus. 
Interestingly, nuclear lamin-associated proteins, such as emerin, which stabilizes nuclear 
architecture for maintaining the structural integrity, [68, 70, 71] are also increased as the 
AuNPs are added at the nuclear membrane as shown in Figure C.7. To investigate this 
mechanism, further studies such as proteomics and high-resolution imaging could be 
fruitful to elucidate the exact role of the AuNPs in inhibiting cell migration.  
The clearance of nanoparticles from body after treatment has great importance to the 
evaluation of long-term effect of nanoparticles. While small nanoparticles (hydrodynamic 
diameter less than 5.5 nm) can be discard rapidly and efficiently through renal/urinary 
excretion. [72] big nanoparticles (over 18 nm) tend to accumulate in liver and spleen. [73] 
Such body deposition of metallic NPs over a long-time raises significant concerns 
regarding their long-term safety. A decrease of the liver content of gold has been reported 
after 1 month from 0.54% to the 0.07%. [74] The fate and the body elimination pattern of 
gold nanoparticles are not well studied. Future work will be focused on studying the effect 
of gold nanoparticles for preventing and treating the metastasis in animals. 
 
4.1.4  Conclusion and Future Outlook 
this is the first study showing that nuclear membrane-targeting AuNPs can increase nuclear 
stiffness and thereby inhibit cell migration and invasion. Compared with the previous 
studies with non-targeted AuNPs at relatively high amount (50-200 µM of AuNRs@BSA 
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[22] and 5-20 g AuNSs@Citrate [20]), the nuclear membrane-targeted AuNPs showed 
higher inhibition effects at significantly lower concentrations (0.1 nM for 35 nm AuNSs 
and 2.5 nM for 25  5 nm AuNRs). The AuNPs were found to be trapped on the nuclear 
membranes from mapping the 3D distributions of the AuNPs under a DIC microscope. The 
trapping of AuNPs at the nuclear membranes could possibly: 1) add to the mechanical 
stiffness of the nucleus, and, 2) stimulate the overexpression of lamin A/C, which is known 
to lead to nuclear stiffness and thus slows down cancer cell migration. This new insight 
takes us one step closer to fully understand the effects on AuNPs on the inhibition of 
metastasis.  
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4.2 Targeting Cancer Cell Integrins Using Gold Nanorods in Photothermal 
Therapy Inhibits Its Migration by Affecting Cytoskeleton Proteins [1] 
Metastasis is responsible for the majority of cancer-related deaths, while the current clinical 
treatments are not effective. Recently, gold nanoparticles were discovered to inhibit cancer 
cell migration and prevent metastasis. However, high doses of gold nanoparticles were 
necessary to achieve good inhibition efficacy, which is not favorable for clinical 
applications. Moreover, the mechanism behind remains largely unexplored. Cytoskeletons 
are cell structure proteins closely related to migration. Within this process, surface receptor 
integrins, play one of the most important roles in controlling the cytoskeletons. Herein, we 
developed a novel strategy to inhibit cancer cell migration using gold nanorods (AuNRs) 
conjugated with RGD peptides, for targeting cancer cell integrins, with 1000 times less 
particle dosage. AuNRs were further activated with 808 nm near infrared (NIR) light to 
generate plamonic photothermal therapy (PPTT), which was controlled not to affect the 
cell viability or proliferation. Our results demonstrated a decreased cell migration speed. 
Changes in cell morphology, observed as cytoskeleton protrusions known as lamellipodia 
and filopodia, were reduced after treatment. The Western-blot analysis indicated that the 
down-stream effectors of integrin were attracted towards the anti-migration direction. 
Proteomics results indicated broad perturbations in four signaling pathways: Rho GTPases, 
actin, microtubule, and kinases related pathways. When we applied PPTT, it further 
inhibited the cancer cell migration by remodeling the cell cytoskeleton proteins. In 
summary, the ability of targeting AuNRs to the cancer cell integrins and the introduction 
of PPTT stimulated wide-range regulating the migration pathways, which provides a 
potential novel medical application for controlling cancer metastasis.  
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4.2.1 Introduction 
Metastasis is a process that enables cancer cells to spread to other sites of the body, and is 
responsible for most cancer-related deaths [2-4]. The migration of cancer cells from one 
site to another requires dramatic remodeling of the cell cytoskeleton [2, 4-6]. Studies on 
the changes of cytoskeleton components could provide novel therapeutic approaches to 
prevent cancer cell migration and metastasis 5. The targeting of cytoskeletal components, 
such as actin or tubulin [7-8], or regulatory proteins, such as Rho-ROCK or LIM kinases, 
has been shown to inhibit the invasive and metastatic behavior of cancer cells [9-10]. 
However, the pharmacological inhibitors of cytoskeleton have not been very effective in 
clinical trials due to their non-specific targeting of cytoskeleton in the normal cells that 
might cause side effects, such as cardiotoxicity [5, 8, 11]. Moreover, in many cases, the 
anti-cancer drugs that target specific proteins might lose their efficacy after several months 
of treatment due to mutations of the proteins that result in the rise of drug resistance in 
cancer cells [12, 13]. 
Recent advancements in nanomedicine provide us with great opportunities to avoid the 
drawbacks of commonly used drugs [14-15]. Due to their small sizes and surface 
modifications, nanoparticles, in general, can target tumors selectively [16]. Because of 
these intrinsic properties, nanoparticles are widely used in cancer diagnosis and therapy 
[17-18]. The recent discovery of nanoparticles’ effect on inhibiting cancer cell migration 
or metastasis has drawn the attention of many researchers [19,20-22]. Among them, several 
groups have reported that this inhibition effect of nanoparticles is closely related to the 
cytoskeletons. Tay et al. found that TiO2, SiO2, and hydroxyapatite nanoparticles could 
disrupt the intracellular microtubule assembly, thus strengthening the intracellular tension 
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and retarding cellular migration [19]. Soenen et al also reported that high concentrations of 
iron oxide nanoparticles within cells affect the cellular cytoskeleton and focal adhesion 
kinase-mediated signaling [23]. Zhou et al. showed gold nanorods (AuNRs) can inhibit F-
actin cytoskeletal assembly and decrease cancer cell migration [21]. However, current 
studies use high concentrations of nanoparticles in µM, which might be an obstacle when 
considering the translation to clinical usage [19, 21, 23]. Additionally, several types of 
nanoparticles, including TiO2, SiO2, iron oxide, etc. have been found to exhibit toxicity 
when used in relatively high concentrations [24, 25, 26].  In order to maintain the 
nanoparticles’ effect on slowing cancer cell migration with a limited amount of 
nanoparticles, an intelligent design and delivery of nanoparticles to regulate the 
cytoskeleton promises to be crucial in helping the development of novel and effective anti-
metastasis therapy.  
 
Gold nanorods (AuNRs), due to their unique chemical, physical and optical properties, 
have been used in drug delivery [27], bio-imaging [28], and the plasmonic photothermal 
therapy (PPTT) of cancer [29-31]. It has been reported that heat stress affects the 
cytoskeleton and induces their rearrangements [32-34]. The use of AuNRs allows us to 
apply near infra-red laser (NIR) to generate heat efficiently through non-radioactive 
processes [14, 35-36]. NIR light as a low energetic (safe) light might deeply penetrate the 
tissues to activate the AuNRs’ effects on cytoskeletal proteins and inhibit migration. Our 
previous study has shown success in treating natural mammary gland tumors in dogs and 
cats using AuNRs assisted plasmonic photothermal therapy (PPTT), where all the cases 
did not have cancer relapse and metastasis [37], hinting the potential effect of PPTT on 
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inhibiting cancer metastasis. Therefore, to overcome the drawbacks of using nanoparticles, 
four aspects were considered to better the nanoparticle design to achieve effective 
inhibition of cancer cell migration:  1) Lower the concentration of nanoparticles to nM 
dosage, as a means for lowering toxicity. 2) Enhance the selectivity to the cancerous cells.  
3) Apply NIR light to activate the AuNRs’ effects on cytoskeletal proteins and inhibit 
migration. 4) Most importantly, enhancing the migration inhibition effect by targeting 
AuNRs to integrin proteins to remodel the cytoskeleton.  
 
Integrins are major adhesion and signaling receptor proteins that play an important role in 
regulating cytoskeleton [38-40], by providing a physical linkage between the cytoskeleton 
and the extracellular matrix (ECM), and receiving signals from the ECM [41]. They could 
perturb the down-stream cell adhesion and migration pathways and modulate the 
cytoskeleton, thus regulating cell motility and migration [42-43]. Numerous studies have 
reported differentially expressed integrins in many cancers. For instance, inducing the 
expression of the αv or β3 integrin subunit in cancer cell lines increases their metastatic 
potential [44-45]. The Arg-Gly-Asp (RGD) peptides are known for specific binding to a 
wide number of surface integrins, including αvβ3, α3β1 and α5β1integrins. [46-48] 
 
In our work, RGD peptides were conjugated on the surface of AuNRs to achieve the 
selective targeting of integrin. Near infrared (NIR) light was applied to the AuNRs to 
generate mild heat. The concentration of the AuNRs and heat were kept well below the 
threshold of those that might affect cell viability or proliferation. We compared both non-
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targeted and integrin-targeted gold nanorods (AuNRs@RGD). Results indicated that, while 
both types of AuNRs decreased cell migration speed, the targeted ones did so with a greater 
effect. After applying NIR light, cell motility was further decreased. We have performed a 
proteomics study to understand the molecular mechanism, explaining how and why AuNRs 
have a wide-range effect in perturbing cytoskeleton proteins and cell migration pathways. 
Compared to the drugs comprised of small molecules that target only a single protein, 
AuNRs show great promise as a novel anti-metastasis strategy to be developed for clinical 
usage.  
 
4.2.2  Experimental methods  
Instrumentation. Gold nanoparticles were imaged using a JEOL 100CX-2 transmission 
electron microscope (TEM) microscope, and their average size was then measured by 
ImageJ software. UV−vis spectra were obtained using an Ocean Optics HR4000CG UV-
NIR spectrometer.  An inverted Nikon Eclipse Ti-E microscope equipped with Perfect 
Focus System (PFS, 25 nm z-axial resolution) was used for imaging under differential 
interference contrast (DIC) microscopy. Proteomics analysis was done on a hybrid dual-
cell quadrupole linear ion trap − Orbitrap mass spectrometer LTQ Orbitrap Elite (Thermo 
Fisher) with Xcalibur 3.0.63 software. Flow cytometry experiments were conducted on a 
BD LSR II Flow Cytometer (BD Biosciences).  
Synthesis, conjugation and characterization of AuNRs:  
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 Gold nanorods (AuNRs) with an average size of 25 x 6 nm (length x width) were 
synthesized using a seedless growth method [49].  5 ml of 1.0 mM HAuCl4 was added to 
a solution of 5 mL of 0.2 M CTAB, 250 μL of 4.0 mM AgNO3, and 8 μL of 37% HCl. 
Then, 70 μL of 78.8 mM ascorbic acid was added, followed by immediate injection of 15 
μL of 0.01M of ice-cold NaBH4. The solution was left undisturbed for 12 hours.  The 
particles were centrifuged at 21000 g for 50 min and dispersed in DI water, followed by a 
second centrifugation at 19000 g for 40 min to remove the extra CTAB. TEM was used to 
measure the sizes and homogeneity of the nanoparticles. 
After rinsing them with water, AuNRs were then conjugated with different surface ligands 
(PEG and RGD). For AuNRs@PEG, mPEG-SH (1 mM) was added to the nanoparticles 
overnight to achieve about 5000 ligands on each particle. For preparing AuNRs@RGD, 
first, mPEG-SH (1 mM) was added to the nanoparticles overnight to achieve about 1000 
ligands on each particle. Then, the PEGylated nanoparticles (1 nM) were treated with RGD 
(1 mM) to achieve 10000 molar excess. The solution was then allowed to shake overnight 
at room temperature. Excess of ligands were removed by centrifugation. UV-vis 
spectrometer and zetasizer were used to test the conjugation.  
Cell culture, AuNRs treatments and PPTT: 
Cells were grown in Dulbecco’s modified Eagles’ medium (DMEM, Mediatech) 
containing 10% (v/v) fetal bovine serum (FBS, Mediatech) and 1% antimycotic solution 
(Mediatech) at 37 oC in a humidified incubator under 5% CO2. Cells were cultured in 60 
mm dishes for 24 hours followed by incubation with AuNRs for 24 hours. Then, a CW 808 
nm laser (5.8 W/cm2, spot size 5.6 mm) was applied to the cells. To cover the entire area 
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of the culture dish, the laser was applied spot by spot using scanning with each spot 
undergoing two minutes of laser exposure time. The cells were then harvested for MS 
analysis, with a final confluence about 80-90%.  
 
Sample preparation for proteomics experiment: 
After treatment for 24 hours, cells were washed twice using PBS. Cell lysates were 
prepared by directly adding the lysis buffer (150 mM NaCl, 50 mM HEPES, pH =7.4, 0.1% 
SDC, 10 units/ mL benzonase, protease inhibitor cocktail) to the cells followed by scraping 
and collecting on ice. Lysates were vortexed for 90 s (30 s x 3 times, 2 min pause), 
sonicated on ice, and centrifuged at 18000 g for 15 min at 4 oC. The supernatant solutions 
were saved and proteins were precipitated by adding 4 x excess volumes of ice-cold 
precipitation solvents (acetone: ethanol: acetic acid=50:50:0.1) and stored at -20 oC 
overnight. After centrifugation, the protein pellet was re-dissolved in an 8 M urea, 50 mM 
HEPES solution (pH=8) [50]. 
Protein disulfide bonds were reduced using 1 mM dithiothreitol (DTT) followed by 
alkylation with 5.5 mM iodoacetamide. After the lysate were diluted two times, (final urea 
concentration 4 M) endoproteinase Lys-C (1:100 w/w) was added to digest proteins for 4 
hours. Then, modified sequencing grade trypsin (1:100 w/w) was used for further digestion 
in a more diluted solution with the final urea concentration of 1 M for overnight [51]. 
Protein concentration was measured by Bradford assay. 
RPLC-MS/MS Analysis for label-free quantitative proteomics:  
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The proteomics analysis was conducted using the previous reported method [52]. Briefly, 
purified and dried peptide samples from the previous step were dissolved in 10 μL solvent 
with 5% acetonitrile and 4% FA, and 4 μL of the resulting solutions were loaded onto a 
microcapillary column packed with C18 beads (Magic C18AQ, 3 μm, 200 Å, 100 μm x 16 
cm, Michrom Bioresources) by a Dionex WPS-3000TPLRS autosampler (UltiMate 3000 
thermostatted Rapid Separation Pulled Loop Wellplate Sampler). A reversed-phase liquid 
chromatography (RPLC) using an UltiMate 3000 binary pump was used for Peptides 
separation, with a 110 min gradient of 8-38% ACN (with 0.125% FA). Peptides were 
detected with a data-dependent Top20 method, i.e. for each cycle, one full MS scan 
(resolution: 60,000) in the Orbitrap was followed by up to 20 MS/MS in the ion trap for 
the most intense ions. The selected ions were excluded from further analysis for 90 
seconds. Ions with singly or unassigned charge were not sequenced. Maximum ion 
accumulation times were 1000 ms for each full MS scan and 50 ms for MS/MS scans. The 
sample at each condition was repeated 6 times (2 biological and 3 technique replicates) for 
label-free quantification.   
Apoptosis/necrosis assay: 
After removing the cell culture media, and cells were washed with PBS and collected after 
trypsinization followed by washing with cold PBS twice again. Then, the cells were 
dispersed in a mixture of 493 mL of Annexin V binding buffer, 5 μL of Annexin V FITC 
(BioLegend), and 2 μL of propidium iodide PI (BioLegend, 100 µg / mL) and incubated 
for 15 min at room temperature. The cells were then filtered and subjected to flow 
cytometry analysis using a BSR LSR II flow cytometer (BD Biosciences). A 488 nm laser 
was applied for excitation, and FITC was detected in FL-1 using a 525/30 BP filter while 
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PI was detected in FL-2 using a 575/30 BP filter. Standard compensation using unstained 
and single-stained cells was done before running actual experiments. FlowJo software 
(Tree Star Inc.) was used for analysis of the viable, apoptotic and necrotic cells from at 
least 10000 events.  
Cell Imaging Using DIC Microscopy: The DIC mode utilized a pair of DIC polarizer and 
analyzer, a high resolution 100×I-R DIC slider, a high numerical aperture (N.A., 1.40) oil 
immersion condenser lens, a Nikon CFI Apo TIRF 100× (N.A., 1.49) oil immersion 
objective, and a 12 V/100 W halogen lamp as light source. Appropriate bandpass filters 
were placed in the light path. Fixed HEYA8 cells on 22 mm × 22 mm glass coverslips were 
rinsed with PBS at pH 7.4 and fabricated into a sandwiched chamber with two pieces of 
double-sided tape and a cleaned glass slide. PBS solution was then added into the chamber 
to fill the space, and the chamber was then sealed by clear nail polish. The so-formed 
sample slide was then place under the microscope for observation.  
Scratch assay: The scratch assay has been performed according to a former report [53]. 
Cells were cultured in a 6 well plate to a confluent monolayer. A p200 pipet tip was used 
to scrape the cell monolayer in a straight line to create an empty gap. The debris was then 
removed by washing the cells once with a culture medium and then replaced with 2 mL of 
fresh medium. Then, the cells were imaged immediately after scratch and 12 hours after 
scratch.  
Proteomics data analysis: Two biological replications and three MS technical replications 
for each condition (control, AuNRs@PEG, AuNRs@PEG/NIR, AuNRs@RGD, 
AuNRs@RGD/NIR) were conducted. Raw data from proteomics was normalized using 
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supervised normalization of the microarray (SNM) [54]. In the SNM procedure, variance 
due to biological and technical replicates were adjusted by setting them as variables in the 
model. Variance explained by different experimental treatments (control, AuNRs@PEG, 
and AuNRs@PEG+NIR for PEG-conjugated AuNRs group; control, AuNRs@RGD, and 
AuNRs@RGD+NIR for RGD-conjugated AuNRs group) was fitted as a biological 
variable in the model. Hierarchical clustering was done with statistical software R [55]. 
Proteomics data was log2 transformed before analysis of variance (ANOVA) which was 
used to detect differential levels of proteins between control and treatment groups. We 
fitted models with treatment conditions and fixed effects. We set P-value threshold at 0.1 
to select differential proteins. The proteins identified as being affected were subjected to 
pathway analysis using the MetaCore pathway analysis software (“MetaCore from 
Thomson Reuters”).  
Western-blot analysis: Briefly, cells were lysed in RIPA buffer (20 mM Tris pH 7.4, 150 
mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.1% Sodium Deoxycholate, 1% Triton X-100, 
0.1% SDS) containing protease inhibitors (Sigma-Aldrich). BCA assay (Pierce) was 
performed to measure the protein concentration, and equal amounts of protein were loaded 
on a SDS-PAGE gel. After SDS-PAGE, the resulting gels were transferred to PVDF 
membranes (Millipore) overnight. Afterwards, the gel was blocked with 5% milk in TBS 
(20 mM Tris, 150 mM NaCl). The primary antibodies (Bethyl Laboratories, Inc.) was 
incubated with the membrane overnight in 4 °C with shaking, followed by adding the 
secondary antibodies (Jackson Immuno Research Laboratories). Blots were washed three 
times for 20 m in TBS after primary and secondary antibodies. 
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4.2.3  Results and Discussion 
AuNR Fabrication, Characterization, Cell Uptake and Cytotoxicity Study: 
AuNRs with size of 25 (± 3)  6 (± 1) nm (length  width) and aspect ratio of 4.2 were 
synthesized according the seedless method [49], as shown in the transmission electron 
microscope (TEM) in Figure 4-6A. The as-synthesized AuNRs were washed twice with 
water to remove cetyltrimethylammonium bromide (CTAB) to decrease the cytotoxicity 
and for the next step of surface modification. Polyethylene glycol thiol (PEG) were applied 
to formulate AuNRs@PEG to increase the biocompatibility [56]. For achieving integrin 
targeting, the PEGylated particles were further functionalized with RGD, which bind to the 
integrin on the surface of cancer cells and enhance the receptor-mediated endocytosis of 
the nanoparticles [46]. Surface modification causes red shift of UV-Vis spectra due to the 
change in the dielectric constant of the surrounding environment of AuNRs. The 
longitudinal surface plasmon resonance (SPR) band of AuNRs is 771 nm (as shown in the 
UV-Vis spectra in Figure 4-6B). After PEGylation, the SPR band red-shifts to 785 nm for 
AuNRs@PEG. Further red-shift to 796 nm for AuNRs@RGD was observed indicating the 
surface binding of RGD (Figure 4-6B). In addition, the zeta potentials of the AuNRs at 
different stages were measured to confirm the surface modifications. As shown in Figure 
4-6C, the as-synthesized CTAB coated AuNRs has very positive surface charge of 22.9 ± 
15.1 mV as the CTAB is a highly cationic surfactant. After PEG modification, the AuNRs 
became negatively charged (-10.2 ± 6.73 mV). The zeta potential of the AuNRs became 
positive again after further modification of the RGD peptides. The characterization results 
are consistent with the results from our and other groups, which indicates the successful 
conjugation of the RGD peptides to the surface of AuNRs [52, 57]. 
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Successful internalization of AuNRs within the cells was observed as monitored by dark-
field (DF) microscope (Figure 4-6D-F), where the brightness of the scattering light from 
AuNRs indicates the internalized amount. The human oral squamous cell carcinoma (HSC-
3) cells were incubated with 2.5 nM of AuNRs for 24 hrs. For AuNRs@RGD, clear 
scattering light of AuNRs was observed while AuNRs@PEG did not show high uptake 
when compared to the AuNRs@RGD. The difference in uptake of these two types of 
AuNRs is due to the binding of RGD to the surface integrin that enhances the endocytosis 
of AuNRs [58]. For further confirmation, the internalization of AuNRs was also measured 
by UV-Vis spectra (Figure C.8.A) and the differential interference contrast (DIC) 
microscopy (Figure C.8.B-D). To measure the cell viability and apoptosis status, flow 
cytometry was used, which indicated the 2.5 nM of AuNRs@PEG and AuNRs@RGD did 
not affect the cell viability or cause apoptosis (Figure 4-6G). A NIR laser was applied for 
1 min to raise the temperature of the culture media to about 42  1 oC. As the temperature 
increased, there was no obvious change in the cell viability and no sign of 
apoptosis/necrosis (Figure 4-6G-K).  In addition, that no apoptosis occurred in the cells 
after AuNRs incubation and slight NIR exposure, was further confirmed by our Western-
blot results (Figure 4-6L), as BAX, an important protein that participate in initiation of 




Figure 4-6. AuNRs synthesis, characterization, HSC-3 cellular uptake and 
cytotoxicity study 
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(A) Transmission electron microscopy (TEM) image of AuNRs. (B) UV-Vis spectrum 
of AuNRs with different surface ligands. Black: the as-synthesized AuNRs with 
CTAB on the surface; Blue: PEGylated AuNRs; Red: AuNRs conjugated with PEG 
and RGD. (C) Zeta potential shows the surface charge before/after conjugations. (D-
F) Dark field image of cells without AuNRs, incubated with AuNRs@PEG or 
AuNRs@RGD, respectively. (G-K) Cell viability/apoptosis/necrosis assay of cells 
under different treatments, using flow cytometry. Q1: necrotic cells; Q2: late 
apoptotic cells; Q3: early apoptotic cells; Q4: viable cells. (L) Western blotting for the 
Bax protein after four groups of treatments. 
 
AuNRs inhibit cancer cell migration and invasion ability 
To evaluate the AuNRs effect on cancer cell migration, we conducted scratch assay [53] on 
the monolayers of cells that were incubated with or without AuNRs for 24 hours. After 
introducing a “scratch” or “wound” into a cell culture, images were captured immediately 
and 12 hours after the scratch. Figure 4-7A indicates that cells in the control group had the 
“wound” completely healed, while cells treated with AuNRs were not completely healed. 
In addition, NIR light exposure demonstrated an enhanced inhibition effect on cancer cell 
migration. Integrin-targeting AuNRs (AuNRs@RGD) have a greater inhibition effect than 
non-targeted AuNRs (AuNRs@PEG). 
As mentioned above, the cell motility decreased upon the AuNR treatment. It is well known 
that the cell morphology change is closely related to the cell motility, which is initiated 
through two types of membrane protrusions: lamellipodia and filopodia. They contain a 
big occupancy of integrins [60] and play major roles in leading cancer cell migration and 
invasion [61-62]. As shown in the scheme of Figure 4-7B, lamellipodia are flat, sheet-like 
structures, while filopodia are needle-like protrusions from actin. To study the cell 
morphology change (lamellipodia and filopodia), differential interference contrast (DIC) 
 287 
microscopy was used. The control sample exhibited a normal and extended lamellipodia 
and filopodia. After treating with AuNRs@RGD alone, the cell shape tended to become 
round after AuNRs@RGD internalization and contains less amount of lamellipodia and 
filopodia, compared with control. When we applied AuNRs@RGD and NIR light, the area 
of lamellipodia was further decreased. The morphology changes of integrin-rich 
lamellipodia and filopodia indicate that the integrin targeted gold nanorods with or without 
laser are effective in changing the cytoskeleton structures, a probable cause for the decrease 
in motility.  
To study the molecular mechanism, we checked the expression levels of several proteins 
that closely associated with integrin and cell migration to examine their response after 
AuNRs treatment. Two important down-stream regulators of integrin, Src and ERK1/2 
were found to be down-regulated with the AuNRs treatment when compared with the 
control (Figure 4-7C). Src is a critical protein which bridges between integrin and Rho 
signaling, which is the main regulator of cytoskeleton [63]. ERK1/2 is a mitogen-activated 
protein kinase, which plays a crucial role in cell migration [38, 64]. The decrease of Src 
and ERK1/2 indicates that targeting the surface integrin using AuNRs@RGD could block 
the down-stream regulators of integrin signaling [65], which contributes to the inhibition 
of cell migration by AuNRs. Moreover, in a further investigation of integrin-related 
proteins, Figure 4-7C showed that E-cadherin and PTEN, were up-regulated upon AuNRs 
treatments, which contributes to the inhibition of cancer migrations [66-69]. 
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Figure 4-7. Cell shape changes upon cell movement 
 (A) Imaging of cell movement using scratch assay of cells incubated with 
AuNRs@RGD displayed arrested healing/closing of the scratch. (B) Shows the change 
in the cell shape using DIC images of cells before and after gold AuNRs treatments. 
(C) Western-blot analysis of integrin and migration related proteins in AuNRs@PEG 
(with or without laser) and AuNRs@RGD (with or without laser).   
 
Proteomics analysis reveals the inhibition of migration pathways:  
To gain a global view of proteome change, label-free quantitative proteomics was 
conducted to identify and quantify protein expression changes in HSC-3 cells after 
incubation with AuNRs. Proteomics results indicated a wide range of perturbations of 
proteins in migration-related pathways after AuNRs treatment. In this experiment, cells 
were lysed and proteins were then extracted, digested, and analyzed by mass spectrometry 
(MS). Two biological replications and three technical replications for each condition were 
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conducted. In total, over 4000 proteins were identified and about 1800 common proteins 
were quantified in four treatment groups (AuNRs@PEG, AuNRs@PEG+NIR, 
AuNRs@RGD, and AuNRs@RGD+NIR) (Figure 4-9A). Hierarchical clustering analysis 
on similarity matrix of proteomics data was carried out to show the reproducibility of the 
experiments. The clustering analysis results (Figure C.9. A and B) indicate that most 
experiments from the control group or experimental groups were clustered together 
correspondingly, indicating a good reproducibility of the proteomics experiments. 
Differential analysis was conducted to obtain the proteins with significant changes at their 
expression level (Figure C.9. C-F). The number of up-regulated and down-regulated 
proteins in each group is shown in Figure C.9. G. Comparison of differentially expressed 
proteins identified in the four treatments is shown in the Venn diagram (Figure C.9. H), 
showing the number of common and unique proteins in different groups. Expression levels 
of key proteins in these pathways are shown as a heatmap in Figure 4-8B, where a wide 
range of cytoskeleton proteins were observed to be affected in the four groups. Pathway 
analysis indicated perturbation of signaling pathways related to cell migration in all groups 
(Figure 4-8C), including cytoskeleton remodeling process, Rho GTPase signaling, 
integrin-mediated cell migration and invasion, etc. Maps of these pathways are shown in 
Figure C.10. It is worth noting that according to the pathway analysis results, 
AuNRs@RGD+NIR is the most effective for inhibiting cancer cell migration, as it shows 
the greatest significance in affecting the migration related pathways; AuNRs@RGD is 
more effective than AuNRs@PEG, and the NIR light increase the efficacy of the treatment 
(Figure 4-8C).  
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A scheme (Figure 4-9) was concluded from the pathway maps (Figure C.10.) to illustrate 
the change of the key protein players in the migration pathways. As shown in Figure 4-9, 
AuNRs regulate the cell migration by affecting the cytoskeleton in four main ways: 1) Rho 
GTPases, 2) actin, 3) microtubule, and 4) kinases related signaling pathways. 
1) Rho GTPases signaling was greatly affected. Rho GTPases regulates actin 
cytoskeleton,70-72 which plays an important role in cellular contractility by directly 
controlling the balance between myosin II and actin, and initiates the force needed 
for cell migration.73-74 75As shown in the scheme (Figure 4-9), many key proteins 
in Rho GTPase signaling pathways were perturbed, including ROCK, MYHC, 
MELC, MLCP, RhoA, -actinin, talin, etc. as shown in Figure 4-8B. All the four 
treatments applied exhibit effect for wide regulation of Rho signaling, to different 
extents. Among the 4 treated groups, the AuNRs@RGD+NIR group has the highest 
statistically significant p-value (1.5x10-10), reflecting this group’s highest efficacy 
in inhibiting the cancer migrations pathways (Figure 4-8C).  
2) Actin-binding proteins were down-regulated after AuNRs incubation (Figure 
4-8B), including alpha-actinin, talin, vinculin, etc. In the integrin-mediated 
signaling pathway, the activated integrins recruit actin-binding proteins, which 
include talin and vinculin, and coupled to the actin cytoskeleton [76]. Our results 
indicated that the connectivity between integrin and actin cytoskeleton was 
decreased, demonstrating the blocking effect of AuNRs on the migration pathways.  
3) Microtubule-associated proteins MAP2 and MAP4 were significantly down-
regulated (Figure 4-8B and Figure 4-9), indicating the rearrangement of 
microtubules, which is one of the most important cytoskeleton structures [77]. 
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4) A large variety of kinases related to integrin signaling pathways were perturbed, 
including integrin linked kinase (ILK), NF-κB, the epidermal growth factor 
receptor (EGFR), caveolin, etc (Figure 4-8B and Figure 4-9). These proteins are 
closely associated with integrin regulation and cell migration [78]. It has been 
reported that the overexpression of ILK could promote the migration and invasion 
of colorectal cancer cells via NF-κB signaling [79]. In our results, the down-
regulation of ILK and NF-κB exhibited a reduced cancer cell migration ability. In 
addition, EGFR, a surface receptor for epidermal growth factor decreased. The 
down regulation of EGFR was also confirmed in the Western-blot results which 
agrees with our proteomics results (Figure 4-8B and Figure 4-9). EGFR is 
regarded as an important target for anticancer therapeutics [80]. Furthermore, 
STAT3, which can be activated by tyrosine phosphorylation in response to the 
addition of EGFR [81] and can promote cell migration, was also down-regulated in 





Figure 4-8. Experimental results of proteomics in the four treatment groups 
(AuNRs@PEG, AuNRs@PEG+NIR, AuNRs@RGD, and AuNRs@RGD+NIR) 
 (A) Heatmap showing the expression levels of all the quantified proteins. (B) 
Heatmap showing identified proteins contributing to migration inhibition. (C) Bar 
graph showing identified significant pathways related to migration. (D) Western-blot 




Figure 4-9 Scheme representing the mechanisms involved in inhibiting cell migration 
upon AuNR treatments 
 When the AuNRs@RGD (in red) target the alpha/beta integrins, four different 
cytoskeleton proteins pathways are regulated: Rho (blue), Actin (yellow), 
Microtubule (green), and Kinase (pink) which all affect the cell contractility and thus 
inhibit cell migration (shown in red at the bottom of the figure). 
 
Current advances of nanoscience and nanomedicine enable us to fabricate “intelligent” 
nanomaterials that can specifically target subcellular locations of cells or cancer cells in 
living animals [82-83]. Our previous study has shown success in treating natural mammary 
gland tumors in dogs and cats using AuNRs assisted plasmonic photothermal therapy 
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(PPTT), where all the cases did not have cancer relapse and metastasis [37], hinting the 
potential effect of PPTT on inhibiting cancer metastasis. Herein, we reported that AuNRs 
assisted PPTT were able to greatly inhibit cancer cell migration than AuNRs alone (while 
the latter is also effective). Furthermore, integrins have been observed to be overexpressed 
in many types of cancer cells, which are closely involved in cancer cell migration because 
of their ability to regulate cytoskeleton proteins. In our work, targeting AuNRs to cancer 
cell surface protein integrins could enhance the inhibition effect on cancer cell migration, 
based on phenotype level results (cell migration speed and cell morphology) as well as 
molecular level results (Western blot and proteomics). 
 
Cell morphology change was cytoskeleton protrusions, namely lamellipodia and filopodia, 
that form the leading edge for cell movement. These cytoskeleton protrusions were reduced 
after treating them with AuNRs@RGD. Furthermore, after applying NIR light, a greater 
morphological change was observed. Integrins are often found in the tips or alone in the 
shaft of filopodia and lamellipodia, which creates the “sticky fingers” and facilitate the 
migration and invasion [84-85].  
The reason for this morphological change has been explored in our Western blot analysis, 
which indicated that the integrin related proteins were obviously affected, resulting in 
inhibition of cell migration pathways. As shown in Figure 4-7C, four integrin related 
proteins, Src, ERK1/2, PTEN, and E-cadherin had altered expressions. Src and ERK1/2, 
two important down-stream regulators of integrin have crucial roles in cytoskeleton 
regulation, were found to be down-regulated upon the AuNRs treatment. The decrease of 
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Src and ERK1/2 is mainly due to the targeting of the surface integrin using AuNRs@RGD, 
which could block the down-stream regulators of integrin signaling. Similar effects 
regarding nanoparticles that could target and block the function of proteins were previously 
reported [86]. Moreover, two proteins, E-cadherin and PTEN, were up-regulated upon the 
AuNRs treatments. Recent discoveries have shown that E-cadherins have cross-talk with 
integrin signaling [87] that alter cytoskeletal organization [66]. Loss of E-cadherin is often 
associated with tumor invasive progressing [67]. In addition, the tumor suppressor protein 
PTEN has been reported to inhibit integrin-mediated cell migration, spreading, and 
adhesion [68-69]. Our results indicated the up-regulation of E-cadherins and PTEN, which 
contributes to the inhibition of cancer migrations, and down-regulation of MAPs, similar 
to previous reports 88. The above results indicate that integrin-targeting AuNRs and NIR 
light exposure possibly change the cytoskeleton structure and shrink lamellipodia and 
filopodia thus impairing cell migration.  
Moreover, for obtain a systematic understanding the AuNRs’ inhibition effect on cancer 
cell migration, proteomics experiment was performed. A scheme (Figure 4-9) concluded 
from the pathway maps illustrates the changes of four groups of proteins in migration 
pathways. Among these proteins, the most important is those participating in actomyosin 
contraction, which create the intracellular tension [89]. Actomyosin contraction is 
generated by active myosin II binding to actin filaments (thus termed actomyosin). Rho 
GTPases family is a predominant regulator in actomyosin contraction by phosphorylating 
the myosin light chain, promoting the cross-linking of actin by myosin, and enhancing 
actomyosin contact [90]. Integrin signaling networks can initiate the regulation of the Rho 
GTPases through Src [74, 91], and then to Rho-associated kinase (ROCK, a 
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serine/threonine kinase), a downstream effector of Rho which plays a major role in the 
rearrangements of the actomyosin cytoskeleton [92-93]. Myosin light-chain 
phosphorylation (MLCP) is regulated by ROCK, which is necessary for the formation and 
maintenance of stress fibers and form a modulatory apparatus for acto-myosin contraction 
through modulation of myosin [92]. In our results, the expression levels of many key 
proteins (such as Src, ROCK, MELC, MLCP and MyHC) were changed (Figure 4-9), 
indicating the disruption of actomyosin contraction, which might prevent the traction force 
from generating during the migration process. 
The effect of AuNRs on focal adhesion through targeting integrin was also observed, as 
the expression levels of the associated proteins were altered, including alpha-actinin, talin, 
vinculin, filamin, etc. Focal adhesions are structures that contains integrin and other 
associated proteins and form links between the intracellular actin cytoskeleton and ECM 
94. The binding of talin to integrin is regarded as a common final step of the cell signaling 
cascades that control integrin activation [95]. In addition, higher concentrations of talin can 
be observed in regions where focal adhesion complexes are formed96. Furthermore, 
vinculin links actin filaments to ECM through talin and integrin [97], and filamin is widely 
engaged in the integrin-actin cytoskeleton interaction [98]. The observed down regulation 
of these focal adhesion complex-associated proteins indicated the integrin-targeting 
nanoparticles could negatively affect the connection between integrin and the cytoskeleton.  
 
4.2.4 Conclusion and Future Outlook  
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Metastasis is the main cause of cancer-related deaths. However, the current clinical 
treatments for anti-metastasis is not effective.  This work aim at developing a novel strategy 
to inhibit cancer cell migration using gold nanorods. The surface functioned gold nanorods 
target integrins, which greatly affect the down-stream cytoskeleton proteins and impair 
cancer cell migration. When we apply the near-infrared light, the heat generated could 
further inhibit migration by remodeling the cytoskeleton. This work provides a new 
strategy for combating cancer metastasis. 
The body deposition of metallic nanoparticles raises significant concerns regarding their 
long-term safety. While small nanoparticles (hydrodynamic diameter < 5.5 nm) can be 
excreted efficiently through urinary system, [99] bigger nanoparticles (> 18 nm in 
diameter) accumulate in organs such as the liver and spleen [100] and decrease slowly 101. 
Our results showed that when compared to the non-targeted AuNRs, the integrin-targeted 
AuNRs showed a larger enhanced effect on migration inhibition with a nanoparticle 
concentration at the nanomolar scale (1000x lower than the literature values [19, 21, 23]. 
The minimized amount of gold nanoparticles we applied is beneficial to decrease the 
nanoparticles’ long-term effects. Future work will be focused on testing the effect of gold 
nanoparticles on preventing and treating cancer metastasis in animals. 
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APPENDIX A: CHAPTER 2 
ADDITIONAL FIGURES AND TABLES 
 
Figure A.1.  TEM of different sizes of AuNRs: A, B, D, E, F, H, and I have been prepared 
using by seed growth technique. Howevere: C, and G samples has been prepared by 
seedless growth technique in (synthesis in section 2.1.2.4). (Right), their equivalent 
wavelengths listed in the table.    
 316 
 
Figure A.2. Comparison between Au nanorods and Au nanobones growth:  A) shows the 
different diffractions between rods and bones. B). 3D visualizations of tomographic 
reconstructions of both types of nanorods and the one in between (semibone). Crystal facets 
are visible in both tomographic reconstructions. D) High-resolution STEM projections of 
both nanorods oriented along the [220] direction. C) the intensity profile acquired from the 
first projection corresponds to a model where the morphology is composed of {220} and 
{200} facets. C)  The intensity profile acquired from the projection of the rod grown with 
the 5-bromosalysilic acid clearly shown the effect of the negative surfactant on producing 





Figure A.3. Emission spectra of AuNRs@BSA (10-4 M) after the addition of various 





Figure A.4. Emission spectra of BSA (10-4 M) after the addition of various concentrations 
of Ptxl (10-4 M) from 0.0 to 140 μL at an increment of 10 μL. 
 


















































































Figure A.5. Emission spectra of BSA (10-4 M) after the addition of various concentrations 
of RF (10-4 M) from 0.0 to 180 μL at an increment of 10 μL. 
 
Figure A.6. A and B are the extinction spectrum and TEM image of AuNSs, respectively. 
Extinction spectrum of AuNSs@BSA also given in A (red trace). 

















































Figure A.7. SERS spectra of various RF conjugated and non-conjugated bAuNRs. Spectra 





Figure A.8. SERS spectra of Ptxl-conjugated and non-conjugated AuNRs. Spectrum of 
pure Ptxl is also included.  
    The AuNRs@BSA-RF showed clear Raman features of RF, which was in concordance 
with the Raman features of pure RF1. Absence of Raman features of CTAB or BSA can be 
due to their low Raman cross-section compared to the RF. In the SERS spectra of RF with 
non-conjugated AuNRs (Fig. S5), the ring stretching vibrations (1578, 1389, and 1339 cm-
1) and carbonyl stretching vibration (1627 cm-1) shifted towards higher wavenumber side 
(1618, 1390, 1356, and 1651 cm-1, respectively) compared to the normal Raman spectra.1 
Whereas, after conjugation with BSA, these bands slightly shifted towards lower 
wavenumber side, which clearly indicates the conjugation of the RF with BSA. This shift 
can be attributed to the hydrogen bonding interactions between the RF and the amino acids 







































    Due to the hydrophobic nature of the molecule, paclitaxel is practically insoluble in 
water. For this reason, dimethylsulfoxide (DMSO) was chosen to be the solvent to increase 
its solubility. The SERS band appeared at 668 cm-1 was the characteristic peaks of DMSO, 
which was taken as an internal standard (Fig. S6). Raman band at 987 cm-1 appeared in the 
spectrum of the drug/BSA complex, which is attributed to the paclitaxel._ENREF_52 600 
and 1340 cm-1 appearing in the spectrum of paclitaxel disappeared from the spectrum of 
the complex (Fig. S6). All of these changes in the spectrum illustrate that there exist high 
affinity of the paclitaxel to the BSA, hence the binding. 
 




Figure A.10. (a) Histograms were generated from flow cytometry data of Annexin V+ Huh7.5 
(human hepatocellular carcinoma), MCF-7 (human breast cancer) or HSC (human squamous 
carcinoma) cells with (PPTT) and without (Ctrl) laser treatment, showing the viable, nectotic and 
apoptotic cell populations. (b) Histograms were generated from flow cytometry data of Annexin 
 324 





Figure A.11. (a) Fluorescence emission spectra of AuNRs@BSA (10-3 M) after the 
addition of various amounts of QE (10-3 M) at an increment of 50 μL. BSA-QE -1 (50 μL) 
BSA-QE -2 (100 μL). BSA-QE -3 (150 μL). BSA-QE -4 (200 μL). (b) UV-Vis spectra 
showing QE release from AuNRs after PPTT. 1 nM of the AuNRs@ QE in solution has 
been irradiates exposed to a near Infra-red (NIR) CW laser (808 nm, M2W dragon laser) 
 326 
at 5.8 W / cm2 for 2 minutes with a spot size of approximately 5.6 mm.   Then we separated 
the AuNRs from the supernatant using centrifugation (15 min at 14 500 RPM). Both the 
supernatant and the pellet were examined using UV-Vis spectrometer. Green line shows 
the supernatant has QE absorbance at 370 nm, indicating the successful release of QE from 













Figure A.12. Differential interference contrast (DIC) microscopy image of the 












Figure A.13. Cell viability (XTT assay) (a) and flow cytometry (apoptosis/necrosis assay) 






Figure A.14. Apoptosis/necrosis assay (a to e) and cell viability assay (f) for the HSC-3 
samples treated with PPTT at different time; Q1 (necrosis), Q2 (apoptosis), Q3 (early 
apoptosis) and Q4 (early apoptosis). 



















Figure A.15. Characterization of AuNSs@PEG@RGD@NLS. (a) Transmission electron 
microscope (TEM) image of conjugated gold nanospheres (AuNSs). Scale bar = 100 nm. 
(b) UV-Vis absorption spectra of the unconjugated AuNSs (black spectrum), PEG 
conjugated AuNSs (red spectrum) and AuNSs conjugated with NLS (green spectrum). (c) 
Zeta potential of AuNSs with different conjugations. (d) The dark field images of HSC-3 

































































Figure A.16. The uptake of AuNRs by HSC-3 cells before and after 24 h incubation. The 






Figure A.17. SERS spectra of a) PPTT on cells with AuNSs alone (without AuNRs) and 




Figure A.18. Additional SERS spectra collected from single HSC-3 cell (incubated with 
AuNRs 24 h prior to PPTT) under NIR laser exposure of (808 nm diode laser 5.8 w/cm2) 





Figure A.19. SERS spectra collected from single HSC-3 cell 12 hours after PPTT 
(incubated with AuNRs 24 h prior to PPTT, under NIR laser exposure of 808 nm diode 

















Figure A.20. Clustering analysis and differential analysis of proteomics and metabolomics 
data. (a) Clustering analysis of proteomics data. Two biological replicates (labeled as B1 
and B2) and three MS technical replicates (labeled as T1, T2, and T3) were conducted. 
Clustering analysis indicated good reproducibility for the proteomics experiments. (b) 
Clustering analysis of metabolomics data. Two biological replicates (labeled as B1 and B2) 
and two MS technical replicates (labeled as T1 and T2) were conducted. Clustering 
analysis indicated good reproducibility for the metabolomics experiments. (c) Volcano plot 
showing that 434 proteins were differentially expressed in AuNR@NLS group compared 
to control group (p=0.1). In total, 1341 proteins are identified. (d) Volcano plot showing 
that 402 proteins were differentially expressed in AuNR@NLS/PPTT group in contrast to 
control group (p=0.1). (e) Volcano plot showing that 238 metabolomics features were 
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differentially expressed in AuNR@NLS group compared to control group (FDR=0.05, 
corresponding to p=0.015). A total of 1122 metabolomics features were detected in 
metabolite extracts, corresponding to 152 metabolites with primary ion ([M-H]-).  (f) 
Volcano plot showing that 483 metabolomics features were differentially expressed in 
AuNR@NLS/PPTT group in contrast to control group (FDR=0.05, corresponding to 






Figure A.21. Heat map showing fold change (log2) of key metabolites related to 
phenylalanine metabolism in treatment experiments (AuNRs@NLS, AuNRs@NLS/PPTT) 





Figure A.22. Quantification accuracy examination of proteomics workflow: Log2 ratio 
distributions of quantified peptides from 2 identical test samples (yeast whole proteome 





















Figure A.23. Pathway map showing that the phenylalanine metabolism pathway was 
perturbed after PPTT and key proteins (HADHA, ACAT1) were down-regulated, which 
triggers apoptosis. (Red) means up-regulation after PPTT, (blue) means down-regulation 
after PPTT. In the thermometer sign, 1 refers to metabolomics results, 2 refers to 
proteomics results. The thermometers are filled to various degrees, corresponding to the 
amount by which the markers were up-regulated or down-regulated. 
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Note: in the figure, “Acetyl-CoA acyltransferase” represents “hydroxyacyl-CoA 
dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), 
alpha subunit”, which is a protein complex catalyzing the 3-hydroxyacyl-CoA 
dehydrogenase and enoyl-CoA hydratase activities. HADHA and HADHB are both 
subunits of this protein complex.  HADHA is down-regulated, while the HADHB is up-
regulated. However, the down-regulation of HADHA is the rate limiting step forming the 
effective protein complex. Therefore, the activity of protein complex Acetyl-CoA 
acyltransferase is down-regulated, contributing to the mitochondria mediated apoptosis 
process. 
ACAT1 is acetyl-CoA acetyltransferase 1, which is a mitochondrially localized enzyme 
that catalyzes the reversible formation of acetoacetyl-CoA from two molecules of acetyl-
CoA. ACAT2 is cytosolic localized acetyl-CoA acetyltransferase 2, which involved in lipid 
metabolism. The mitochondrial isoform ACAT1 is down-regulated hints its perturbation 
contributes to mitochondria mediated apoptosis processes, while the cytosolic isoform 







Figure A.24. Significant pathways identified from proteomics (red bars) and metabolomics 








Figure A.25. Other apoptosis pathways revealed by proteomics results. 
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Table A.1. Zeta potential of 1m of conjugated nanorods (AuNRs) at different conjugations 
conditions; AuNRs@ CTAB, AuNRs conjugated to BSA, AuNRs conjugated to RF, 
AuNRs conjugated QE. 
Nanoparticle type Zata potential 
AuNRs with citrate 22.9 ± 15.1 mV 
AuNRs@BSA -8.08 ± 4.97 mV 
AuNRs@BSA@RF -21.7 ± 5.55 mV 
AuNRs@BSA@QE -11.7 ± 5.47 mV 
 
Table A.2. Zeta potential results for AuNRs with different surface modifications 
Nanoparticles Zeta potential value/ mV 
CTAB-coated AuNRs 22.9±15.1 
AuNRs@PEG -10.2±6.73 





Table A.3. Tentative assignment of Raman bands in the SERS spectra collected from HSC 
cells (Panikkanvalappil, S. R. et al, 2014; Panikkanvalappil, S. R. et al, 2016) 
Wavenumber (cm-1) Tentative assignments of SERS bands 
495-510 -S-S- 
640−660 -C-S- 
820−850 Tyr and lipids O−C−C−N symmetric stretches  
990-1010 Phe ring breathing 
748-758 pyrrole breathing mode ν15 in cytochrome c 
1012−1030 In-plane bending mode of Phe and ring breathing of 
Trp 
1200−1210 C6H5−C stretch of Phe and Tyr 
1584−1592 Phe 
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Figure B.1. Characterization and TU686 cell uptake of rifampicin-conjugated 
AuNRs@RF. (A) Transmission electron microscopic (TEM) image of conjugated 
nanorods (AuNRs). Scale bar = 100 nm; (B) UV-vis absorption spectra of the as-
synthesized AuNRs (black line), BSA and RF conjugated AuNRs@RF (red line), free RF 
in solution (green line), AuNRs after PPTT (blue) and the supernatant after PPTT (cyan); 
(C) BSA fluorescent emission quenching of BSA (10-4 M) after adding various amounts of 
RF (10-4 M) from 0 to 130 L; (D) Zeta potential of AuNRs with different surface ligands: 
cetyl trimethylammonium bromide (CTAB), BSA, BSA+RF; (E) Dark field microscopic 
imaging showing TU686 cellular uptake of 2.5 nM AuNRs@RF after 24 h incubation. 
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Scale bar = 50 m; (F) UV-vis absorption spectra of the nanoparticle-media mixture before 
and after incubation with cells. 
 
 
Figure B.2. Characterization of AuNRs@PEG (25  5.5 nm). (A) UV-Vis spectra 
showing the surface plasmon peaks of as-synthesized AuNRs and the red-shifted peak of 
PEGylated AuNRs; (B) Zeta potential of AuNRs@CTAB (black) and AuNRs@PEG 
(green); (C) Dark field images of cells with and without 2.5 nM AuNRs@PEG incubation 
for 24 h. Scale bar = 50 m; (D) UV-Vis spectra showing the intensities of AuNRs plasmon 
peaks before and after incubation with cells; (E) DIC images of cells incubated with 2.5 
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nM AuNRs@PEG. The red circle and black arrow indicate a nanoparticle aggregate inside 
the cell. Scale bars are 10 µm. For comparison with other studies, 5 nM = 1 O.D. (optical 




Figure B.3. Three dimensional reconstruction of AuNRs@RF inside cells.  Z-stacks 
were acquired using the Multi-Dimensional Acquisition function in Micro-Manger. More 
specifically, the DIC optical sectioning through the whole cell thickness was achieved by 
moving the objective on the motorized nosepiece using PFS at 65 nm/step at 33 ms (30 
fps) of AuNRs@RF inside cells. (A) cells incubated with AuNRs@RF; (B) cells after 
PPTT. (For more details, see supporting videos “3D DIC imaging of AuNRs@RF inside 





Figure B.4. AuNRs-PPTT efficiently inhibits cell viability and induces apoptosis (in 
vitro). (A) Cell viabilities of five HNSCC cell lines under treatment with various 
concentrations of small AuNR for 2h followed by 2 W/cm2 NIR laser power for 2 min. 72h 
after laser treatment, cell viability was analyzed by SRB assay. The percentage of cell 
viability was then calculated based on the absorbance values relative to the non-treated 
samples. Error bars are mean ± SD from 3 independent experiments; (B) Cell viability 
analysis as above of MDA686TU cells 72h after treatment with AuNRs@PEG-PPTT and 
AuNRs@RF-PPTT (error bars are mean ±SD from 3 independent experiments). (C) 
 352 
Apoptosis/necrosis assay of cells treated with PPTT under different conditions. Q1: 
necrosis cells; Q2+Q3: apoptosis cells; Q4: normal cells. For comparison with other 
studies, 5 nM = 1 O.D. (optical density) for small AuNRs (35). 
 
 
Figure B.5. Characterization of large AuNRs with size of 72 (± 7) nm × 16 (± 4) nm. 




Figure B.6. Tumor weight of treated mice. Mice were sacrificed, tumors were collected 
from each treatment group on Day 25 and tumors were weighed (error bars are mean ±SD, 
n=5). Statistical analysis (t-test) shows that the difference between control (PBS, Laser, 
AuNRs@PEG) vs the big AuNRs@PEG treated group was not significant (NS), while 
control (PBS, Laser, AuNRs@PEG) vs other treated groups was *p <0.01. For comparison 
with other studies, 5 nM = 1 O.D. (optical density) for small AuNRs (35). 
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Figure B.7.  Lower power of laser with AuNRs is unable to reduce tumor growth in a 
MDA686TU xenograft model. (A) Tumor growth (tumor volume = 0.5×l×w2) 
progression in groups: PBS, 2 W/cm2 laser, 10 nM small AuNRs as control groups; 5 nM, 
10 nM small AuNRs with 0.5 and 1 W/cm2 laser.   First dose was given on Day 1 (tumor 
volume ~100mm3) and tumor growth was monitored until Day 25 (endpoint of tumor 
volume 1800 mm3) (error bars are mean ±SE, n=5); (B) Mice were sacrificed, tumors were 
collected from each treatment group on Day 25 and tumors were weighed (error bars are 
mean ±SD, n=5). For comparison with other studies, 5 nM = 1 O.D. (optical density) for 
small AuNRs (35). 
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Figure B.9. Modulation of PPTT toward inducing cancer cell apoptosis. 
Notes: (A–D) shows the MCF-7 cell apoptosis/necrosis states of the in vitro experiment. 
(A) Cells without AuNRs. (B) Cells incubated with AuNRs (no laser). (C) Cells incubated 
with AuNRs and 2 minutes laser irradiation. (D) Cells incubated with AuNRs and 5 
minutes laser irradiation. (E) Laser irradiation spots of animals. The 5-minute irradiation 
caused burning of the tumor, whereas 2-minute irradiation shows no obvious change in 
appearance. The in vitro and in vivo experiments were conducted at the same condition. 




Figure B.10. (A–C) are photographs complete for Case 7 (Tumor 6: caudo-inguinal 




Figure B.11. Case 2 before treatment. 
Notes: (A) The X-ray shows there is no metastasis in the internal organs. (B) Ultrasound 
shows the tumor location, shape, and dimensions. 
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Figure B.12. Photographs for Case 2 (Tumor 4: left caudothoracic mammary gland and 
Tumor 9: right abdominal mammary gland) showing the tumor regression 2 weeks after 
first treatment. 





Figure B.13. (A–C) are photographs for case 3 (Tumor 2: left caudothoracic mammary 
gland and Tumor 13: right abdominal mammary gland) showing the tumor regression after 





Figure B.14. Histopathology images (stained with H&E [×400]) for Case 3. 
Notes: (A) Well-differentiated tubular adenocarcinoma before treatment. Carcinoma 
arranged in tubular pattern. Mass characterized by an intra-acinar deeply basophilic 
secretion and corpora amylecea. Connective tissue stroma infiltrated with mononuclear 
cells (tumor Grade III). (B) 2 weeks after the third treatment, there was absence of epithelial 
lining of acini and absence of acini and basement membrane. Also, loss of acinar pattern 
proliferation of fibrous connective stroma was seen (tumor Grade 0). Magnification of 
histopathology images stained with H&E: (A) ×200; (B) ×100. 
Abbreviation: H&E, hematoxylin and eosin. 
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Figure B.15. X-ray lateral exposure for Case 3 after treatment. 




APPENDIX C: CHAPTER 4 
ADDITIONAL FIGURES AND TABLES 
 
Figure C.1. HEY A8 cell uptake of AuNRs@NLS and AuNSs@NLS. (a) Dark field 
images of cells without AuNPs incubation (Ctrl), with 2.5 nM of AuNRs@NLS and 0.1 
nM of AuNSs@NLS incubation. (c) UV-Vis spectra of 2.5 nM of AuNRs@NLS or 0.1 
nM of AuNSs@NLS (d) in culture media before incubation with cells (black spectrum), 







Figure C.2. Characterization for AuNPs@BSA and HEY A8 cell uptake. (a) UV-Vis 
extinction spectra of the unconjugated AuNSs@Citrate (black spectrum) and 
AuNRs@BSA (red spectrum). (b) UV-Vis extinction spectra of the unconjugated 
AuNRs@CTAB (black spectrum) and AuNSs@BSA (red spectrum). (c) XTT assay of 
HEY-A8 cells after 24 h incubation with AuNSs@NLS at concentrations 0.05 nM (light 
blue), 0.1 nM (medium blue) and 0.2 nM (dark blue), n=3. (d) XTT assay for cells after 






















































































1.5 nM (light blue), 2.5 nM (medium blue) and 5 nM (dark blue) of AuNRs@NLS 





Figure C.3. The introduction of Au nanoparticles in cells does not affect the Fluorescent 
























Figure C.4. Nuclear stiffness increase with the increased quantity of AuNRs. AFM result 
(left) and dark field images (right) show the stiffness and the nanoparticle uptake of AuNRs 






Figure C.5. Three dimensional (3D) view of HEY A8 cells incubated with AuNPs. (a and 
b) 3D figures of cells with 2.5 nM of AuNRs@NLS and 0.1 nM of AuNRs@NLS, showing 
xy, xz and yz planes (c and d) showing the z-stacking of 3 layers from the bottom of the 
cell (close to the attached glass surface as shown in the scheme), the middle of the cell, and 
























Figure C.6. The nuclear membrane targeting for AuNRs@NLS indicated by differential 






Figure C.7.  Western blot of expression levels of Dynamin, Ran, emerin proteins and beta-
actin from HEY-A8 cells (without AuNPs), HEY A8 cells with 0.1 nM of AuNSs@NLS 
















Figure C.8. HSC cell uptake of gold nanorods. (A) UV-Vis spectra of AuNRs before and 
after incubation with cells. (B-D) Differential interference contrast (DIC) microscopy 
images of cells without nanoparticle incubation (B), incubated with AuNRs@PEG (C), and 








































Figure C.9. Experimental results of proteomics. (A) Clustering analysis showing good 
reproducibility of proteomics experiments using AuNRs@PEG and corresponding NIR.  
(B) Clustering analysis showing good reproducibility of proteomics experiments using 
AuNRs@RGD and corresponding NIR. Volcano plot showing the differential protein 
under perturbation by (C) AuNRs@PEG, (D) AuNRs@PEG+NIR, (E) AuNRs@RGD and 
(F) AuNRs@RGD+NIR. 
 (G) Bar graph showing number of proteins identified in each experiment. (H) Venn 
















Figure C.10. Key pathways perturbed by AuNRs related to cytoskeleton identified with 
MetaCore. (Red) means up-regulation compared to control; (blue) means down-regulation 
compared to control. In the thermometer sign, 1 refers to AuNRs@PEG; 2 refers to 
AuNRs@PEG+NIR; 3 refers to AuNRs@RGD; and 4 refers to AuNRs@RGD+NIR. The 
thermometers are filled to various degrees, corresponding to the amount by which the 
markers were up-regulated or down-regulated. (A) Pathway map of “Cell 
adhesion_Integrin-mediated cell adhesion and migration”. (B) Pathway map of 
“Cytoskeleton remodeling_Cytoskeleton remodeling”. (C) Pathway map of “Cytoskeleton 
remodeling_Regulation of actin cytoskeleton by Rho GTPases”. (D) Pathway map of 




Table C.1. Zeta potential of AuNPs with different surface ligands 
Au nanoparticles with different surface 
ligands 
Zeta potential (mV) 
AuNRs@CTAB 50.9 ± 7.97 
AuNRs@PEG  -13.6 ± 11.8 
AuNRs@PEG@RGD@NLS 14.9 ± 3.13 
AuNSs@Citrate -29.7 ± 4.72 
AuNSs@PEG -12.1 ± 5.79 
AuNSs@PEG@ RGD@NLS 18.3 ± 7.55 
AuNRs@BSA -19.6 ± 9.89 
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